ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN BIOSYNTHETIC GENE CLUSTER AND ALTERING THE GLYCOSYLATION PATTERNS OF TETRACENOMYCINS AND MITHRAMYCIN-PATHWAY MOLECULES by Nybo, Stephen Eric
University of Kentucky 
UKnowledge 
University of Kentucky Doctoral Dissertations Graduate School 
2011 
ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN 
BIOSYNTHETIC GENE CLUSTER AND ALTERING THE 
GLYCOSYLATION PATTERNS OF TETRACENOMYCINS AND 
MITHRAMYCIN-PATHWAY MOLECULES 
Stephen Eric Nybo 
University of Kentucky, senybo2@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Nybo, Stephen Eric, "ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN BIOSYNTHETIC GENE 
CLUSTER AND ALTERING THE GLYCOSYLATION PATTERNS OF TETRACENOMYCINS AND 
MITHRAMYCIN-PATHWAY MOLECULES" (2011). University of Kentucky Doctoral Dissertations. 812. 
https://uknowledge.uky.edu/gradschool_diss/812 
This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been 
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
 
 
ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN BIOSYNTHETIC 
GENE CLUSTER AND ALTERING THE GLYCOSYLATION PATTERNS 
OF TETRACENOMYCINS AND MITHRAMYCIN-PATHWAY MOLECULES 
 
 
 
____________________________________ 
 
DISSERTATION 
 
____________________________________ 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Pharmacy at the University of Kentucky 
 
 
 
By 
 
Stephen Eric Nybo 
 
Lexington, Kentucky 
 
Director: Doctor Jürgen Rohr, Professor of Pharmaceutical Sciences 
 
Lexington, Kentucky 
 
2011 
 
Copyright © Stephen Eric Nybo 2011
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN BIOSYNTHETIC 
GENE CLUSTER AND ALTERING THE GLYCOSYLATION PATTERNS 
OF TETRACENOMYCINS AND MITHRAMYCIN-PATHWAY MOLECULES 
 
 
 Natural products occupy a central role as the majority of currently used antibiotic 
and anticancer agents.  Among these are type-II polyketide synthase (PKS)-derived 
molecules, or polyketides, which are produced by many representatives of the genus 
Streptomyces.  Some type-II polyketides, such as the tetracyclines and the anthracycline 
doxorubicin, are currently employed as therapeutics.  However, several polyketide 
molecules exhibit promising biological activity, but due to toxic side effects or solubility 
concerns, remain undeveloped as drugs. 
 Gilvocarcin V (GV) (topoisomerase II inhibitor) has a novel mechanism of 
action:  [2+2] cycloaddition to thymine residues by the 8-vinyl side chain and cross-
linking of histone H.  Mithramycin blocks transcription of proto-oncogenes c-myc and c-
src by forming an Mg2+-coordinated homodimer in the GC-rich minor groove of DNA.   
The purpose of this research was to investigate the biosynthesis of several type II 
polyketide compounds (e.g. chrysomycin, elloramycin, and mithramycin) with the goal of 
improving the bioactivities of these drugs through combinatorial biosynthesis.  Alteration 
of the glycosylation pattern of these molecules is one promising way to improve or alter 
the bioactivities of these molecules.  To this end, an understanding of the 
glycosyltransferases and post-polyketide tailoring enzymatic steps involved in these 
biosynthetic pathways must be established.  Four specific aims were established to meet 
these goals.  
In specific aim 1, the biosynthetic locus of chrysomycin A was successfully 
cloned and elucidated, which afforded novel biosynthetic tools.  Chrysomycin 
monooxygenases were found to catalyze identical roles to their gilvocarcin counterparts.  
Cloning of deoxysugar constructs (plasmids) which could direct biosynthesis of 
ketosugars, NDP-D-virenose, and NDP-D-fucofuranose in foreign pathways was 
undertaken in specific aim 2.  Finally, these “sugar” plasmids were introduced into 
producer organisms of elloramycin and mithramycin pathways in specific aims 3 and 4 to 
interrogate the endogenous glycosyltransferases in order to alter their glycosylation 
patterns.  These experiments resulted in the successful generation of a newly glycosylated 
tetracenomycin, as well as premithramycin, and mithramycin analogues.  In specific aim 
4, a new mithramycin analogue with an altered sugar pattern rationally designed and 
improved structural features was generated and structurally elucidated. 
 
 
KEYWORDS:  Polyketides, Combinatorial Biosynthesis, Gene Cluster, 
Glycosyltransferases, Glycodiversification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Eric Nybo________________________________                                                                 
      Student’s Signature 
9-27-2011________________________________ 
      Date
 
 
ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN BIOSYNTHETIC 
GENE CLUSTER AND ALTERING THE GLYCOSYLATION PATTERNS 
OF TETRACENOMYCINS AND MITHRAMYCIN-PATHWAY MOLECULES 
 
 
By 
 
 
Stephen Eric Nybo 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. Jurgen Rohr____________________________ 
                                                                             Director of Dissertation               
 
 
Dr. Jim Pauly   ____________________________ 
                                                                             Director of Graduate Studies 
 
 
9-27-2011________________________________ 
  
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to Minji Sohn and my family 
  
iv 
 
DEDICATIONS 
 
Human beings will be happier - not when they cure cancer or get to Mars or eliminate 
racial prejudice or flush Lake Erie but when they find ways to inhabit primitive 
communities again. That's my utopia. - Kurt Vonnegut 
 
Heavy Horses, move the land under me/ Behind the plough gliding --- slipping and 
sliding free/ Now you're down to the few/ And there's no work to do/ The tractor's on its 
way…A Heavy Horse and a tumbling sky/ Brewing heavy weather. –Jethro Tull, “Heavy 
Horses” 
 
This dissertation is composed of five years of intensive singular effort and study, 
but its composition would have been doubtful without the tremendous contributions of 
several extraordinary individuals.  First, my Dissertation Chair, Dr. Jurgen Rohr deserves 
the highest thanks and praise for his support, his optimism and encouragement, and 
certainly for the high level of scientific training and deductive reasoning he employed in 
evaluating and critiquing my work.  His mentoring is directly responsible for the 
scientific maturation I have today.  Next, I would like to thank my Dissertation 
Committee for their time and their helpful suggestions, and the outside examiner, 
respectively:  Dr. Kyung-bo Kim, Dr. Chris Schardl, Dr. Steven van Lanen, Dr. Janice 
Buss, and Dr. David Watt.  Their suggestions and expertise were essential to developing 
the theoretical aspects of this project. 
In addition to the mentoring and expertise of my committee members, I would 
like to thank my girlfriend, Minji, for her unconditional love and support throughout my 
doctoral process.  I could not ask for a more desirable companion and her patience 
through my working long hours. 
Without my colleagues, I simply would not have had the disposition or scholarly 
counseling on a day to day basis necessary to survive this process.  Dr. Madan Kharel, 
my senior and molecular biology mentor, essentially trained me from the ground up with 
regards to molecular cloning, biosynthetic pathways, and Streptomyces manipulations.  I 
am very greatful for the training he provided me in my time in the Rohr lab.  Dr. Miranda 
Beam helped me to understand that it was “OK” to not be so high-strung in the 
laboratory.  Mike Smith’s sarcasm and light-hearted outlook made for a very pleasant 
work environment.  Dr.  Mohammed Abdelfattah and Dr. Irfan Baig always encouraged 
me in my first two years and instructed me in basic extraction techniques.  Dr. Pallab 
Pahari was always quick with a joke, and was gracious in taking many NMR 
measurements for me.  Micah Shepherd’s off-the-wall humor always mirrored my own, 
and he served as an inspiration for hard work and organization.  Dr. Mary Bosserman 
always challenged me to become a better scientist, and her questioning approach to 
science has assuredly benefited my work.  Dr. Guojun Wang always helped when I had a 
Streptomyces quandary, and I owe a huge debt of gratitude to Dr. Khaled Shaaban for 
helping transform me into a better experimental chemist with regards to chromatography 
and structure elucidation.  To Theresa Downey, it is a long process but you will 
eventually reach the culmination of your Ph.D., too.  Keep your strong work ethic and 
your sense of humor.  They will propel you through periods of tough experimentation. 
v 
 
My family remains my stronghold, and I am lucky to have two loving and world-
class parents.  My dad would always offer a kind word and advice when I needed a dad’s 
perspective.  My mother’s selflessness is the reason for my success as an individual; her 
life lessons that she instilled in me at an early age, her trips to Lexington to go grocery 
shopping and do laundry, and the countless times she has been there for me must simply 
be praised.  My grandparents (of whom I am fortunate to have with me in my graduate 
career) have always afforded their love and kindness, as well as the sharpness of their 
perception and charming wit.  My uncle and aunt have frequently gone above and beyond 
the call of duty with regards to spoiling their nephew; my uncle’s penchant for gambling 
and never growing up have served as tremendous inspiration for me.  My sister’s support 
and love and zeal for life and happiness encouraged me to leave the lab and find a life of 
my own. While an individual effort, this work was made possible by the support of a cast 
of extraordinary human beings, indelible in character and invaluable in terms of 
contributions. 
 
  
vi 
 
ACKNOWLEDGEMENTS 
 
Dr. Madan Kharel and Micah Shepherd are thanked for the initial work on the 
Streptomyces albaduncus cosmid library.  Drs. Carsten Fischer and Lili Zhu are 
acknowledged for their work generating the gilL and gilN-deleted cosG9B3 cosmids.  Dr. 
Jose Salas and co-workers are acknowledged for the numerous contributions to in vivo 
deoxysugar biosynthesis and generation of several parent plasmids that formed the 
platform from which much of this present work proceeded.  Dr. Khaled Shaaban is 
acknowledged for his assistance in collecting spectroscopic data and in natural product 
isolation techniques. 
 
vii 
 
 
TABLE OF CONTENTS 
 
 
DEDICATIONS ..................................................................................................... iv 
ACKNOWLEDGEMENTS ................................................................................... vi 
LIST OF TABLES ........................................................................................................ X 
LIST OF FIGURES ..................................................................................................... XI 
LIST OF ABBREVIATIONS ................................................................................... XIII 
CHAPTER 1: BACKGROUND AND INTRODUCTION ................................................ 1 
INTRODUCTION ......................................................................................................... 1 
General Overview and Pharmaceutical Relevance of Polyketides ........................... 1 
Type I Polyketide Synthase-Derived (PKS) Molecules ............................................. 3 
Type II Polyketide Synthase (PKS) Molecules .......................................................... 6 
Type III PKS Molecules ............................................................................................. 8 
Post-PKS Tailoring steps .......................................................................................... 8 
Oxygenases ................................................................................................................ 9 
Methyltransferases, Aminotransferases, and glycosyltransferases ......................... 11 
Introduction to Gilvocarcin (GV) Biosynthesis ....................................................... 14 
Introduction to Mithramycin (MTM) Biosynthesis .................................................. 20 
SPECIFIC AIMS .......................................................................................................... 25 
CHAPTER 2: ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN 
BIOSYNTHETIC GENE CLUSTER ............................................................................... 29 
INTRODUCTION ....................................................................................................... 29 
Previous isolation of benzo[d]naphtho[1,2-b]pyran-6-one C-glycoside antibiotics
 ................................................................................................................................. 29 
Biological activity of chrysomycin A ....................................................................... 29 
Rationale for cloning chrysomycin A biosynthetic gene cluster ............................. 30 
RESULTS AND DISCUSSION .................................................................................. 30 
Construction of cosmid library for S. albaduncus AD819 ...................................... 30 
Positive hybridization of probes of NDP-glucose-4,6-dehydratase, 3-oxoacyl-acyl 
carrier protein-reductase (chryF), and Ketoacyl synthase (KSα) cosmid DNA ..... 31 
Southern blot studies of cosChry1-1, cosChryF1, cosChryF2, cosChryF3 ............ 32 
Shotgun sequencing of cosChry1-1, primer walking of cosChryF1-cosChryF3, 
subcloning of chryF fragment ................................................................................. 35 
Bioinformatics analysis of DNA .............................................................................. 35 
Minimal ‘PKS’ genes and genes implicated in polyketide cyclization, 
ketoreduction, aromatization................................................................................. 36 
Oxygenases, oxidoreductase, and methyltransferase genes .................................. 39 
Genes involved in self-defense, regulation, and other functions .......................... 44 
Genes involved in biosynthesis and attachment of NDP-D-virenose ................... 45 
Attempts at heterologous expression and inactivation of chrysomycin biosynthetic 
genes ........................................................................................................................ 49 
viii 
 
Cross complementations using chrysomycin oxygenases ....................................... 50 
SUMMARY ................................................................................................................. 53 
EXPERIMENTAL ....................................................................................................... 54 
DNA Isolation, Subcloning, and cloning of plasmids .......................................... 54 
Bacterial strains and culture conditions ................................................................ 55 
Construction and Screening of S. albaduncus Genomic Library .......................... 58 
Introduction of chry cosmids into Streptomyces lividans via Conjugation .......... 59 
Production and Isolation of Gilvocarcin-related metabolites ............................... 59 
CHAPTER 3:  IN VIVO STUDIES AND CLONING OF DEOXYSUGAR CASSETTES 
DIRECTING BIOSYNTHESIS OF NDP-D-FUCOFURANOSE AND NDP-D-
VIRENOSE ....................................................................................................................... 62 
INTRODUCTION ....................................................................................................... 62 
Common examples of branched sugar biosynthesis ................................................ 63 
Nature’s strategies for catalyzing pyranose-furanose transformations .................. 63 
RESULTS AND DISCUSSION .................................................................................. 67 
Identification of gilL and gilN candidate genes for NDP-D-fucofuranose 
biosynthesis ............................................................................................................. 67 
Generation of a G9B3-gilN- and G9B3-gilL- deletion cosmids and heterologous 
expression ................................................................................................................ 68 
Structure determination of metabolites accumulated by S. lividans TK 24 
(cosG9B3-gilN-) strain ............................................................................................ 69 
SUMMARY ................................................................................................................. 74 
EXPERIMENTAL ....................................................................................................... 74 
Isolation of metabolites from S. lividans TK 24 (cosG9B3-GilN-) ...................... 79 
PCR Redirect inactivation of gilN and conjugal transfer of cosG9B3-gilN- ........ 80 
Cloning of 6-deoxy-2’-hydroxy-hexose biosynthesizing plasmids ...................... 81 
CHAPTER 4:  ALTERING THE GLYCOSYLATION PATTERN OF 
TETRACENOMYCINS ................................................................................................... 84 
INTRODUCTION ....................................................................................................... 84 
ElmGT is one of the most flexible glycosyltransferases in secondary metabolism . 86 
Aminosugars:  their importance for glycodiversification, bioactivity, and solubility
 ................................................................................................................................. 88 
RESULTS AND DISCUSSION .................................................................................. 92 
Reconstitution of cos16F4 8-demethyl tetracenomycin C heterologous production
 ................................................................................................................................. 92 
Heterologous expression of aminosugar and 2’-hydroxysugar synthesizing 
cassettes ................................................................................................................... 94 
Heterologous expression of 2-hydroxysugar plasmids and ketosugar plasmids .... 96 
Structural Elucidation of Metabolites Accumulated by the S. lividans (cos16F4)/ 
pKOL strain ............................................................................................................. 99 
Biological activity of 127 towards Streptomyces prasinus ................................... 101 
Glycosyltransfer of ketosugars is a rare phenomenon; expanding the catalogue of 
known substrates for ElmGT ................................................................................. 102 
ix 
 
SUMMARY ............................................................................................................... 103 
EXPERIMENTAL ..................................................................................................... 103 
Bacterial Strains and Culture Conditions ............................................................ 103 
Generation of plasmids directing the biosynthesis of ketosugars, aminosugars, and 
2-hydroxysugars .................................................................................................. 104 
Isolation of tetracenomycins from recombinant S. lividans (cos16F4) strains ... 108 
CHAPTER 5:  ALTERING THE GLYCOSYLATION PATTERN OF 
MITHRAMYCINS ......................................................................................................... 110 
INTRODUCTION ..................................................................................................... 110 
Biological activity of mithramycin ........................................................................ 110 
Pathway engineering studies to alter the mithramycin/premithramycin polyketide 
skeleton .................................................................................................................. 111 
Altering the glycosylation pattern of premithramycins/mithramycins through 
“flooding” of the pathway with nucleoside-diphosphate-activated deoxysugars and 
inactivation experiments ....................................................................................... 115 
MtmOIV is the Baeyer-Villiger Monooxygenase (BVMO) that catalyzes fourth ring 
scission in biosynthesis of mithramycin ................................................................ 117 
RESULTS AND DISCUSSION ................................................................................ 119 
Generation of S. argillaceus wildtype strains overexpressing NDP-activated L- 
sugars .................................................................................................................... 119 
Expression of aminosugar and 2’-hydroxysugar plasmids in S.argillaceus wildtype
 ............................................................................................................................... 122 
Generation of Streptomyces argillaceus (pKOL) .................................................. 126 
Generation of Streptomyces argillaceus M7W1/pKOL strain and identification of 
metabolites ............................................................................................................ 129 
Isolation and structure elucidation of demycarosyl-3D-β-D-digitoxosyl 
mithramycin SK ..................................................................................................... 132 
Generation of Streptomyces argillaceus M7W1/pKAM ........................................ 134 
EXPERIMENTAL ..................................................................................................... 139 
Bacterial Strains and Culture Conditions ............................................................ 144 
Generation of plasmids directing the biosynthesis of ketosugars, aminosugars, and 
2-hydroxysugars .................................................................................................. 145 
Isolation of mithramycins from recombinant S. argillaceus M7W1/ (pKOL) 
strains .................................................................................................................. 145 
     
VITA............................................................................................................................168 
 
  
x 
 
LIST OF TABLES 
 
Table 1  Plasmids used in Chapter 2 ................................................................................. 55 
Table 2  Bacterial strains used in Chapter 2 ..................................................................... 56 
Table 3  Oligonucleotide Primers used in Chapter 2 ........................................................ 57 
Table 4 Bacterial strains and plasmids used in Chapter 3 ................................................ 74 
Table 5  Physico-chemical characterization of metabolites of S. lividans (cosG9B3-GilN-) 
strain .................................................................................................................................. 78 
Table 6  Oligonucleotides used in Chapter 3 .................................................................... 79 
Table 7  Plasmids used in Chapter 4 ............................................................................... 104 
Table 8  Bacterial strains used in Chapter 4 ................................................................... 106 
Table 9  Physicochemical characterization and NMR data of 8-Demethyl-8-(4'-keto)-α-L-
olivosyl-tetracenomycin C (127). ................................................................................... 107 
Table 10  Plasmids used in Chapter 5 ............................................................................. 139 
Table 11  Bacterial strains used in Chapter 5 ................................................................. 141 
Table 12  Physicochemical and NMR Data for Demycarosyl-3D-β-D-digitoxosyl 
mithramycin SK (135). ................................................................................................... 143 
 
  
xi 
 
LIST OF FIGURES 
 
Figure 1 Representative examples of clinically-relevant type I, type II, and type III-
derived polyketides. ............................................................................................................ 2 
Figure 2 Comparison of fatty acid biosynthesis with the incomplete reduction cycle of a 
prototypical type I PKS. ...................................................................................................... 4 
Figure 3 Elucidation of the EryA polyketide megasynthase. ............................................. 5 
Figure 4 Spontaneous cyclization of polyketides. .............................................................. 7 
Figure 5 Mechanisms of cofactorless and FAD-dependent monooxygenases. ................ 10 
Figure 6 Depictions of methyltransfer, aminotransfer, and glycosyltransfer reactions. ... 13 
Figure 7 Deoxysugar biosynthesis from D-glucose-1-phosphate (30). ............................ 14 
Figure 8  Structures of gilvocarcin-class antitumor antibiotics. ....................................... 16 
Figure 9 Gilvocarcin labeling pattern, after incorporation experiments using [1,2-13C2] 
acetate and [1-13C, 18O2]-acetate of gilvocarcin, respectively. ......................................... 17 
Figure 10 Hypothesis for GV (39) biosynthetic pathway. ................................................ 18 
Figure 11 Depiction of oxygenase cascade between UWM6 (18) and Jadomycin A (69).
........................................................................................................................................... 20 
Figure 12 Mithramycin A (70) and structures of related aureolic acid antibiotics (71-75).
........................................................................................................................................... 21 
Figure 13 Biosynthetic pathway of Mithramycin (70). .................................................... 23 
Figure 14 Premithramycins and mithramycins previously generated by combinatorial 
biosynthesis. ...................................................................................................................... 25 
Figure 15 Amplification of probes and colony hybridization. .......................................... 33 
Figure 16 Southern blot studies of chry cosmids. ............................................................. 34 
Figure 17 Map of the chry cluster using arrows to indicate direction of candidate ORFs.
........................................................................................................................................... 36 
Figure 18 Proposed biosynthetic pathway to chrysomycin A and B (42 and 43). ............ 38 
Figure 19 Theoretical routes to C5-C6 carbon carbon bond cleavage of the chrysomycins.
........................................................................................................................................... 42 
Figure 20 Hypothesized biosynthetic route to NDP-D-virenose (96). ............................. 46 
Figure 21 Table of proposed chrysomycin ORFs, predicted functions of their producers, 
and identity/similarity scores among closest homologues. ............................................... 48 
Figure 22 HPLC chromatograms of pChryOIV complementations ................................. 51 
Figure 23 HPLC chromatograms of pChryOII and pChryOIII chromatograms............... 52 
Figure 24 Structures of NDP-D-fucofuranose (97) and NDP-D-virenose (96). ............... 62 
Figure 25 SAM-dependent C-methylation by ChryCMT of NDP-4-keto-6-deoxy-D-
glucose to afford 95. ......................................................................................................... 63 
Figure 26 Crystal structures of pyranose-furanose contraction enzymes. ........................ 65 
Figure 27 Routes to NDP-D-fucofuranose ring contraction. ............................................ 66 
Figure 28 Biosynthetic pathways to NDP-D-fucofuranose and NDP-D-virenose. .......... 68 
Figure 29 1H-NMR spectrum of gilvocarcin V isolated from S. lividans (cosG9B3-gilN-) 
(500 MHz). ........................................................................................................................ 71 
Figure 30 Structures of metabolites isolated from S. lividans (cosG9B3-gilN-). ............. 72 
Figure 31 DNA electrophoresis gels of D-fucofuranose and D-virenose constructs........ 77 
Figure 32 Biosynthetic routes to elloramycin (106) and tetracenomycin C (8). .............. 85 
Figure 33 Elloramycin analogues generated by combinatorial biosynthesis. ................... 88 
xii 
 
Figure 34 Biosynthetic pathways of aminosugars encoded by plasmids. ......................... 91 
Figure 35 (Upper) HPLC Chromatogram trace of S. lividans (cos16F4) ......................... 93 
Figure 36 HPLC chromatogram of S. lividans (cos16F4)/pDmnI extract. ....................... 95 
Figure 37 Ketosugar plasmid maps generated for this work. ........................................... 96 
Figure 38 Deoxysugar biosynthesis for ketosugars encoded by pKOL, pDKOL, and 
pFL952. ............................................................................................................................. 97 
Figure 39 HPLC analyses of the metabolites:................................................................... 99 
Figure 40 Selected 2D-NMR for 127.............................................................................. 100 
Figure 41 Premithramycin and mithramycin-type compounds ...................................... 112 
Figure 42 Spontaneous rearrangements of Mithramycin SK (128), mithramycin SDK 
(129) and mithramycin SA (130). ................................................................................... 114 
Figure 43 Structures of mithramycin-type compounds resulting from S. argillaceus 
mtmTIII- and mtmC- (83-86) inactivations. ..................................................................... 116 
Figure 44 MtmOIV-catalyzed Baeyer-Villiger monooxygenative cleavage of 
premithramycin B. .......................................................................................................... 118 
Figure 45 HPLC traces of metabolites of S. argillaceus (pLNBIV)............................... 122 
Figure 46 HPLC chromatogram of the metabolites from S. argillaceus (pDmnI) strain.
......................................................................................................................................... 123 
Figure 47 HPLC chromatogram of the metabolites from NDP-D-virenose expressing 
strains. ............................................................................................................................. 125 
Figure 48 HPLC chromatogram trace of metabolites from S. argillaceus (pKOL) strain.  
The main compound accumulated is demycarosyl-3D-β-D-digitoxosyl mithramycin 
(131).  NDP-4-keto-L-olivose structure indicated as a reference for the sugar that pKOL 
biosynthesizes. ................................................................................................................ 128 
Figure 49 Sugar biosynthesis of deoxysugar plasmids in S. argillaceus. ....................... 128 
Figure 50 HPLC chromatogram of metabolites from S. argillaceus M7W1/pKOL strain.
......................................................................................................................................... 130 
Figure 51 (Upper) Suggested structures of new mithramycin-type compounds ............ 131 
Figure 52 1H-1H-COSY (▬), and selected HMBC (→) correlations for demycarosyl-3D-
β-D-digitoxosyl-mithramycin SK. .................................................................................. 134 
Figure 53 Biosynthetic pathways to trideoxygenated sugars. ......................................... 135 
Figure 54 HPLC chromatogram of metabolites from S. argillaceus M7W1/pKAM. ..... 137 
Figure 55 1H-NMR data for demycarosyl-3D-β-D-digitoxosyl mithramycin SK recorded 
at 500 MHz. .................................................................................................................... 148 
Figure 56 13C-NMR data for demycarosyl-3D-β-D-digitoxosyl mithramycin SK recorded 
at 125 MHz. .................................................................................................................... 149 
  
xiii 
 
LIST OF ABBREVIATIONS 
 
ACAT Acetyl-Coenzyme A acetyltransferase 
ACP acyl carrier protein 
APCI atmosphere pressure chemical ionization 
AT acyl transferase 
ATP adenosine triphosphate 
BLAST Basic-Localized Alignment Search Tool 
bp (nucleotide) base pair 
CLF chain length factor 
CoA co-enzyme A 
chry chrysomycin gene cluster 
COSY correlation spectroscopy 
CV chrysomycin V 
DEBS 6-deoxyerythronolide B synthase 
DH 4,6-dehydratase/ dehydratase 
DNA deoxyribonucleic acid 
DMSO dimethylsulfoxide 
E. coli Escherichia coli 
ESI electrospray ionization  
FAD flavin adenine dinucleotide   
FLP flippase 
FRT FLP recombinase recognition target 
GT glycosyltransferase 
GV gilvocarcin V 
HMBC heteronuclear multiple bond correlation 
HPLC high performance liquid chromatography 
KSα ketoacyl synthase 
KSβ chain length factor (CLF) 
LB lysogeny broth (also Luria-Bertani broth) 
MCAT malonyl-CoA acyl carrier protein transacylase 
MT methyltransferase 
xiv 
 
MTM mithramycin (mtm= mithramycin gene cluster) 
SDK mithramycin shortened diketone 
SK mithramycin shortened ketone 
NAD nicotinamide adenine dinucleotide (oxidized) 
NAD(P)H nicotinamide adenine dinucleotide phosphate 
(reduced)   
NMR nuclear magnetic resonance 
ORF open reading frame 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PKS polyketide synthase 
PV polycarcin V 
Rt HPLC retention time (relative) 
RV ravidomycin V 
TCMC tetracenomycin C 
TE thioesterase 
TLC thin layer chromatography   
UV ultraviolet  
UV-VIS       ultraviolet visible spectrum 
 
1 
 
CHAPTER 1: BACKGROUND AND INTRODUCTION  
 
INTRODUCTION 
 
General Overview and Pharmaceutical Relevance of Polyketides 
 
Since the earliest development of scientific thought, natural products have occupied 
a central role as pharmaceutical agents in the treatment of human disease.  The 
etymology for pharmaceutic stems from the Greek word, pharmakon, meaning “a remedy 
or poison.” This distinction keenly demonstrates that the earliest Hippocratic physicians 
understood drugs to have beneficial or harmful effects on human physiology.  With the 
advent of modern pharmacognosy, natural products have served an integral role as first-
resort therapeutic agents, models for elucidating biosynthetic pathways, and as targets for 
chemical total synthesis (1). 
Within the greater context of natural products, polyketides are a family of bacterial- 
and fungi-derived natural products that serve in many pharmaceutically relevant 
capacities (2).   Polyketides are produced by polyketide synthases (PKS) through a series 
of linear condensation steps between a starter unit (e.g. acetyl-CoA, propionyl-CoA) and 
several extender units (e.g. malonyl-CoA) to yield in type II PKS systems an enzyme-
tethered poly-β-ketoester.  Many polyketides are biosynthesized by gram positive, soil-
dwelling bacteria of the Actinomycetes family, with most of these compounds being 
produced by the genus Streptomyces (3).  
Polyketide-derived molecules are unmatched in structural diversity and many of 
them possess anticancer and other biological activities (Figure 1) (4).  These activities 
include immunosuppressant, antimicrobial, antineoplastic, and cholesterol-reducing 
drugs, to name a few; the sales of polyketide-derived pharmaceutics are in excess of 
fifteen billion dollars per annum (2).  So far, three types of polyketide synthases have 
been described with respect to the nature of their biosynthesis:  type I, type II, and type 
III.  As such, these families of polyketide synthases are capable of generating very 
diverse chemical structures.  Resveratrol (1) is a type III stilbene-type compound that has 
received considerable interest for its anti-inflammatory and cancer-preventive activities, 
while tetrangulol (2) is the first such characterized type II PKS-derived angucycline 
antibiotic  (5).  Methymycin (3) and especially erythromycin A (7) are 12-membered and 
2 
 
14-membered macrolides, respectively, studied for their antimicrobial activities (6-7).  
Amphotericin B (4) is a clinically important type I PKS-derived antifungal agent (8).  
Lovastatin (6) is a highly reduced iterative type I PKS-derived product that possesses 
nanomolar inhibition of HMG-CoA reductase, and as such, is representative of the 
blockbuster statin drugs (9-10).  Oxytetracycline (5) is a type II PKS-derived antibiotic, 
whereas tetracenomycin C (8) was important in initial studies for aromatization and 
cyclization of nascent polyketide intermediates in context with type-2 PKSs (11). 
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Figure 1 Representative examples of clinically-relevant type I, type II, and type III-
derived polyketides. 
 
The pharmaceutical importance of polyketide-derived molecules has generated 
tremendous interest in elucidating the biosynthetic machinery responsible for generating 
their chemical diversity (4).  The advent of molecular biology has allowed for cloning of 
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entire biosynthetic loci of polyketide-type compounds.  Ever since the cloning and 
heterologous expression of the entire actinorhodin biosynthetic locus (12), recombinant 
techniques have become indispensable for understanding the role of individual enzymes 
(e.g. gene inactivation) or groups of enzymes (e.g. heterologous expression of minimal 
polyketide synthase) in generation of polyketide scaffolds.  As a result, these preliminary 
studies can allow for manipulation of these pathways to generate novel derivatives with 
more advantageous pharmaceutical properties. 
 
Type I Polyketide Synthase-Derived (PKS) Molecules  
 
The Type I polyketide synthases are “megasynthases” composed of many modules, 
which are  roughly analogous to the fatty acid synthase from primary metabolism (13).  
As such, both the highly functionalized type I “megasynthase” domains and fatty acid 
synthases share similar biosynthetic routes (Figure 2), with two major differences:  1) 
type I polyketide synthases utilize more diverse extender units and starter units than 
simply malonyl-CoA and acetyl-CoA, respectively (e.g. methylmalonyl-CoA for 
extender units, propionyl-CoA starter unit, etc.), and 2) type I polyketide synthases often 
have incomplete reduction cycles (13).  Type I polyketide synthases are unlike their fatty 
acid counterparts that produce exclusively a saturated chain, and type I PKSes require 
subsequent desaturases to introduce double bonds.  In fatty acid biosynthesis, priming of 
acetyl-CoA onto the acyl carrier protein (ACP) by ACAT is followed by its binding to a 
sulfhydryl group on a nearby enzymatic site.  Malonyl-CoA is loaded onto the ACP via 
MCAT, then malonyl -ACP undergoes decarboxylation, and then the resulting carbanion 
condenses with acetyl-S-Enz.  The β-ketone is then stepwise reduced to a fully saturated 
sp3 bond.  Subsequent elongations give a fully reduced fatty acid.  In the type I PKS, the 
reduction cycle is abrogated at one of several steps, often the result of missing or 
inactivated modules along the megasynthase, which functionalizes the resulting C2 
extender units with ketone, hydroxyl, olefinic, or fully saturated moieties (6-7, 14).   
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The products of type I PKS megasynthases polyketides are 12-, 14-, and 16-
membered macrolides, polyenes, and polyethers (14).  The loading domains may consist 
of solely an ACP (e.g. in the case of avermectin and erythromycin type I PKS) or may 
also contain a ketoacyl synthase domain with a glutamine substitution for cysteine (14).  
These synthases are subdivided into modules consisting of acyltransferase (AT), acyl 
carrier protein (ACP), ketoreductase (KR), dehydratase (DH), enoyl reductase (ER), 
ketosynthase (KS). The last module possesses an additional thioesterase domain (TE) for 
hydrolysis and lactonization of the linear polyketide chain (Figure 3).  The type I PKS 
has a co-linearity between its modules, and as such, a nascent polyketide chain is passed 
along from the sulfhydryl group of the ACP of one domain to the next ACP until the TE 
domain hydrolyzes it (14).  
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In the early 1990’s, the sequence and linearity of erythromycin A biosynthesis was 
firmly established as representative of type I PKS molecules with the cloning of the entire 
6-deoxyerythronolide B (6-dEBS) PKS cluster (7).  The PKS region (eryA) is coded on 
three ORFs spanning ~35kb of chromosomal DNA, and its enzymatic domains are 
encoded within 6 PKS modules (7) (Figure 3). 
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Figure 3 Elucidation of the EryA polyketide megasynthase. 
Domains are color-coded by function. AT=Green, ACP=Pink, KS=Blue, KR=Red, 
DH=Yellow, ER=Orange, TE=Black. 
 
The elucidation of the linear organization of EryA suggested possible domain functions 
in which inactivation of specific domains could result in predictable structures.  Indeed, 
inactivation of the ketoreductase in module five resulted in a corresponding 5,6-deoxy-3-
α –L-mycarosyl-5-oxoerythronolide B compound (not shown), lacking the desosamine 
residue due to the establishment of a 5-keto group instead of the alcohol, to which the 
sugar could have been attached (14).  The use of genetic data to predict domain function, 
and consequently, to hypothesize about structures resulting from inactivation of specific 
domains was somewhat successfully employed also for other type I PKS systems (14). 
6 
 
Type II Polyketide Synthase (PKS) Molecules 
 
Type II polyketides consist primarily of the polyaromatic/cyclized classes of 
polyketide-derived molecules (13, 15).  The poly-β-ketothioester is installed iteratively 
by a type-II PKS, also called the “minimal PKS” (16), consisting of β-ketoacyl synthase 
(KSα), chain length determinant enzyme (CLF/KSβ) (KSα and KSβ form a close 
heterodimer), and an acyl carrier protein (ACP) for successive transfer of malonate to the 
growing polyketide chain, in addition to the necessary enzymes for chain initiation (4).  
This “minimal” polyketide synthase has the minimal number of enzymes necessary to 
produce the first visualized intermediates in type II pathways. MCAT transfers malonyl-
CoA to the ACP as in other PKS pathways for use as the extender units; however, 
different starting units can also be utilized in type II PKS pathways (e.g. malonamyl-
CoA, propionyl-CoA, crotonyl-CoA, butyryl-CoA).  Specialized enzymes have been 
evolved to biosynthesize and load these starter units (17-19).  Chain initiation begins 
when the starter unit is loaded onto the KSα-KSβ.  Malonyl-ACP is decarboxylated in β-
ketoacyl synthase and is condensed with the starter unit, and the extended polyketide 
chain is transferred to the β-KS to release the ACP, which is now free to accept another 
malonyl-CoA (4, 20).  X-ray crystallography studies on the actinorhodin  KSα-KSβ 
complex revealed its heterodimeric nature; as a rule, these two enzymes are almost 
always translationally coupled (16).  A tunnel in the heterodimer allows for expansion of 
the growing nascent (and highly reactive) poly-β-ketothioester, thereby shielding it from 
nucleophilic water molecules (16).  In the actinorhodin KSα- KSβ heterodimer, cysteine 
169 is the catalytic amino acid residue required for formation of the thioester, and 
phenylalanine 116 a gating residue, which prevents further condensations of acetate units 
beyond a heptaketide (16). 
The cyclization strategies employed in type II polyketide pathways give rise to the 
structural diversity observed among the anthracycline, angucycline, tetracycline, and 
tetracenomycin-type molecules (Figure 4a) (4).  The poly-β-ketothioester is highly 
reactive, and therefore every type II PKS cluster has a functional set of closely-associated 
cyclases/aromatases/oxoacyl-ketoreductases necessary to steer the cyclization(s) of the 
polyketide core towards a certain skeletal framework (4).   
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Figure 4 Spontaneous cyclization of polyketides.   
a) Cyclization events yielding skeletal frameworks for families of type II polyketides.  b)  
Example of spontaneous cyclization event in the absence of cyclase enzyme and 
examples of spontaneously cyclized shunt products.  
 
The minimal PKS directs the folding pattern to the nascent polyketide chain, and the 
cyclases and aromatase enzymes are responsible for “locking-in” the skeleton, or in the 
case of angucycline polyketides, installing the angular shape by initiating C4-C17 
cyclization (4, 14).   In the case of tetracycline and aureolic acid polyketide cyclization, 
C7-C12 are linked in the first ring cyclization, followed by C5-C14 linking in the second 
ring cyclization, C3-C16  linking in the third ring cyclization, and finally C1-C19 linking 
in the fourth ring cyclization in the case of the tetracyclines (16) (21-22) (Figure 4a).  In 
the case of premithramycin type molecules (e.g. 17), it is possible that tandem 
oxygenations by MtmOI (?)/MtmOII act on a tricyclic intermediate, which establishes an 
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epoxide.  The epoxide is reductively opened, thereby allowing fourth ring cyclization 
(23-24).  These four ring cyclizations yield a linear molecule.  In the case of the 
angucyclines, the first two ring cyclizations are similar to the tetracycline/aureolic acid 
cyclizations, C7-C12 and C5-C14, but a specialized C4-C17 third ring cyclase is 
responsible for creating the angular appearance of these molecules, followed by C2-C19 
fourth ring cyclization, resulting in intermediate UWM6 (18) (Figure 4a). 
 In the absence of the polyketide-associated ketoreductase or cyclase/aromatase 
enzymes, spontaneous cyclization processes occur involving the highly reactive poly-β-
ketothioester.  These aberrant cyclizations result in “shunt products,” which are 
polyketide metabolites that accumulate in the pathway that are not intermediates for 
downstream pathway enzymes.  In general, shunt products are biosynthetically 
unproductive but they reveal some information about the preceding biosynthesis (Figure 
4b). 
Type III PKS Molecules 
 
Type III PKS molecules are produced predominantly in plants, but some are also 
biosynthesized in bacteria.  Type III polyketides are biosynthesized by a single β-
ketoacyl synthase enzyme without the assistance of an ACP (25), and the enzyme makes 
use of a variety of starter units (e.g. coumaroyl-CoA, etc.).  Resveratrol, 1, is an example 
of a stilbene-type polyketide from this pathway. 
 
Post-PKS Tailoring steps 
 
After the core skeleton has been assembled, the post-PKS tailoring steps 
functionalize the molecule, thereby supplying it with the chemical moieties that 
contribute to its biological activity (26).  The oxygenations, methylation, glycosylations, 
aminotransfer reactions, halogenations, reductions that tailor these polyketide skeletons 
are catalyzed by highly specialized sets of enzymes (26).  Post-PKS tailoring enzymes 
have evolved to bind restrictively to a particular substrate and many have stringent 
cofactor requirements for catalysis.  The genetic and biochemical characterization of 
specific tailoring enzymes and their substrates is often the first objective for 
combinatorial biosynthesis (27).  Combinatorial biosynthesis, the modification and 
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recombining of heterologous genes in a biosynthetic pathway to achieve novel natural 
products, is practically often concerned with the characterization and interchange of these 
post-PKS tailoring enzymes (27).  As such, an introduction to some of these post-PKS 
enzymes is merited. 
 
Oxygenases 
 
 Oxygenases are some of the most common and diverse enzymes employed in 
secondary metabolic pathways (27).  In general, oxygenases install oxygen moieties as 
aldehydes, ketones, or hydroxyl groups.  These oxygen moieties are handles for 
important chemical transformations and can serve as mediators of biological activity.  For 
example, the installation of a hydroxyl or a ketone moiety creates an additional hydrogen 
bond donor or acceptor.  Ketones reduce the pKa of α-hydrogens, which allows for more 
facile abstraction by a base.   In addition, oxygenases mediate carbon-carbon bond 
cleavage, and some oxygenases may install highly reactive epoxides, for example (27).  
Oxidoreductases also add or remove hydrogens (dehydrogenases, ketoreductases) and 
oxidize C-O bonds (e.g. oxidases, secondary alcohol to ketone), and dehydratases 
catalyze the elimination of water to install double bonds. 
Oxygenases are easily characterized by their cofactor requirements, conserved 
amino acid moieties, and the number of oxygens that are installed on a substrate.  
Cofactor free monooxygenases have no cofactor involved in their mechanism; rather, the 
substrate assists in the installation of molecular diatomic oxygen.  These oxygenases are 
also referred to as anthrone oxygenases or also “internal monooxygenases” (27).  The 
HypC anthrone oxygenase from Aspergillus parasiticus was overexpressed in E. coli and 
purified for in vitro conversion of norsolorinic acid anthrone to norsolorinic acid (Figure 
5).  HypC possesses two catalytic domains that are conserved across emodinanthrone 
oxygenases- QLXXQWSRIFY and RXLXXPL (the active site residues are underlined) 
(28).  Tryptophan 43, tyrosine 48, and arginine 140 are involved in coordinating an 
enzyme-stabilized zwitterion of norsolorinic acid anthrone (19) that allows for molecular 
oxygen to attack para to the anthrone oxygen (Figure 5).  Glutamine 38 stabilizes the 
reaction product by hydrogen bonding with the newly-formed quinone oxygen in 
norsolorinic acid (20) (28). 
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Flavin-dependent monooxygenases possess an N-terminal domain (GXGXXG) 
which is involved in binding of FAD (27).  These oxygenases also bind NAD(P)H for 
reduction of FAD to FADH2, which then binds diatomic oxygen to form the key 
peroxyflavin intermediate (27).  A nucleophile present on the substrate then attacks the 
peroxide, thereby forming a new bond with oxygen and forming water (27).  Cytochrome 
P-450 oxygenases possess a prosthetic heme group, which coordinates a Fe3+ cation.  
These CYP-450 oxygenases often require an accessory ferredoxin protein to regenerate 
NADPH (27).  One FAD- and NADPH-dependent oxygenase (DnrF) and a P450 
monooxygenase from the doxorubicin biosynthetic pathway (DoxA) are depicted with 
cofactor requirements in Figure 5. 
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Figure 5 Mechanisms of cofactorless and FAD-dependent monooxygenases. 
a) Mechanism of cofactor-free oxygenase HypC.  b) FAD- and NADPH- dependent 
monooxygenase DnrF and P450 oxygenase DoxA from doxorubicin pathway. 
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DnrF is involved in 11-hydroxylation of aklavinone to afford ε-rhodomycinone in an 
FAD and NADPH-dependent manner, whereas DoxA is a CYP-450 that catalyzes both 
13-hydroxylation and hydroxymethyl formation at C-14 (27, 29). 
 
Methyltransferases, Aminotransferases, and glycosyltransferases 
Methyltransferases and aminotransferases are important enzyme classes for post-
PKS decoration.  These enzymes modify the reactivity and lipophilicity/ hydrophilicity of 
natural products through the addition of methyl groups and amino functionalities, 
respectively.  Methyltransferases add an additional C1 unit by means of a nucleophilic 
attack by an electron-rich donor moiety on S-adenosyl methionine to afford S-adenosyl 
homocysteine and a methylated compound.  One pertinent example of O-methylation is 
catalyzed by MtmMI from the mithramycin biosynthetic pathway of Streptomyces 
argillaceus (23).  MtmMI catalyzes the removal of a proton from the 4-OH group, and 
the resulting oxygen nucleophile attacks the methyl group of S-adenosyl methionine that 
is positioned in the methyltransferase active site to give premithramycinone (27) (Figure 
6) (30).  N-methylation or O-methylation increases the hydrophobicity of a compound by 
removing a hydrogen bond donor (27).  N-methylations can form tertiary amines, which 
give very important pharmaceutical properties to a drug (27).  C-methylations are 
employed biosynthetically to introduce a “branch” into a deoxysugar or onto a polyketide 
skeleton. 
Aminotransferases catalyze the transfer of an amine group to a corresponding 
carbonyl.  The amino group donor is usually pyridoxamine phosphate (PMP), which 
forms an imine with the carbonyl carbon, which is then hydrolyzed to yield the newly 
transaminated substrate and pyridoxal phosphate (PLP) (31).  Aminotransfer reactions 
require a carbonyl handle.  The transformation of a carbonyl into an amine converts a 
hydrogen bond acceptor into a hydrogen bond donor, which is often important for 
biological activity.   As such, this greatly enhances the hydrophilicity of a compound.  In 
the oxytetracycline pathway, the PMP-dependent aminotransferase OxyQ is used to 
transaminate the 4-keto position of 4-ketoanhydrotetracycline (28), a very unstable 
pathway intermediate, to afford 4-aminoanhydrotetracycline (29) (Figure 6).   OxyQ 
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tailors one of the canonical tetracycline reactions (amine group at 4 position), and 
effectively “captures” the labile 28 (21, 31).  
Glycosyltransferases (GTs) are among the most numerous and utilitarian enzymes 
in all of nature.  As such, glycosylations are invaluable to the biological activity of 
polyketides.  Indeed, many polyketides are inactive without their appended sugars (32).  
Glycosylation increases biological activity and hydrophilicity of a compound by virtue of 
installing several –OH hydrogen bond donors present on a sugar.  Glycosyltransferases 
require a pool of “donor substrates,” nucleotide diphosphate-bound (NDP) sugars that 
often are deoxygenated at one or more positions, and an “acceptor substrate,” which in 
most cases is an aglycone or suitable polyketide core that will receive the sugar donor 
(33).  Glycosyltransferases have evolved into two predominant families characterized by 
the nature of their Rossman folds, GT-A and GT-B superfamilies (34).  Most polyketide 
glycosyltransferases are members of the GT-B superfamily of glycosyltransferases, and 
they possess two domains with an α/β Rossman fold involved in the binding of the sugar 
donor substrate in the C-terminus and the acceptor substrate in the N-terminus (34-35).  
Glycosyltransferases can either catalyze glycosylation with inversion or retention of 
configuration; in most cases with the GT-B superfamily of glycosyltransferases, 
glycosylation involves inversion of configuration, which is the underlying reason for the 
earliest discovery of Klyne’s Rule (36) (Figure 6). 
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In addition to glycosyltransferases, nature has evolved many different deoxysugar 
tailoring enzymes involved in the modificiation of sugar donors (37).  These deoxysugar 
pathways begin with D-glucose-6-phosphate, which is interconverted to D-glucose-1-
phosphate (30) by phosphoglucomutase  (Figure 7).  D-glucose-1-phosphate (30) is 
captured by NDP-glucose synthase, a specialized enzyme that catalyzes the coupling of 
NMP from a corresponding NTP with the phosphate group of 30.  A second enzyme that 
is usually clustered near NDP-glucose synthase is NDP-D-glucose-4,6-oxidoreductase 
(38) (or simply NDP-4,6-dehydratase).  This enzyme catalyzes the NAD-dependent 
removal of two electrons and two protons from C-4 and 4-OH, and dehydrates across the 
5,6 bond of 31 to afford a double bond, which is then reduced by 4,6 dehydratase to 
generate NDP-4-keto-6-deoxy-D-glucose (32) (Figure 7) (32). 
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Figure 7 Deoxysugar biosynthesis from D-glucose-1-phosphate (30). 
D-glucose-1-phosphate (30) coupled with NMP via NDP-glucose synthase to give NDP-
D-glucose (31) in an NTP-dependent manner.  31 is dehydrated and reduced across the 5, 
6 bond and oxidized at C-4 to afford NDP-4-keto-6-deoxy-D-glucose (32), which is a 
universal intermediate for downstream deoxysugar tailoring enzymes, which can generate 
tremendous chemical diversity as witnessed in sugars 33-38. 
 
A series of downstream tailoring enzymes can catalyze further deoxygenations, 
epimerizations, and other reactions to generate chemical diversity in sugar donors.  The 
cloning of these deoxysugar pathways and their subsequent heterologous introduction 
into foreign hosts has become a very important strategy for altering the glycosylation 
pattern of polyketides (39). 
 
Introduction to Gilvocarcin (GV) Biosynthesis 
Gilvocarcin V (GV) (39) (toromycin A, anandimycin A) is the most important 
representative compound of the benzo[d]naphtho[1,2-b]pyran-6-one C-glycoside 
antibiotics (40).  It was first isolated in 1981 in Japan from a fermentation of 
Streptomyces gilvotanereus (NRRL 11382) along with its congeners gilvocarcin M (40) 
and gilvocarcin E (41) (from S. anandii), and the antibiotic gets its name from the grayish 
yellow color of this strain after it has aged (40) (Figure 8).  It was also isolated from 
fermentations of Streptomyces arenae, Streptomyces anandii, and Streptomyces 
griseoflavus Gö 3592 (41-42).  Gilvocarcin V was determined to have excellent 
biological activity against Staphylococcus aureus and Bacillus subtilis, and weak activity 
against gram negative bacteria.  However, it demonstrated remarkable antitumor activity 
against sarcoma 180 solid tumors and Ehrlich ascites carcinoma in murine cell lines 
(Increased Life Span of 126%) (40, 43).  Interestingly, 39 maintained a very low in vivo 
cytotoxicity profile despite its considerable antitumoral effects (43).   Experiments by 
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Elespuru et al. confirmed that treatment of 39 with visible light photoactivated a [2+2] 
cycloaddition of 39 with thymine residues of DNA.  This contrasts with the mostly 
inactive gilvocarcin M (40), which possesses an 8-methyl side chain.  Gilvocarcin M 
lacks the photosensitizing effect exhibited by gilvocarcin V, most likely because it lacks 
the 8-vinyl sidechain (44).  Further studies confirmed that 39 binds to histone H3 and 
cross-links DNA, which the C-glycosidically-linked D-fucofuranose may play an 
essential role in its binding to the histone H3 protein (45-47). 
 Additional C-glycosidically linked gilvocarcin-type analogues, the chrysomycins 
(42-44) and the ravidomycins (45-48) were soon isolated from fermentations of S. 
albaduncus AD0819 and S. ravidus (48-50) (Figure 8).  Chrysomycin was originally 
isolated in 1955 by Strelitz et al., however, the structure elucidation of these compounds 
was not conducted until the 1980s (51).  Structure elucidation using 1H-NMR and 13C-
NMR experiments revealed that 42 and 43 shared the same benzo[d]naphtho[1,2-
b]pyran-6-one chromophore as 39, yet differed with respect to the 8-side chain  (vinyl in 
the case of chrysomycin A and methyl in the case of chrysomycin B) (50).  Furthermore, 
the chrysomycins possess a C-glycosidically-linked branched sugar called D-virenose 
(named for virenomycin, which was the name given to these compounds by the Russian 
group who elucidated the structure of the sugar moiety of 42-44) (52).  The ravidomycins 
were elucidated to possess the same chromophore.  However, they possessed an 
aminosugar, D-ravidosamine, C-glycosidically linked at 4-position, with 4’-O-acetyl 
groups present in some of the isolated compounds (48, 53).  Ravidomycin V (RV, 45) 
and chrysomycin A (CV, 42) demonstrated promising antitumor activities, with RV (45) 
and 4’-O-desacetyl RV demonstrating the most potent biological activities against cancer 
cell lines (48) (47).  
The isolation of other related natural products: L-rhamnosylated O-glycosides BE- 
12406A and B (not shown), polycarcin V (53), and C-glycosidically-linked ketopyranose 
and ketofuranose compounds (Mer- 1020 dA-dD, 49-52, respectively) greatly expanded 
the library of known gilvocarcin-type compounds (54-57) (Figure 8). 
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Figure 8  Structures of gilvocarcin-class antitumor antibiotics. 
 Structures of the gilvocarcins (39-41), the chrysomycins (42-44), the ravidomycins (45-
48), and other gilvocarcin-type C-glycosides (49-53). 
 
 Feeding experiments of gilvocarcin V and chrysomycin A with [1-13C] and [2-
13C]acetate  by Takahashi et al.(58) and Carter et al.(59) revealed that 9 aromatic carbons 
were enriched, and feeding with [3-13C] and [2-13C]-labeled propionate revealed that the 
vinyl side chain of gilvocarcin V was the result of incorporation of a propionate starter 
unit.  Labeling with [1,2-13C2]acetate produced the labeling pattern seen in (Figure 9). 
Feeding with [1-13C, 18O2]-labeled acetate by Liu et al. demonstrated that the oxygens at 
C-1, C-10, and C-12 derived from acetate units (Figure 9) (60).  The labeling of C-6 with 
one carbon from labeled acetate presupposes a C-C bond cleavage at carbons C-5 and C-
6 of an angucycline intermediate, in addition to the oxygens at 5 and 6 positions that must 
derive from atmospheric oxygen (60). 
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Figure 9 Gilvocarcin labeling pattern, after incorporation experiments using [1,2-13C2] 
acetate and [1-13C, 18O2]-acetate of gilvocarcin, respectively. 
 
 Subsequently, the entire gilvocarcin biosynthetic gene cluster was cloned from 
genomic DNA of  gilvocarcin-producing Streptomyces griseoflavus Gö 3592 onto a 
single pOJ446-derived E. coli-Streptomyces shuttle cosmid, named cosG9B3 (61).  When 
cosG9B3 was heterologously expressed in host Streptomyces lividans TK 24,  39 and 40 
were produced with yields comparable to wildtype S. griseoflavus Gö 3592 (61).  With 
the entire gilvocarcin gene cluster in hand, gene inactivation experiments of the 
gilvocarcin oxygenases, glycosyltransferase, oxidoreductases, and methyltransferases 
shed considerable light on the order of biosynthetic events for 39 (60, 62-64).  Of 
considerable interest in this biosynthetic pathway are the enzymatic steps necessary to 
generate the oxidative cleavage of the 5,6 bond, the genes encoding NDP-D-fucofuranose 
biosynthesis and attachment, and the enzymes responsible for the installation of the 8-
vinyl side chain (60, 62-64). 
 The biosynthetic pathway of 39 was laid out through bioinformatic analysis of the 
gil gene cluster and inactivation experiments.  GilP and GilQ were identified as 
functional malonyl-CoA and propionyl-CoA acyltransferases for the transfer of starter 
units to the minimal PKS, which consists of GilABC (Figure 10) (65).  Oxoacyl 
ketoreductase GilF presumably reduces the resulting C-9 carbonyl, which is then 
dehydrated to aromatize ring D, then cyclases GilG and GilK aromatize ring C and 
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cyclize rings A and B to afford the first postulated angucycline intermediate of this 
pathway, homo-UWM6 (18) (66).  GilOIV and GilOI were found to encode dual-function 
FAD-dependent monooxygenases/dehydratases, presumably involved in the oxygenation 
cascade (60, 63).   
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Figure 10 Hypothesis for GV (39) biosynthetic pathway. 
Enzymatic transformations are indicated in blue.  Shunt products accumulated in 
indicated G9B3 gene-deletion mutants are depicted in red. 
 
Inactivation of gilOIV in G9B3 resulted in accumulation of rabelomycin (54) and 
homorabelomycin (55) as shunt products, which are not capable of being processed by 
downstream oxygenases (Figure 10).  Rabelomycin (54) and homorabelomycin (55) are  
likely spontaneously oxidized at C-12 to afford the quinone (66).  Inactivation of gilOI 
yielded intermediates 58 and 59, prejadomycins, which are dehydrated across C-2 and C-
3.  This demonstrated that GilOIV likely acts first, dehydrating across the 2-3 bond, 
followed by dehydration by GilOI across the 4a-12b bond to aromatize ring A. 
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Shunt products 56 and 57 suggest a C-5 oxygenation by GilOIV or GilOII, but the 
exact order of oxygenation events is not well understood.  Inactivation of the jadomycin 
A FAD-monooxygenase/dehydratases JadF (GilOIV homologue) and JadH (GilOI 
homologue) gave similar results as the respective GV oxygenase inactivations (63, 67) 
(Figure 10).  JadH was found to complement the cosG9B3-gilOI- strain, and JadF was 
found to complement the cosG9B3-gilOIV- strain to reconstitute 39 production (68).  
These experiments demonstrated that GilOI/GilOIV/GilOII act in a co-dependent, multi-
oxygenase complex as do the jadomycin counterparts JadF/JadH/JadG.  Further evidence 
of JadH/GilOI function was recently provided by Yang et al. to demonstrate that JadH is 
an FAD, NADPH-dependent dehydratase/ oxygenase that dehydrates C-4a, C-12b of 58, 
then acts as a C-12 oxygenase to afford the C-3 methyl homologue of 60 as a shunt 
product (69).  Therefore, it is proposed that GilOI dehydrates C-4a, C-12b 59, then 
oxygenates C-12 to yield the hydroquinone.  Shortly after the first ring is aromatized, it is 
likely that GilOIII hydroxylates at the benzylic position of the 3-propionyl side chain, 
which resultantly undergoes dehydration to afford the vinyl moiety (this is evinced in the 
shunt product vinyl-dehydrorabelomycin, 61) (70).  Subsequent oxygenations by GilOIV 
and/or GilOII result in a Baeyer-Villiger intermediate, which subsequently cleaves the 
5,6 C-C bond, affording an acid and an aldehyde intermediate (as determined by 
pregilvocarcin V, a hemiacetal isolated from the GilR-deleted cosG9B3 strain) (71).  It 
should be noted that an analogous ring-cleaved intermediate is also hypothesized to be an 
intermediate of the jadomycin pathway just before L-isoleucine incorporation (Figure 
11).  In the gilvocarcin pathway, GilM theoretically captures this intermediate and 
methylates at the 7-hydroxyl, effectively steering this pathway away from an 
angucycline-framework towards the gilvocarcin chromophore (Unpublished Results, 
Madan Kharel, Tao Liu).  Further 10-O-methylation by GilMT, C-glycosylation using 
NDP-D-fucofuranose at C-4 by GilGT, and dehydrogenation of the 6-OH by GilR to 
afford the lactone completes biosynthesis of 39 (70-71). 
 Gene disruption experiments of the gilvocarcin biosynthetic pathway have been 
important not only for shedding some light into the sequence of enzymatic steps, but they 
have also resulted in generation of novel gilvocarcin analogues (70-72).  Disruption of 
gilGT led  
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Figure 11 Depiction of oxygenase cascade between UWM6 (18) and Jadomycin A (69). 
 
to the accumulation of defucogilvocarcins E and M (62 and 63), which clearly revealed 
GilGT’s role in C-4 glycosylation with the structurally distinct D-fucofuranose (70).  
Furthermore, the S. lividans (cosG9B3-GilGT-) is an important strain for combinatorial 
biosynthesis involving heterologously expressed C-glycosyltransferases from related 
pathways, such as the chrysomycin pathway.  Also, disruption of 4-ketoreductase GilU 
from NDP-D-fucofuranose biosynthesis resulted in 4’-hydroxy-gilvocarcins, with 
improved bioactivity against cancer cell lines as compared to 39, as well as improved 
solubility due to the additional 4’-OH group (72).  Such a finding reveals unexpected 
substrate flexibility by the sugar ring contraction enzyme and by GilGT towards an 
unnatural NDP-furanose donor substrate.  As a result, the elucidation of biosynthetic gene 
clusters of related gilvocarcin-type antibiotics, e.g. chrysomycin and ravidomycin, is not 
only an important exercise for understanding the role of uncharacterized gil genes 
(gilLMN), but it can yield valuable tools for recombining genes to generate novel 
gilvocarcins. 
 
Introduction to Mithramycin (MTM) Biosynthesis 
 Mithramycin (MTM) (70) is a representative member of the aureolic acid family 
of antineoplastic antibiotics (Figure 12).  It is accumulated in strains of Streptomyces 
plicatus and Streptomyces argillaceus.  Aureolic acid antibiotics are named after their 
yellow color (Latin, aurum= gold), and they are distinguished by their many saccharidal 
chains O-glycosidically linked at 2-position and 6-position, as well as the highly oxidized 
pentyl side chain at 3-position (Figure 12) (73-74).  The other representative members, 
chromomycin A3, UCH9, durhamycin A, olivomycin A all possess the highly oxidized 3-
aliphatic side chain, but differ with respect to the nature of the sugars, the nature of their 
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linkage, and the degree of O-methylation or O-acetylation of the various sugar residues, 
or in the case of durhamycin A, C-acylation at C-7 position (75-77). 
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Figure 12 Mithramycin A (70) and structures of related aureolic acid antibiotics (71-75). 
 
Mithramycin was discovered by Grundy et al. in 1953, and its structure was subsequently 
revised several times with regard to the linkage of the trisaccharide chain and the 
stereochemistry of the sugars; ultimately, Rohr et al. confirmed the structure as being 70 
using 2D NMR spectroscopic methods (78).  Mithramycin has been employed in the 
treatment of Paget’s bone disease, testicular carcinomas, and hypercalcemia (79-85).  
Mithramycin’s mode of action is that it binds to the GC-rich minor groove of 
protooncogenic regions, such as c-myc, c-src, and other Sp1-dependent pathways in a 
homodimer, coordinated head to tail with another molecule of 70 by an Mg2+ cation (86-
88).  However, despite its promising activity, prolonged mithramycin treatment is not 
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well-tolerated.  It has major cytotoxic side effects, including bone marrow, hepatic, and 
kidney cytotoxicities (89).  Additional biological activities for the aureolic acid family 
include nanomolar HIV Tat protein inhibition by durhamycin A, and mithramycin has 
potential Sp1-dependent therapeutic value in treating Alzheimer’s disease and 
Huntington’s disease (90-94). 
 The biosynthesis of mithramycin (70) has been studied extensively by the Salas 
and Rohr groups during the 2000s, and the functions of most of the candidate enzymes 
were identified through gene disruption experiments (23-24, 89, 95-108) (Figure 13).  
Inactivation of the mtmPKS genes led to a nonproducing mithramycin mutant, and 
inactivation of monooxygenase MtmOII lead to an improperly cyclized shunt product, 
premithramycinone G (87, Figure 14) (24, 106, 108).  This latter observation caused re-
envisioning of the early mithramycin cyclization steps as going through a putative 
tricyclic intermediate, which would be oxygenated by MtmOI and/or MtmOII, then 
cyclized to yield the first tetracyclic premithramycin compound in the pathway, 4-
demethylpremithramycinone (17) (23-24, 101).  Subsequent 4-O-methylation by MtmMI 
leads to premithramycinone (27), which was accumulated by the S. argillaceus 
(MtmGIV-) (100).  Subsequent glycosylation of the first D-olivose by MtmGIV 
(premithramycin A1, 76), and the second sugar of the trisaccharide D-oliose by MtmGIII 
(premithramycin A2, 77) were revealed through inactivation of both mtmGIV and 
mtmGIII in S. argillaceus, respectively (100).  However, as there are five deoxysugars in 
biosynthesis of 70, and only four glycosyltransferases, either MtmGIV or MtmGIII were 
anticipated to be responsible for transfer of the third sugar of the trisaccharide chain, D-
mycarose, with MtmGIV being the preferred candidate for this dual action (100).  
Individual inactivation experiments of mtmGI and mtmGII , and cross-feeding of 79 into 
both the S. argillaceus (MtmGI-) and S. argillaceus (MtmGII-) revealed that MtmGI is 
responsible for attaching the first D-olivose to the 6-O position and then MtmGII O-
glycosidically links the last D-olivose to the 3A-O position of 79 to yield the fully-
glycosylated premithramycin B 80 (96, 105).  Premithramycin B was determined to be 
the substrate for a novel Baeyer-Villiger monooxygenase, MtmOIV, and this enzyme has 
been crystallized and modeled to identify the active site residues necessary for catalyzing 
ring cleavage of 80 to 81 (95, 103, 109-110) .  This is perhaps the single most important 
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unifying step for this biosynthesis, because MtmOIV acts as a “gatekeeper” that 
necessarily allows for generation of active mithramycin molecules (tricyclic with highly 
functionalized aliphatic side chain branching from C-3) from inactive premithramycin 
molecules (tetracyclic) (95).  Finally, MtmW captures the labile mithramycin β-diketone 
intermediate, and reduces the 4’-ketone to afford 70. 
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Figure 13 Biosynthetic pathway of Mithramycin (70). 
Highlights include individual glycosylation steps catalyzed by MtmGI, MtmGII, 
MtmGIII, and MtmGIV, and Baeyer-Villiger-oxidative cleavage by MtmOIV, and final 
reduction by associated ketoreductase MtmW.  
 
 Combinatorial biosynthesis of the mithramycin pathway has been an invaluable 
tool for generating novel premithramycin and mithramycin analogues shown in Figure 
14 (23, 89, 96-98, 100, 103, 105, 109, 111-113).  Inactivation experiments of the various 
glycosyltransferases have generated premithramycins with different lengths of 
saccharidal chains (76-80).  Inactivation experiments of the various methyltransferase 
genes (mtmMII, mtmMI, mtmC) have resulted in a 7-demethylmithramycin analogue (82), 
4-demethylpremithramycinone (17), and inactivation of the mtmC and mtmTIII genes has 
resulted in isolation and characterization of novel ketopremithramycins and 
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ketomithramycins (83-86), respectively.  Recombination with glycosyltransferase 
urdGT2 and lanGT4 from the urdamycin and landomycin pathways, respectively, 
resulted in novel premithramycin 7-C-glycosides (88-92) (113).  Furthermore, 
recombination with deoxysugar biosynthetic genes from heterologous hosts has resulted 
in many novel mithramycin-type molecules with altered saccharidal moieties (e.g. 93) 
(111-112) (Figure 14).  Therefore, combinatorial biosynthesis remains the best 
methodology for generating novel mithramycins.  Synthetic approaches towards total 
synthesis of aureolic acids have proven to be step-intensive and difficult with respect to 
maintaining stereochemical control.  For example, Roush et al. have synthesized the 
tetrasaccharide and the chromophore of durhamycin A, the latter being composed of >13 
synthetic steps (77, 114).  In contrast, the problems of stereochemical control and poor 
step economy are more readily overcome with combinatorial biosynthesis.  
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Figure 14 Premithramycins and mithramycins previously generated by combinatorial 
biosynthesis. 
 
 
SPECIFIC AIMS 
 
Combinatorial biosynthesis has emerged as a key strategy for generating novel 
derivatives of complex natural products, particularly with regards to modification of post-
polyketide tailoring steps.  Over the last few years, significant illumination into the 
biosynthesis of the gilvocarcins and jadomycins has been accomplished through the 
cloning and genetic investigation of these pathways, yet some enzymes of these pathways 
remain enigmatic.  In the spirit of furthering knowledge about the biosynthesis of these 
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clinically promising molecules, this present research is conducted to clone the gene 
cluster for the related benzo[d]naphtho[1,2-b]pyran-6-one C-glycoside antibiotic 
chrysomycin A.  Furthermore, characterization of this gene cluster is conducted with an 
emphasis on the monooxygenase enzymes and the deoxysugar tailoring enzymes for 
generation of NDP-D-virenose.  Another purpose of this work is to generate novel 
tetracenomycin and aureolic acid derivatives with altered glycosylation patterns using 
combinatorial biosynthesis.  For this, cloning of novel deoxysugar-biosynthesizing 
cassettes and introduction of these plasmids into producing strains was conducted.  
Resulting metabolites were isolated, and their structures were determined in order to 
draw conclusions about the substrate flexibility of the endogenous glycosyltransferases. 
 
Specific Aim 1:  To clone and analyze the entire chrysomycin A biosynthetic gene 
cluster.  To prove its functional role in chrysomycin biosynthesis experiments by cross-
complementing chrysomycin monooxygenases in gilvocarcin-oxygenase deficient 
mutants. 
 
The cloning of entire Streptomyces sp. biosynthetic gene clusters was possible using 
cosmid vectors, which can often contain 30-40kb of genomic DNA.  Using the cloning of 
the gilvocarcin biosynthetic gene cluster as a template for this study, the complete 
chrysomycin gene cluster was cloned on one or more cosmids, probed, and sequenced. 
The sequencing of this cluster gave valuable information about the shared enzymes 
between these pathways and their shared roles in 39 and 42-43 biosynthesis.  
Furthermore, the identification of novel enzymes responsible for biosynthesis and 
attachment of NDP-D-virenose will be useful for heterologous expression of these 
enzymatic components in other producing organisms.  Cross-complementation of the 
oxygenases from this cluster into the respective blocked mutants of the gilvocarcin 
pathway can prove the role of this biosynthetic locus in production of chrysomycin.  This 
aim will be discussed in chapter 2. 
 
Specific Aim 2:  To investigate the potential role of enzymes in D-fucofuranose ring 
contraction in biosynthesis of gilvocarcin V.  Structure elucidation of the metabolites 
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accumulated in this strain will give valuable analysis about its role.  Furthermore, this 
information will be used to clone constructs for the biosynthesis of NDP-D-virenose and 
NDP-D-fucofuranose in vivo. 
 
Recombination of deoxysugar biosynthetic genes is one effective means of exploiting 
endogenous glycosyltransferase donor substrate flexibility.  Inactivation of the putative 
glycosyltransferase GilN proved that it plays no role in NDP-D-fucofuranose 
biosynthesis.  This finding was an important step towards identifying the enzyme 
responsible for furanose ring contraction.  Furthermore, plasmids directing the 
biosynthesis of NDP-D-virenose and NDP-D-fucofuranose and their biosynthetic 
intermediates were cloned for heterologous expression and interrogation of endogenous 
glycosyltransferases from other pathways.  These aims will be discussed in chapter 3. 
 
Specific Aim 3:  To interrogate the substrate flexibility of the glycosyltransferase, 
ElmGT, towards a variety of deoxysugar donor substrates. Various constructs directing 
the biosynthesis of novel deoxysugars will be transformed into a recombinant strain 
harboring the genes for 8-demethyl-tetracenomycin C biosynthesis and the sugar donor 
flexible glycosyltransferase, ElmGT. 
 
The substrate flexibility of glycosyltransferases is one important factor in generating 
novel derivatives with altered glycosylation patterns.  Another factor is the introduction 
of recombinant plasmids that direct biosynthesis of novel deoxysugars, which are not 
present in a producing organism.  For this, a recombinant strain, namely S. lividans 
(cos16F4), which harbors the biosynthetic genes for the production of 8-demethyl-
tetracenomycin C and the sugar flexible glycosyltransferase, ElmGT, will be used as an 
expression host.  Glycodiversification studies will further clarify the substrate flexibility 
of ElmGT and the role of these cassettes in biosynthesizing various NDP-deoxysugars.  
These aims will be discussed in Chapter 4. 
 
Specific Aim 4:  To generate novel mithramycin derivatives with altered glyosylation 
patterns.     
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The mithramycin biosynthetic pathway of Streptomyces argillaceus has five 
glycosyltransfer steps and four glycosyltransferases, which presents an excellent system 
for glycodiversification experiments involving novel deoxysugar plasmids.  For this, 
plasmids directing the biosynthesis of various deoxysugar cassettes will be 
heterologously introduced into Streptomyces argillaceus and several blocked mutants 
using protoplast transformation.  Any accumulated novel mithramycin derivatives were 
structurally elucidated to yield important compounds for biological testing.  These 
objectives will be discussed in Chapter 5. 
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CHAPTER 2: ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN 
BIOSYNTHETIC GENE CLUSTER 
 
INTRODUCTION 
 
Previous isolation of benzo[d]naphtho[1,2-b]pyran-6-one C-glycoside antibiotics 
 
The chrysomycins (42 and 43) were historically the first gilvocarcin-type C-
glycosides isolated, by Strelitz and Flonne in 1955 (51), though their structures were not 
determined, and only published in the 1980s by Weiss et al. (50).   The initial structure 
determination of the sugar moiety of 42 and 43 by Weiss et al. was suggested to have a 
1C4 configuration.  However, their assignments were based on relative stereochemistry 
assigned by coupling constants.  Brazhnikova et al. isolated the sugar component of 42 
and 43 (their group had referred to it as virenomycin) through methanolysis and 1D- and 
2D-NMR analysis of the sugar moiety identified it to be methyl-β-D-virenoside, thereby 
disproving the 1C4 configuration suggested by Weiss et al. (52) 
 
Biological activity of chrysomycin A 
 
 The antitumor activity of chrysomycin A was established in a murine P 388 
lymphocytic leukemia cell line (50).  Chrysomycin A protected the mice with an 
increased lifespan of 54% compared to control mice.  As such, the antitumor activity of 
chrysomycin A was established as being very similar to gilvocarcin V in this cell line 
(57% increased life span and LD50 at doses greater than 1 g/kg), while exhibiting no 
lethal effects at the dose administered (50).  Photoactivation studies confirmed the role of 
the 8-vinyl side-chain of 42 DNA-binding using a [2+2] cycloaddition to thymine 
residues (115-116).  Studies on the crosslinking of histone H3(116) suggest an important 
role for the binding of the C-glycoside moiety to this densely positively-charged protein 
(117).  Matson et al. reached the same conclusions about the activity of chrysomycin A, 
while suggesting that another factor of its binding, other than photoactivation of the 8-
vinyl side, was responsible for the binding of chrysomycin A to DNA (118).  Structure-
activity relationships by the Mercian company on the 4-keto-D-virenose derivative 51 
showed that this derivative has improved activity in solid tumor cell lines over 42, an 
observation only attributable to the presence of a ketosugar.   
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Rationale for cloning chrysomycin A biosynthetic gene cluster 
 
Previous work on the gilvocarcin biosynthetic gene cluster was paramount for 
development of a coherent biosynthetic pathway and for generation of novel derivatives 
through inactivation experiments and glycodiversification experiments (72, 119).  
Therefore, cloning of the chrysomycin A gene cluster will be important for expanding the 
combinatorial biosynthetic toolbox with NDP-D-virenose biosynthetic genes.  
Furthermore, because chrysomycin A possesses a pyranose C-glycosidic moiety 
compared to the furanose moiety of gilvocarcin, the C-glycosyltransferase responsible for 
attachment of NDP-D-virenose to the polyketide acceptor substrate is valuable for 
interrogation of other pyranose substrates.  As it is anticipated that 39 and 42 share 
identical biosynthetic steps towards the generation of the gilvocarcin-type chromophore, 
the chry cluster should possess a homologous set of genes to the characterized gil gene 
cluster. Additionally, direct comparison of the genes present in the chrysomycin A gene 
cluster with those that are present in the gilvocarcin gene cluster as well as the gene 
cluster of the ravidomycins, will possibly illuminate the roles of some still unknown 
gilvocarcin biosynthetic enzymes, among these are gilLMNV.   
 
RESULTS AND DISCUSSION 
 
Construction of cosmid library for S. albaduncus AD819 
 
A library screening approach was envisioned for the isolation and sequencing of 
cosmid DNA pertinent to the biosynthesis of chrysomycin.  Cosmid vector pOJ446 was 
selected as the cosmid cloning vector for this (previously used for cloning of the 
gilvocarcin gene cluster) (61).  The vector pOJ446 possesses several useful features: its 
cos sites allow for packaging 35-40 kilobase pair fragments of genomic DNA; it 
possesses origins of replication for cloning in both E. coli and Streptomyces sp. (SCP2*). 
It also has an oriT site for conjugal transfer into Streptomyces sp. hosts.  For this, a 
cosmid library of Streptomyces albaduncus AD819 was generated by ligating partially-
digested Sau3AI fragments of genomic DNA into pOJ446, prepared with HpaI/BamHI 
(3).   The evaluation of the amount of the genome that is covered in the cosmid library 
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can be modeled using a mathematical equation.  This equation factors the average size of 
genomic DNA inserted into a single plasmid, the number of E. coli colonies transformed 
with cosmids harboring genomic DNA, and the size of the genome.  To calculate the total 
coverage of the cosmid library, the following equation was used: 
N=log(1-fc) / log(1-L/G) 
Where N= the total number of clones, fc is the fractional coverage of the genome, L is the 
length of genomic DNA present in each cosmid clone, and G is equal to the total length 
of the genome (3).  G for the total genomic length of Streptomyces albaduncus is 
approximated by comparing the lengths of the characterized Streptomyces lividans TK 66 
(NCBI data) (8,318,010 bp) and Streptomyces coelicolor A3(2) (8,667,507 bp) genomes, 
or about 8,500,000 bp (120).   Fc is usually calculated to be >95% coverage of a genome, 
and L was determined by restriction analysis of ten random cosmids from the titering 
reaction (Figure 15).  This analysis indicated that an average insert size of ~38 kb was 
present in the cosmids so digested.  Therefore, approximately 670 unique colonies from a 
titering reaction would be required for >95% coverage.  The resulting number of colonies 
from titering was 2300 colonies, which is roughly ~4x the theoretical coverage of the 
entire S. albaduncus genome. 
 
Positive hybridization of probes of NDP-glucose-4,6-dehydratase, 3-oxoacyl-acyl 
carrier protein-reductase (chryF), and Ketoacyl synthase (KSα) cosmid DNA 
 
For the isolation of cosmids pertinent to chrysomycin biosynthesis, two DNA 
fragments were designed for probing the genomic library corresponding to genes that 
were theorized to be a part of the gene cluster of 42.  Two degenerate fragments 
corresponding to conserved regions of β-ketoacyl synthase (KSα) and NDP-4,6-
dehydratase were synthesized (38, 61, 121).  KSα is an essential component of the 
“minimal polyketide synthase” responsible for polymerizing additional acetate units to a 
growing poly-β-ketothioester (Figure 10).  NDP-4,6-dehydratase is an essential early-
acting deoxysugar enzyme (Figure 7). Such an approach of using two probes increases 
the chances of finding clusters that are pertinent to chrysomycin biosynthesis, because 
deoxysugar biosynthetic genes and polyketide synthase genes were expected to be 
clustered together.  Furthermore, polyketide gene clusters are fairly ubiquitous among 
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streptomycetes, and screening with a single KSα probe may uncover multiple polyketide 
gene clusters from S. albaduncus.  For example, in the chartreusin biosynthetic pathway, 
cosmids positively hybridizing to PKS probes were isolated from at least 3 different 
PKS-encoding pathways (122).  
It was necessary to design a second NDP-4,6-dehydratase probe than the one used 
by Bechthold et al. upon discovering a conserved downstream region (e.g. reverse primer 
synthesized from BEWLHVDDHC region) that is absolutely conserved among 4,6-
dehydratases.  Colony hybridization with the two digoxigenin (DIG)- labeled probes 
(~650 basepair KSα probe and ~600  basepair 4,6 dehyratase probe) resulted in colonies 
that hybridized with both the KSα and the NDP-4,6-dehydratase probe (Figure 15).  One 
of these cosmids, namely cosChry1-1, was chosen for Southern Blot analysis and shotgun 
sequencing. 
After sequencing revealed that cosChry1-1 was lacking a polyketide-associated 
ketoreductase, a “gilF” candidate gene essential for biosynthesis of the polyketide, a third 
DIG-labeled-probe based on conserved amino acid residues for 3-oxoacyl-ACP-
reductases was generated.  A second round of colony hybridization resulted in 3 more 
colonies that positively hybridized to the chryF probe.  The cosmids isolated from these 
colonies were called cosChryF1, cosChryF2, and cosChryF3, because they each harbored 
the putative chryF gene. 
 
Southern blot studies of cosChry1-1, cosChryF1, cosChryF2, cosChryF3 
 
CosChry1-1 was digested with BamHI and was hybridized with both DIG-labeled 
KSα and NDP-4,6-dehydratase probes (Figure 16).  The Southern Blot of BamHI-
digested cosChry1-1 indicated positive binding of the KSα probe to a 7.0 kilobase pair 
region, and the NDP-4,6-dehydratase probe was confirmed to bind to a ~7.8 kilobase pair 
fragment.  Therefore, cosChry1-1 was confirmed to contain both the putative KSα and 
4,6-dehydratase genes necessary for chrysomycin biosynthesis clustered together on the 
same cosmid.  As a result, cosChry1-1 was used for further “shotgun” sequencing 
experiments. 
It was necessary to confirm the presence of chryF in each of the three cosmids 
identified by colony hybridization.  Therefore, each of the three cosmids were digested 
33 
 
with BamHI and were hybridized with the DIG-labeled chryF probe (Figure 16).  In all 
three cases, chryF was found to strongly hybridize with a ~4 kilobase pair region on the 
cosmids.  An additional PCR experiment using the KSα primers amplified the expected 
KSα fragment from each cosmid, confirming that the chryF and the putative β-ketoacyl 
synthase genes were clustered together on each of cosChryF1, cosChryF2, cosChryF3.   
 
Figure 15 Amplification of probes and colony hybridization. 
(Upper Left) 0.7% agarose gel of KSα probe and NDP-4,6-dehydratase probe (Upper 
Middle).  (Upper Right) BamHI digest of 7 randomly selected cosmids to determine size 
of inserts from restriction analysis. (Bottom) Plaques from colony hybridizations with 
DIG-labeled KSα and 4,6-dehydratase probes.  Darkest colonies are clones that are 
positively hybridizing. 
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Figure 16 Southern blot studies of chry cosmids. 
(Upper Row) Southern blots of selected BamHI digested cosmids with DIG-labeled KSα 
and NDP-4,6-dehydratase probes, respectively.  (Lower Left)  Southern blot of DIG-
labeled chryF with BamHI-digested cosChryF1, cosChryF2, cosChryF3 on left and 
cosChryF1, cosChryF2, cosChryF3 digested with PstI on the right.  (Lower Right) 
Amplification of chryA (0.65 kb) from cosChryF1, cosChryF2, cosChryF3. 
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Shotgun sequencing of cosChry1-1, primer walking of cosChryF1-cosChryF3, 
subcloning of chryF fragment 
 
CosChry1-1 was shotgun sequenced using a Mu transposon-based insert to allow 
for generation of short (800 bp-1000 bp) reads by a sequencer (HyperMu Transposase, 
Materials and Methods) (123-124).  The resulting short reads were combined by the 
Phred/Phraps/Consed software package, which was used to generate contiguous sequence 
reads (contigs).  From this sequencing, three contiguous regions of ~8 kilobases, ~12 
kilobases, and ~13 kilobases were generated.  To sequence the overlapping regions of 
these contigs, subcloning experiments of cosChry1-1 were undertaken.  CosChry1-1 was 
digested with BamHI, and two resulting fragments of ~7.8 kilobases and 3 kilobases were 
rescued and cloned into the same sites of pBluescript II K/S+, and these resulting 
constructs (pBS7PQ and pBS3U, respectively) were used for primer walking.  An 80 
basepair overlap of pBS7PQ between chryQ and chryX1 revealed one connection, and the 
other came from sequencing pBS3U from the 5’-end of chryU to the 3’-end of chryRM.  
To sequence chryF, a ~4kb BamHI fragment was subcloned into the same 
restriction sites of pBluescript II K/S+ to give pBS4F, which was primer walked outward 
from the center of chryF (this sequence being provided by sequencing the chryF probe in 
a pGEM-T vector) until arriving at known sequence from cosChry1-1.  A combination of 
primer walking and subcloning revealed the upstream chryF-containing region and 
connected it with known chryOI ORF from the cosChry1-1 shotgun sequencing 
experiments.  The sequencing of the upstream region was stopped when all genes 
necessary for biosynthesis of 42 were determined (based on direct comparison with the 
GV gene cluster).  A further sequencing of 1000 base pairs revealed ORFs whose 
encoded proteins seemed to be irrelevant for biosynthesis of 42, and were likely involved 
in primary metabolism, which effectively bounded the upstream region of the cluster.  
 
Bioinformatics analysis of DNA 
 
The resulting sequence reads were analyzed via the FramePlot and NCBI BLAST 
databases for the determination of discrete open reading frames (ORFs) and assignment 
of putative functions to chry genes from similarity searches (Materials and Methods).  
ORFs were also judged to possess a relatively high percentage of GC bases in the wobble 
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base position of their codons.  Streptomyces sp. genes are characterized by a relatively 
high percentage of guanines and cytosines (high GC %) residing in the third base pair, or 
wobble base pair, of codons.  As a result, analysis of the 34,654 nucleotide sequence 
resulted in 35 open reading frames that were identified for genes putatively responsible 
for biosynthesis of 42, self-defense from chrysomycin, regulation of the pathway, or 
constituted genes whose encoded protein products were of unknown function (chryLV).  
Prospective gene candidates were named according to their gil cluster homologues.  
Therefore, the nomenclature of the chry cluster reflects the precedence of the gilvocarcin 
gene cluster and the similarities between their biosynthetic components.  A table of ORFs 
and proposed functions of encoded enzymes is included in Figure 20.  The complete chry 
cluster nucleotide sequence is assigned the NCBI Accession No. FN565166. 
 
OI G C1 K OIV A B C OIII Y P Q X1 X2 E D
J X3 GT MT OII RM U CMT X4 L X5 X6 X7 X8 X9
HVFX
0 6 9 12 153
21 24 27 30 33.0  (Kb)18 34.7  (Kb)
chry
 
 
Figure 17 Map of the chry cluster using arrows to indicate direction of candidate ORFs. 
Polyketide biosynthesis enzymes depicted in Black, deoxysugar biosynthetic and 
glycosyltransferase enzymes are Green, monooxygenases are Red, enzymes involved in 
regulation or export of CV are Grey, polyketide O-methyltransferase in Light Blue, and 
putative ORFs encoding proteins of unknown function are White. 
 
Minimal ‘PKS’ genes and genes implicated in polyketide cyclization, 
ketoreduction, aromatization 
 
The minimal polyketide synthase, consisting of chryABC, is clustered towards the 
upstream region of the chry cluster, near the polyketide cyclases chryGK and the PKS-
associated ketoreductase, chryF (Figure 17).  ChryABC are translationally-coupled with 
one another, which is a common feature of type-II polyketide synthase genes.  ChryA 
encodes the ketoacyl synthase for chrysomycin biosynthesis; its protein product consists 
of 422 amino acids, and demonstrates strong sequence identity and similarity to other 
known ketoacyl synthases (KSα).  It particularly exhibits strong sequence similarity to 
the Streptomyces ravidus RavA KSα protein (423 amino acids, 90% identity/94% 
similarity) and the S. fradiae UrdA KSα protein (426 aa, 80% identity, 88% similarity).  
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It has a KAS type I-II domain, a FabF domain, a putative dimer interface for interaction 
with ChryB, and a putative conserved catalytic cysteine residue, C169 (16).  ChryB, the 
chain length determinant-encoding gene (KSβ), encodes a 402 amino acid chain length 
determinant, which forms a heteromeric complex with ChryA.  ChryB demonstrates 
similarity to known type II KSβ proteins (71%/83% with UrdB, 51%/67% GilB, 
77%/85% RavB).  ChryC encodes the PKS-associated acyl carrier protein (ACP) of the 
“minimal” PKS.  The 87 amino acid product bears similarity to the ACPs of the 
jadomycin and ravidomycin pathways (JadC 61%/71%, RavC 79/84%).   
Amazingly, the chry cluster possesses another ACP homologue, namely chryC1, 
which is transcribed in the same direction as and is between the cyclases chryGK.  
ChryC1 possesses strongest sequence similarity with acyl carrier proteins RavC1 
(71%/81%) and SimA3 from S. antibioticus (59%/72%).  It is unclear what role a second 
ACP has in the chry cluster, however, it may be used for extending the polyketide chain 
with either the malonate or propionate starter unit selectively.  Because chrysomycin 
biosynthesis involves both malonate and propionate starter units, the presence of two 
ACPs might help steer the pathway towards production of either 42 or 43.  However, 
Shepherd et al. have shown that sister protein RavC1 loads both propionyl-CoA and 
malonyl-CoA comparably (65).  The chry and rav gene clusters represent an anomaly in 
type II polyketide biosynthesis encoding two functional acyl carrier proteins in the same 
gene cluster (65). Only in a couple other type II PKS gene clusters have two encoded 
ACPs been found clustered together- the frenolicin and R1128 clusters (65).  Therefore, it 
is possible that ChryC1 is an ancillary ACP that assists in extending the growing 
polyketide chain along with ChryC.  ChryP (protein product is 322 amino acids) and 
chryQ (protein product is 327 amino acids) encode a malonyl-CoA acyltransferase 
(MCAT) and a propionyl-CoA acyltransferase, respectively.  The gil biosynthetic 
machinery also possesses a homologous pair of MCAT and propionyl-CoA 
acyltransferase enzymes, GilP and GilQ, respectively, however, MCATs can also be 
recruited from the fatty acid biosynthesis (18).  A BLAST database search of ChryP 
reveals sequence similarity to MCATs from other type II PKS pathways (PgaH 
50%/64%).  ChryQ resembles the closely related RavQ propionyl-CoA acyltransferase 
from the rav gene cluster (65%/72%). 
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ChryF encodes the putative polyketide-associated ketoreductase (261 aa) 
necessary for ketoreduction at the C-9 carbonyl of the polyketide chain (Figure 18).  It 
has significant similarity to known oxoacyl-ACP-ketoreductases RavF (86%/92%) and 
Orf7 from S. echinatus (72%/84%).  Interestingly, chryF is in stand alone at the 
beginning of the chry cluster (Figure 17), whereas in the gil cluster gilF is transcribed 
directly after the gilvocarcin minimal polyketide synthase, gilABC, reflecting the intimate 
nature of its interaction with GilABC.  However, clustering of chryF with the minimal 
PKS genes is not an absolute requirement.  The cyclases-encoding genes chryGK are 
immediately upstream of chryOIV and chryABC (Figure 17). ChryG (109 aa) and chryK 
(314 aa) encode the cyclases responsible for installing the angucycline framework of CV.  
ChryG (OvmC- 71%/84%, UrdF 74%/84%) exhibits strong similarity to other 
angucycline-type C4-C17 cyclases, and ChryK exhibits similarity to bifunctional 
dehydratases/cyclases (RavK 72%/81%, SaqL 61%/72%).  In theory, ChryK acts first, 
dehydrating the C-9 position, which results in spontaneous aromatization of the first ring 
and cyclization of the second ring, and cyclase ChryG acts next, cyclizing the third ring 
and performing C4-C17 angular cyclization of ring A of homo-UWM6 (18) (Figure 18). 
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Figure 18 Proposed biosynthetic pathway to chrysomycin A and B (42 and 43). 
Transformations catalyzed by chry enzymes are indicated in blue. 
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Oxygenases, oxidoreductase, and methyltransferase genes 
 
The oxygenases of the chry cluster are integral for the transformations that result 
in 18 being rearranged into the distinctive gilvocarcin-chromophore (Figure 18).  Four 
oxygenase encoding genes were identified in the chry cluster, which is in agreement with 
a complement of four oxygenases being required for biosynthesis of GV (Figure 10) (60, 
62, 68-69).  ChryOI, chryOII, chryOIII, and chryOIV encode the four monooxygenase 
homologues so identified in this gene cluster.  ChryOIV and chryOI encode putative 
FAD-dependent oxygenases.  Furthermore, their products ChryOIV (491 aa) and ChryOI 
(513 aa) demonstrate sequence similarity with one another (46%/55%), which is also the 
case with FAD-dependent monooxygenase pairs JadF/H and GilOIV/OI from the 
jadomycin and gilvocarcin pathways, respectively.  The product of chryOIV demonstrates 
sequence similarity to GilOIV (36%/48%) and JadF (55%/63%), which are known to 
catalyze the 2,3-dehydration step of homo-UWM6 (Figure 18).  ChryOIV is also 
believed to play a vital role in the installation of a 5-OH, which in a presently unclear and 
perhaps concerted manner with ChryOII, undergoes a Baeyer-Villiger oxidative cleavage 
of a hypothetical intermediate to afford a ring-opened acid/aldehyde compound (Figure 
18). The encoded product of chryOI demonstrates sequence similarity to JadH 
(60%/69%) and GilOI (43%/55%), which has been shown to catalyze the 4a, 12b- 
dehydration of 2,3-dehydro-homo-UWM6 (59).  Furthermore, it is proposed that ChryOI 
installs a 12-hydroxyl moiety to afford a hydroquinone, which Chen et al. refer to as CR1 
(69).  However, this compound rapidly oxidizes to the dehydrorabelomycins (60 and 61, 
Figure 10).   
ChryOIII encodes a P450 monooxygenase responsible for installation of the 8-
vinyl side chain of 42.  The encoded product (394 aa) has considerable sequence 
similarity to P450 monooxygenases from other pathways, including GilOIII (72%/81%).  
It is believed that as soon as the A ring is fully aromatized and either just before or after 
12-hydroxylation that ChryOIII acts as to install the 3-vinyl side chain (Figure 18).  
ChryY encodes a ferredoxin accessory protein just downstream of chryOIII: P450 
monooxygenases utilize either their own ferredoxin accessory protein, or recruit 
ferredoxin from the electron transport chain.  It is unclear by what mechanism the 3-vinyl 
side chain is installed.  However, by employing chemical logic, ChryOIII could install a 
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hydroxyl group on the 1” benzylic position of the 3-ethyl group.  This hydroxyl group 
could be potentially installed via a radical mechanism, for example.  Once the hydroxyl 
moiety has been installed, a facile dehydration would afford the vinyl side chain that 
serves as the warhead for chrysomycin’s biological activity.   
ChryOII encodes a putative anthrone monooxygenase that initially was 
hypothesized to catalyze 12-hydroxylation.  It demonstrates similarity to other putative 
anthrone monooxygenases (JadG 53%/71%, GilOII 65%/76%).  However, JadH has been 
shown to catalyze this 12-hydroxylation, and furthermore, the absence of 12-
hydroxylated shunt products in the GilOI- and JadH-deleted strains indicate that ChryOI 
probably catalyzes a similar step in the biosynthesis of 42 (60, 69).  However, C-12 
hydroxylation could also occur spontaneously as a shunt process, as in the case of 
rabelomycin.  This assignment is purely suppositional, and the assignment of GilOII-type 
cofactorless monooxygenases as anthrone monooxygenases may just reflect that little is 
known about this intriguing class of oxygenases.    It is more likely that C-12 
hydroxylation occurs during an oxygenase cascade in a concerted and mechanistically-
controlled fashion after ring A aromatization, thereby affording a hydroquinone 
intermediate (Figure 18).  Therefore, ChryOII might be responsible for the C5-C6 
carbon-carbon bond cleavage reaction, perhaps as a novel Baeyer-Villiger (BVMO) type 
reaction (Figure 19).  It may act in a concerted fashion with ChryOIV to generate the 
acid-aldehyde ring-opened intermediate.  Furthermore, BLAST analysis suggests that 
ChryOII has a conserved histidine, H185 that is in common with the larger antibiotic 
monooxygenase superfamily.  It is possible that this residue may be involved in the ring 
cleavage reaction; this H185 is absolutely conserved in JadG/GilOII/RavOII as well.  To 
prove this hypothesis, in theory a simple mutagenesis experiment of ChryOII H185 to 
alanine could confirm this catalytic role.  For example, the vancomycin dioxygenase 
DpgC involves conversion of 3,5-dihydroxyphenylacetyl coenzyme A to 3,5-
dihydroxyphenylglyoxylate using a single-electron transfer mechanism from the substrate 
to one oxygen of diatomic oxygen (125).  Therefore, it could be proposed that H185 
serves as a conserved base in ChryOII for abstraction of a proton from C5, which allows 
for subsequent attack of the substrate onto diatomic oxygen (Figure 19).  The following 
mechanism can either follow a BVMO route (A) or proceed via a dioxetane route (B) 
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(Figure 19), as was suggested by the DpgC crystal structure (125).  The BVMO route 
(A) proposes oxygenation at C5 by ChryOII, reduction catalyzed by an unknown enzyme, 
and oxygenation by ChryOIV.  One of the mechanistic limitations of this route is the 
requirement for another reduction event.  The dioxetane route (B), however, generates a 
dioxetane intermediate and subsequent rearrangement affords the acid and aldehyde.  
However, one limitation of this route (B) is that ChryOIV only serves as the 2,3-
dehydratase in this pathway and has no oxygenase function.  This route may be supported 
by inactivation experiments, however, because in the S. lividans (cosG9B3-GilOIV-) 
mutant production spectrum, a small amount of gilvocarcin M is produced along with the 
major products of rabelomycin and homorabelomycin (Madan Kharel, unpublished 
results), only using GilOI and GilOII.  Therefore, in the absence of GilOIV, GilOI may 
possess slight flexibility towards UWM6 (18) enough to catalyze both the 2,3-
dehydrations and 4a-12b dehydrations, which then allows for GilOII to perform the 
dioxygenase reaction in the absence of GilOIV, resulting in the accumulation of small 
amounts of GM.  Additionally, it is interesting to note that upon feeding 
dehydrorabelomycin (3-methyl congener of 60) to a PKS-deficient mutant strain of S. 
venezuelae that both CR1 and dehydrorabelomycin were both fully-converted to 
jadomycin A, whereas feeding of 60 to the S. lividans (cosG9B3-gilOIV-) strain did not 
result in conversion to 39 (68).  Cross-complementation of the jadG gene into the GilOII-
deleted mutant failed to complement the pathway and restore production of 39.  As a 
result, GilOII/ChryOII and JadG may bind different pathway molecules, in the case of the 
gilvocarcins and chrysomycins, a hydroquinone. 
ChryMT encodes a putative 340 amino acid protein that serves in O-methylation 
of the chromophore of chrysomycin (Figure 18).  ChryMT exhibits strong sequence 
similarity to O-methyltransferases from other pathways (e.g. MetLA1 50%/64%).  
ChryMT is hypothesized to be a SAM-dependent O-methyltransferase that O-methylates 
either the 12-hydroxyl or 10-hydroxyl moieties.  ChryMT is proposed to O-methylate the 
10-hydroxyl position due to the suspected involvement of ChryRM in catalyzing an 
unusual methylation immediately after the C5-C6 cleavage step, which becomes 12-O-
methyl.  The substrates for these reactions are completely unknown, however.  
Furthermore, it is uncertain if 10-O-methylation occurs before or after glycosylation with 
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D-virenose.  It seems plausible that the presence of the 4-C-virenoside moiety is not an 
essential requirement for ChryMT methylation, as defucogilvocarcins (62-64), which are 
O-methylated at 10- and 12-positions, are accumulated in the S. lividans (cosG9B3-
gilGT-) strain and other producing organisms.   
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Figure 19 Theoretical routes to C5-C6 carbon carbon bond cleavage of the 
chrysomycins. 
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H185 of ChryOII is portrayed as a predicted catalytic base.  A) Baeyer Villiger-catalyzed 
route towards the ring-cleaved acid/aldehyde intermediate.  B)  Dioxygenase and 
dioxetane formation by ChryOII route to acid/aldehyde intermediate. 
 
ChryRM encodes a putative two-domain protein that involves both a GilM-type 
methylation step and a GilR-type dehydrogenation step of prechrysomycin V (96).   
ChryRM (N-terminal domain=518 aa, C-terminal=243 aa) demonstrates sequence 
similarity to GilM (41%/58%) and GilR (50%/63%).  Initially, the putative chryR was 
suspected to be sequenced wrong, in that an extra nucleotide insertion appeared to have 
happened in the initial sequencing file.  Upon re-sequencing and confirmation that the 
chryR sequence was indeed correct, it was determined that chryRM composed a single 
ORF whose product would be a dual domain protein, ChryRM.  Sequence comparison 
with ravRM confirmed that both the rav and chry clusters encode such a predicted two 
domain protein.  The 761 aa predicted ChryRM could potentially have important 
ramifications for elucidation of the late-acting chrysomycin biosynthetic steps from the 
ring-cleaved acid-aldehyde intermediate to the final dehydrogenation step of 
prechrysomycin V 94 to chrysomycin V 42.  It is interesting that in the case of the 
ravidomycin and chrysomycin clusters, these two proteins are fused versus in the 
gilvocarcin cluster where GilM and GilR are separate entities.  The rav and chry clusters 
very likely share a common ancestor, given that their genetic organization is almost 
identical, and this may account for the presence of a fused protein.  This protein very 
likely was originally fused in an ancestor, and then over time genetic mutation may have 
caused the chryRM/ravRM to become two functional ORFs gilR and gilM in the gil 
cluster.  However, both the rav and chry clusters encode deoxyhexose tailoring enzymes, 
in essence the only major difference between these clusters, and the presence of a 
deoxyhexose of the prechrysomycin/preravidomycin intermediates may require a very 
specialized RavR or ChryR domain to catalyze dehydrogenation of the hemiacetal to the 
lactone (as compared to the fucofuranose-containing pregilvocarcin). Kharel et al. 
demonstrated that GilR catalyzes the turnover of pregilvocarcin V (kcat =2.29±0.03 min-
1), but also the unglycosylated predefucogilvocarcin V less effectively (kcat=0.65±0.086 
min-1).  Interestingly, prechrysomycin V (94) turned over poorly by GilR (71).  This 
observation clearly demonstrates the preference and substrate specificity for these 
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dehydrogenases towards a very particular type of glycosylated molecule, a deoxyfuranose 
for GilR, and deoxypyranoses for RavRM and ChryRM.  Therefore, ChryRM is unusual 
in that it is anticipated to accept two separate substrates- the acid/aldehyde intermediate, 
and a fully-glycosylated prechrysomycin compound (94).  Its overexpression would be 
useful in studies aimed at determining the nature of collaboration between the R and M 
enzyme-activities.  This could be used to interrogate turnover of various pyranosyl 
pregilvocarcins that could be generated with “sugar plasmid” recombination experiments 
in vivo. 
 ChryH encodes a putative NAD(P)H-dependent FAD reductase with significant 
sequence similarity to other similar reductases (e.g. Kfla_5747, 64%/75%).  It is thought 
that ChryH binds NAD(P)H and provides reduced FADH2 to the FAD-dependent 
oxygenases ChryOIV/ChryOI.  Disruption of GilH did not abrogate biosynthesis of 39, 
and heterologously-expressed GilH evinced a yellow color indicative of FAD binding, 
thereby confirming its role as an accessory protein (64). 
 
Genes involved in self-defense, regulation, and other functions 
 
The chry cluster has several ORFs which are predicted to encode proteins 
essential for regulation and export of chrysomycin.  ChryX demonstrates sequence 
similarity to spore-associated protein precursors (SapA, 73%/84%), which may have 
some role in regulating sporulation of S. albaduncus.  Upstream of chryX is an ORF 
encoding a Zinc-finger SWIM protein >700 bp long, therefore this region demarcates one 
boundary of the cluster with genes whose encoded functions are not necessary for 
biosynthesis of chrysomycin.  ChryX1 and chryX2 encode an apparent two-component 
response regulation system that is also encoded by ORFs ravJ (54%/70%) and ravX5 
(67%/82%) that are likely involved in regulating expression of chry biosynthetic genes.  
ChryX3, X5, X6, X7,X8 represent various regulators putatively involved in chrysomycin 
biosynthesis, with chryX3 encoding a putative MarR type regulator, and chryX5, X7, and 
X8 pertaining to putative TetR family regulators.  ChryJ encodes a drug efflux permease, 
and would be similar in this respect to gilJ.  It is believed that ChryJ is essential for 
export and self-defense for S. albaduncus from chrysomycin.  ChryX9 encodes a putative 
Acyl-CoA dehydrogenase (SSDG_02680, 84%/89%), which is an enzyme from fatty acid 
45 
 
β-oxidation from primary metabolism.  ChryX4 putatively encodes hexokinase 
(Tfu_1012 61%/75%), which catalyzes the transfer of a phosphate to the 6-position of D-
glucose in the first step of glycolysis. Interestingly, chryL (GilL, 37%/50%) is also 
present, and it encodes a putative NAD-dependent epimerase/dehydratase, but its role in 
the biosynthesis of 42 can only be speculated about.  This gene demonstrates similarity to 
gilL, an ORF encoding a protein of unknown function in gilvocarcin biosynthesis.  ChryV 
is another gene of unknown function related to gilV; BLAST analysis indicates that 
ChryV has a domain that is related to the chlorite dismutase family of enzymes.  
Enzymes of this family are largely hypothetical proteins, however, chlorite dismutase is 
responsible for dissociation of chlorite into its composite chlorine and oxygen species.  
 
Genes involved in biosynthesis and attachment of NDP-D-virenose  
 
NDP-D-virenose is a key structural feature of 42, and the genes involved in 
deoxysugar biosynthesis are a unique feature of the chry cluster.  ChryDE are 
translationally-coupled and encode an NDP-glucose synthase (ChryD, 355 aa, 
SSEG_09374, 78%/90%) and an NDP-4,6-dehydratase (ChryE, 328 aa; SSDG_01263 
77%/84%), respectively.  It is believed that these two enzymes are responsible for the 
first two transformation steps from D-glucose-1-phosphate (30) to NDP-D-glucose (31) to 
NDP-4-keto-6-deoxy-D-glucose (32) (Figure 20).  Very often, the genes encoding these 
two enzymes are translationally coupled; however, in some clusters, these genes are 
located in another chromosomal locus, far-removed from the antibiotic biosynthetic 
genes.  For example, the elloramycin producer Streptomyces olivaceus clusters the 8-
demethyl tetracenomycin C antibiotic genes in a separate chromosomal locus from the 
rhaABCD genes necessary to supply NDP-L-rhamnose (126).  ChryCMT (411 aa, 
PCZA361 61%/72%) and chryU (Acel_0416 46%/55%) are clustered together and 
encode a putative C-methyltransferase and a truncated 4-ketoreductase, respectively.  
ChryCMT is predicted to use a SAM cofactor, and ChryU could be an NAD(P)H-
dependent ketoreductase enzyme.  ChryCMT and ChryU could potentially catalyze the 
last two transformations of 32 to a 3-C-methylated ketosugar, 95, and ChryU could 
potentially reduce 95 to an axial 4-OH, to yield NDP-D-virenose.  The assignments of the 
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enzyme functions encoded by these genes and their cloning into overexpression vectors 
will be covered in Chapter 3. 
ChryGT (379 aa, GilGT, 44%/62%) encodes the only candidate 
glycosyltransferase in the chry cluster.  It is hypothesized to use 96 as the donor substrate 
to transfer D-virenose the polyketide acceptor substrate, which at this point remains a 
hypothesized intermediate.  The mechanism for direct C-glycosylation of the 
chrysomycin chromophore is anticipated to involve the phenolic 1-OH group, but an 
additional Fries-like rearrangement has also been postulated (56).  However, chryGT 
potentially encodes a valuable C-GT for pathway engineering.  For example, chryGT 
could be placed under the strong ermE* promotion and subsequently integrated into the 
chromosome of the S. lividans (cosG9B3-gilGT-) genome for interrogation with foreign 
deoxysugar donor substrates.   These could easily be supplied as plasmid-borne sugar 
“cassettes” over-expressing deoxysugar biosynthetic enzymes from exogenous hosts. 
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Figure 20 Hypothesized biosynthetic route to NDP-D-virenose (96). 
ChryD catalyzes 1-phosphonucleotide transfer to D-glucose-1-phosphate (30).  ChryE 
catalyzes 4-oxidation and 6-reduction of NDP-D-glucose (31) to afford NDP-4-keto-6-
deoxy-D-glucose (32).  ChryCMT catalyzes 3-C-methyltransfer to 32 to afford NDP-4-
keto-D-virenose (95), and ChryU catalyzes 4-ketoreduction of 95 to afford NDP-D-
virenose (96). 
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ORFs Size[a] ID/SM 
(%)[b] 
Origin Nucleotide 
accession no. 
 
Proposed function 
chryX 149 84/89 S. griseoflavus Tu 4000 ZP_05536903 Spore-associated 
protein precursor 
 
chryF 261 71/83 fabG, S. echinatus ABL09955 Ketoreductase 
 
chryV 110 31/52 GilV, S. griseoflavus ABE03981 Hypothetical Protein 
 
chryH 189 62/73 Kribbella flavida DSM 
17836 
ZP_03859638 Oxidoreductase/NADH-
dependent FMN  
Reductase 
 
chryOI 513 59/70 PgaE, Streptomyces sp. 
PGA64 
2QA1_A FAD-Dependent 
Monooxygenase 
 
chryG 109 70/83 OvmC, S. antibioticus  CAG14964 Cyclase 
 
chryC1 83 58/71 SimA3, S. antibioticus AAL15582 Acyl Carrier Protein 
 
chryK 314 61/71 Tfu_1222, Thermobifida 
fusca YX 
YP_289283 Bifunctional 
Cyclase/Dehydratase 
 
chryOIV 491 55/63 OvmOII, S. antibioticus CAG14970 FAD-Dependent 
Monooxygenase 
 
chryA 422 79/87 Pd2A, Streptomyces sp. 
WP 4669 
AAO65362 Ketoacyl Synthase 
(KSα) 
chryB 402 70/82 UrdB, S. fradiae CAA60570 Chain Length Factor 
(KSβ) 
 
chryC 120 60/70 Acp, S. venezuelae AAB36564 Acyl Carrier Protein 
 
chryOIII 394 71/80 GilOIII, S. griseoflavus  AAP69584 Cytochrome P-450 
Monooxygenase 
 
chryY 62 44/62 FdxD, Mycobacterium 
tuberculosis H37rv 
NP_218020 Ferredoxin 
 
chryP 322 49/63 PgaH, Streptomyces sp. 
PGA64 
AAK57533 Malonyl-CoA Carrier 
Protein Transacylase 
 
chryQ 327 49/58 AknF,  S. galileus AAF70110 Propionyl-CoA Carrier 
Protein Transacylase 
 
chryX1 265 38/50 AurIO, S. aureofaciens AAK59995 Regulator 
 
chryX2 201 56/72 Gra-orf10, S. 
violaceoruber 
CAA09631 Two-Component 
Response Regulator 
 
chryE 328 77/84 SSDG_01263, S. 
pristinaespiralis ATCC 
25486 
YP_002200633 TDP-glucose-4,6-
dehydratase 
chryD 355 78/90 SSEG_09374, S. sviceus 
ATCC 29083 
YP_002205669 Glucose-1-phosphate 
thymidylyltransferase 
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chryJ 623 78/87 SGR_4823, S. griseus 
subsp. griseus NBRC 
13350 
YP_001826335 Major facilitator 
superfamily permease 
 
chryX3 293 71/82 SGR_4824, S. griseus 
subsp. griseus NBRC 
13350 
YP_001826336 MarR family 
transcriptional regulator 
chryGT 379 44/62 GilGT, S. griseoflavus AAP69578 C-glycosyltransferase 
 
chryMT 340 49/63 MetLA1, S. tubercidicus AAT45282 O-methyltransferase 
 
chryOII 236 65/76 GilOII, S. griseoflavus AAP69583 Anthrone 
Monooxygenase 
 
chryRM 761 52/67; 
41/58 
ORF 22, S. 
echinatus/GilM, S. 
griseoflavus 
ABL09969/ 
AAP69591 
Oxidoreductase/ 
Methyltransferase 
chryU 302 46/55 Acel_0416, 
Acidothermus 
cellulolyticus 11B 
YP_872176 TDP-4-
dehydrorhamnose 
ketoreductase 
 
chryCMT 411 61/72 PCZA361, 
Amycolatopsis orientalis  
CAA11777 C-methyltransferase 
chryHK 309 61/75 Tfu_1012, Thermobifida 
fusca YX 
YP_289073 Hexokinase 
chryL 210 37/50 GilL, S. Griseoflavus AAP69590 NAD-dependent 
epimerase/dehydratase 
 
chryX4 135 70/82 SGR_2879, S. griseus 
subsp.  
griseus NBRC 13350 
YP_001824391 TetR Family 
transcriptional regulator 
chryX5 120 61/74 SC2H2.18, S. coelicolor 
A3(2) 
NP_631661 Hypothetical Protein 
chryX6 
 
 
202 78/83 SGR_429, S. griseus 
subsp.  
griseus NBRC 13350 
YP_001821941 
 
TetR Family 
transcriptional regulator 
chryX7 
 
chryX8 
545 
 
129 
83/89 
 
61/68 
SSDG_02680, S. 
pristinaespiralis ATCC 
25486 
SCD31.02c, S. 
coelicolor A3(2) 
YP_002198950 
 
NP_628836 
 
Acyl-CoA 
Dehydrogenase 
 
Regulatory Protein 
 
chryX9 155 62/79 Caul_2306, Caulobacter 
sp. K31 
YP_001683931 TetR Family 
transcriptional regulator 
[a]: number of amino acids; [b]: identity/similarity 
Figure 21 Table of proposed chrysomycin ORFs, predicted functions of their producers, 
and identity/similarity scores among closest homologues. 
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Attempts at heterologous expression and inactivation of chrysomycin biosynthetic 
genes 
 
In order to prove the role of the chry cluster in production of chrysomycin, 
heterologous expression experiments of the various cosmids encoding chrysomycin 
biosynthetic genes were undertaken.  Chry1-1 and CosChryF2 were chosen for 
heterologous expression in Streptomyces lividans, because they contained the greatest 
portion of the chry cluster genes as determined by restriction analysis.  Streptomyces 
lividans TK 24 is a preferred transformation host because of its genetic pliability, and 
because under normal conditions it fails to express antibiotic biosynthetic genes, making 
it effectively “background neutral” (3).  The cosmids were transformed into S. lividans 
TK 24 by a well-characterized conjugation protocol between a special E. coli host and 
Streptomyces lividans (See Materials and Methods) (3).  Exconjugants were fermented 
for 4-5 days, and methanolic extracts were chromatographed via HPLC/MS to evaluate 
the production of chrysomycin-related metabolites (See Materials and Methods). 
Expression of cosChry1-1 or cosChryF2 in S. lividans failed to result in the production of 
metabolites with the characteristic chromophore of angucycline or gilvocarcin-related 
compounds when compared to extracts of S. lividans (pOJ446) as a negative control.  
Because chryABCFGKP were present on cosChryF2, at least rabelomycin or UWM6 
should have been accumulated in the S. lividans (cosChryF2) strain.  The lack of 
accumulated metabolites likely resulted from poor cosmid expression or 
missing/dysfunctional regulators necessary for chrysomycin biosynthesis. 
As an alternative, classical inactivation experiments were envisioned for 
disruption of the chryA and chryCMT genes.  Inactivation of chryA would result in a non-
producing mutant and inactivation of chryCMT was anticipated to disrupt NDP-D-
virenose biosynthesis, and depending on the substrate flexibility of ChryGT, would result 
in a novel gilvocarcin with a C-glycosidically linked pyranose moiety.  ChryA and 
chryCMT were cloned into pKC1139, which is an RK2-derived vector that is used for 
gene deletion experiments in Streptomyces.  pKC1139 features a temperature-sensitive 
replicon that prevents it from replicating autonomously, so any surviving AprR 
transformants must be single-crossover mutants (3).  A thiostrepton resistance cassette 
was cloned and inserted into unique restriction sites in the middle of chryA and chryCMT 
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(XmaI for chryA and BglII in chryCMT) (See Materials and Methods).  The resulting 
constructs, pKC1139-chryCMT and pKC1139-chryA, were unable to be transformed into 
S. albaduncus via protoplast transformation, electroporation, and conjugation procedures.  
S. albaduncus may simply be recalcitrant to genetic manipulation due to a severe 
restriction system. 
 
Cross complementations using chrysomycin oxygenases 
 
In order to prove the chrysomycin biosynthetic gene cluster was responsible for 
biosynthesis of 42, when inactivation experiments and heterologous expression of the 
chrysomycin cluster were not feasible, in vivo cross-complementation experiments were 
envisioned using chry biosynthetic genes and gilvocarcin blocked mutants.  For this, the 
four chry monooxygenases were selected for overexpression, because they are crucial for 
the 12-position hydroxylation, C5-C6 bond cleavage, and installation of the 8-vinyl side 
chain, steps that are unmistakably characteristic for the biosynthesis of the chrysomycin 
chromophore.  ChryOI, chryOII, chryOIII, and chryOIV were cloned into pEM4 under 
the strong, constitutive ermE* promoter (see Materials and Methods).  The resulting 
constructs, pChryOI, pChryOII, pChryOIII, pChryOIV were transformed into gilvocarcin 
mutants deficient in the oxygenases GilOI, GilOII, GilOIII, and GilOIV respectively.      
When pChryOI was transformed into S. lividans TK 24 (cosG9B3/GilOI-), for 
unexplained reasons, the resulting transformant neither produced gilvocarcin (39), as 
expected, nor even prejadomycins (58) or (59), as are typically accumulated in the gilOI-
deleted strain.  This is likely explained by poor host utilization of the cosG9B3-GilOI- 
cosmid.  The S. lividans TK 24 (cosG9B3/GilOIV-)/pChryOIV strain successfully 
restored production of gilvocarcin biosynthesis, producing 39 and 40 (see Figure 22).  
Because chryOIV and chryOI both encode FAD-dependent monooxygenases and are 
quite similar to each other, it could be possible that ChryOIV might actually be the 
GilOI-homologue, or it may be able to catalyze both 2,3-dehydration and 4a,12b-
dehydration steps.  Therefore, pChryOIV was cross-complemented into the S. lividans 
TK 24 (cosG9B3/GilOI-) mutant.  The resulting transformant failed to recapitulate 
gilvocarcin biosynthesis, indicating that ChryOIV is responsible for 2,3-dehydration in 
chrysomycin biosynthesis (see Figure 22). 
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Figure 22 HPLC chromatograms of pChryOIV complementations   
A)  S. lividans (cosG9B3-GilOIV-) extract- rabelomycin (54) (Rt=13.0 min-1) and 
homorabelomycin (55) (Rt=14.9 min-1).  B)  S. lividans (cosG9B3-GilOIV-)/pChryOIV 
extract- gilvocarcin M (40) (Rt=14.2 min- 1) and gilvocarcin V (39) (Rt=14.7 min-1).  C)  
S. lividans (cosG9B3-GilOI-) extract-prejadomycin (58) (Rt=14.5 min-1) and homo-
prejadomycin (Rt=15.8 min -1)D) S. lividans (cosG9B3-GilOI-)/pChryOIV extract. 
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Figure 23 HPLC chromatograms of pChryOII and pChryOIII chromatograms. 
A)  S. lividans (cosG9B3-GilOII-) extract-dehydrorabelomycin V (61) (Rt=24.3 min-1) and 
dehydrorabelomycin E (60) (Rt= 25.3 min-1).  B)  S. lividans (cosG9B3-GilOII-)/pChryOII 
extract- gilvocarcin M (40) (Rt=14.2 min- 1), gilvocarcin V (39) (Rt=14.7 min-1), 
gilvocarcin E (41) (Rt= 15.0 min.-1), rabelomycin (54) (Rt=13.0 min-1)   C)  S. lividans 
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(cosG9B3-GilOIII-) extract- gilvocarcin M (40) (Rt=14.2 min- 1) gilvocarcin E (41) (Rt= 
15.0 min.-1)  D) S. lividans (cosG9B3-GilOIII-)/pChryOIII extract- gilvocarcin M (40) 
(Rt=14.2 min- 1), gilvocarcin V (39) (Rt=14.7 min-1), and gilvocarcin E (41) (Rt= 15.0 min.-
1) . 
 
The failure of pChryOIV to completely restore gilvocarcin production probably indicates 
that ChryOIV is not a perfect fit with GilOI and/or GilOII in the hypothetical multi-
oxygenase complex, and therefore, some of the pathway continues towards unproductive 
accumulation of shunt rabelomycins. 
 Both pChryOIII and pChryOII completely restored production of 39 and 40 
(Figure 23), which indicates that ChryOIII is responsible for installation of the 8-vinyl 
side chain, likely through hydroxylation and spontaneous dehydration at 1”-position of 
the ethyl side chain of a still undetermined pathway intermediate.  Simultaneously, this 
experiment also indicates that ChryOII is capable of functioning in a surrogate capacity 
when GilOII is not present in the oxygenase cascade.  However, the presence of 
rabelomycin indicates that some UWM6 is incompletely converted in this 
complementation strain.  Furthermore, the presence of gilvocarcin E, 41, may be 
explained by an incomplete activity of GilOIII in this strain.   In the GilOII-deleted strain, 
both dehydrorabelomycin E and V are accumulated, which may indicate that GilOIII acts 
on a hydroquinone intermediate. This result suggests that ChryOII is involved in the C5-
C6 carbon-carbon bond cleavage reaction, however, the mechanism by which it acts is 
elusive.  
 
SUMMARY 
 
 The chrysomycin biosynthetic gene cluster was cloned successfully onto four 
cosmids that spanned 34,654 nucleotides and possessed 35 open reading frames pertinent 
to biosynthesis of chrysomycin A.  The involvement of the chrysomycin biosynthetic 
gene cluster in biosynthesis of chrysomycin was successfully demonstrated by 
heterologous complementation of the GilOII-, GilOIII-, and GilOIV-deleted mutants of 
the gilvocarcin pathway by expression constructs pChryOII, pChryOIII, and pChryOIV 
in these pathways.  As a result, the chry cluster affords novel genes for expression in 
other pathways, such as chryGT, which is likely responsible for the 4-C-glycosylation of 
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the chrysomycin chromophore.  Furthermore, the identification of NDP-D-virenose 
biosynthetic genes is intriguing for further heterologous expression experiments to 
characterize the encoded products of chryD, chryE, chryCMT, chryU, and possibly chryL. 
 
EXPERIMENTAL 
 
DNA Isolation, Subcloning, and cloning of plasmids 
 
For general cloning conditions, the protocols in Sambrook and Russel were 
followed with regards to introduction of DNA into E. coli.  For isolation of plasmid 
DNA, the Fermentas GeneJET MiniPrep spin columns were used as per the 
manufacturer’s protocol.  For isolation of DNA fragments from electrophoresis gels, the 
QIA QG buffer (Qiagen, California) was used for extracting DNA from gel fragments.   
High fidelity pfu DNA polymerase was used to generate PCR fragments via the following 
program (Hot start, 1 cycle @ 96 °C for 3 minutes, 30 cycles- 94 °C for 30 seconds, 
lowest Tm-5 °C for 1 minute, 72 °C @ 1 min/1kb amplified DNA, 1 cycle 3 minutes @ 
72 °C).  PCR fragments were ligated into PCR-Blunt-IITOPO vector (Invitrogen).  For 
cloning pChryOI, pChryOII, pChryOIII, pChryOIV the corresponding oxygenase genes 
chryOI, chryOII, chryOIII, and chryOIV were amplified from cosChry1-1 cosmid DNA, 
cloned into TOPO vector, then cut with XbaI/EcoRI and ligated into the exact sites of 
pEM4 to give the expression vectors.  For cloning pKC1139-chryA and pKC1139-
chryCMT, a ~3kb chryA or chryCMT fragment was ligated into the EcoRI/HindIII sites of 
pKC1139 vector.  A thiostrepton resistance gene, tsr, was amplified from pEM4 and 
ligated into into a unique restriction marker in the middle of the target gene for 
inactivation (chryA- XmaI, chryCMT- BglII).  Plasmids used in this study are summarized 
in Table 2.1.  Primers used in this study are summarized in Table 2.3. 
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Table 1  Plasmids used in Chapter 2 
 
Plasmid Name Relevant Characteristics Reference 
pOJ446 Streptomyces-E. coli shuttle 
vector for cosmid library 
generation 
(127) 
cosChry1-1 Partial chrysomycin cluster 
cloned into pOJ446 
This work 
cosChryF1 Partial chrysomycin cluster 
cloned into pOJ446 
This work 
cosChryF2 Partial chrysomycin cluster 
cloned into pOJ446 
This work 
cosChryF3 Partial chrysomycin cluster 
cloned into pOJ446 
This work 
pEM4 E. coli-Streptomyces shuttle 
plasmid that contains 
ermE* for the expression of 
genes in Streptomyces 
(128) 
pChryOI chryOI cloned into pEM4 This work 
pChryOII chryOII cloned into pEM4 This work 
pChryOIII chryOIII cloned into pEM4 This work 
pChryOIV chryOIV cloned into pEM4 This work 
PCR-Blunt-TOPO-II Clone blunt PCR products Invitrogen 
 
 
Bacterial strains and culture conditions 
 
Streptomyces albaduncus AD819 and Streptomyces lividans TK 24, and S. 
lividans TK 24 (cosG9B3) and derivative strains were routinely cultivated and 
maintained on M2 agarose plates (1.5% agar, 0.4% glucose, 1% malt extract, 0.4% yeast 
extract, and 0.1% CaCO3).  For production of spores, S. lividans TK 24 was grown on 
M2 agar for 5-6 days until the production of white-grey spores was visible on top of the 
mycelia, which were harvested by scraping with a toothpick then deposited in a sterile 1.5 
mL Eppendorf-style tube, which were then immediately used for conjugation (see 
Introduction of chry cosmids into Streptomyces lividans via Conjugation).  For 
production of metabolites, S. albaduncus or recombinant S. lividans (cosG9B3) and 
derivative strains were grown in liquid SG medium (See Production and Isolation of 
Gilvocarcin-related metabolites). 
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For growth in liquid medium to prepare protoplasts or for genomic DNA, S. 
albaduncus or S. lividans TK 24 were grown in 100 mL YEME media (0.3% yeast 
extract, 0.5% bacto-peptone, 0.3% malt extract, 1% glucose, 10.3% sucrose, 1L) for 3-4 
days at 28 °C in an orbital shaker (250 RPM).  For protoplasts, 200μL MgCl2 (2.5M) and 
2.5 mL Glycine (20%) were added to each 100 mL flask.  Protoplasts were regenerated 
on R2YE agar (10.3% sucrose, K2SO4 0.25 g/L, MgCl2 10.12 g/L, Glucose 1%, 
Casaminoacids 0.1 g/L, Yeast extract 5 g/L, agar 15 g) (added to the solution after 
autoclaving:  KH2PO4 10 mL (0.5%), CaCl2 80 mL (3.68%), L-proline 15 mL (20%), 
TES Buffer 100 mL (5.73%, adjusted to pH 7.2), Trace elements 2 mL, NaOH 5 mL 
(1N)).  All solutions were sterilized by autoclaving before usage. 
Escherichia coli XL1 blue MRF cells (Stratagene) were used for routine cloning 
procedures and propagation of plasmids and cosmid DNA.  E. coli strains were grown in 
lysogeny broth (LB) or LB agar containing appropriate antibiotics to select for 
recombinant plasmids:  (kanamycin 50 μg/mL; chloramphenicol 25 μg/mL; apramycin 50 
μg/mL, and ampicillin 100 μg/mL) whenever necessary at 37 °C (in an orbital shaker, 
250 RPM for liquid cultures).  E. coli ET12567/pUZ8002 was used as a demethylating 
strain for conjugation with Streptomyces sp..  S. albaduncus was used as a source of 
genomic DNA.  Strains generated and used in this study are summarized in Table 2.2. 
 
 
Table 2  Bacterial strains used in Chapter 2 
 
 
Strain Name Relevant Characteristics Reference 
E. coli XL1-Blue-MRF Host for routine cloning 
work and genomic library 
construction 
Stratagene 
E. coli ET12567/pUZ8002 Host for conjugal transfer of 
plasmids into Streptomyces 
(129) 
Streptomyces albaduncus Chrysomycin wildtype 
producer 
(59) 
Streptomyces lividans TK 
24 
Streptomyces host (3) 
S. lividans (cosG9B3-
GilOI-) 
Produces 56-59.  S. lividans 
with cosG9B3-GilOI 
deleted cosmid. 
(130) 
S. lividans (cosG9B3- Produces 56-59.  pChryOIV This work 
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GilOI-)/pChryOIV transformed into previous 
strain 
S. lividans (cosG9B3-
GilOII-) 
Produces 60, 61.  S. lividans 
with cosG9B3-GilOII 
deleted cosmid. 
(68) 
S. lividans (cosG9B3-
GilOII-)/pChryOII 
Produces 39-41, 55.  
pChryOII transformed into 
previous strain. 
This work 
S. lividans (cosG9B3-
GilOIII-) 
Produces 39, 41.  S. lividans 
with cosG9B3-GilOIII- 
deleted cosmid. 
(70) 
S. lividans (cosG9B3-
GilOIII-)/pChryOIII 
Produces 39, 40.  pChryOIII 
transformed into previous 
strain. 
This work 
S. lividans (cosG9B3-
GilOIV-) 
Produces 54, 55.  S. lividans 
with cosG9B3-GilOIV- 
deleted cosmid. 
(130) 
S. lividans (cosG9B3-
GilOIV-)/pChryOIV 
Produces 39, 40.  
pChryOIV transformed into 
previous strain. 
This work. 
 
Table 3  Oligonucleotide Primers used in Chapter 2 
 
 
Primer Name Oligonucleotide Sequence 
chryOI_for 5’- CTGGTCTCTAGAGCTGGAGCCGGTCCGCCG 
AGGAGGGCG -3’ 
chryOI_rev 5’- ATGTGCGAATTCGTCGGCCGGGACCGCACG-3’ 
chryOII_for 5’-ATTCTAGACCACCCGTACCGAGCCAC-3’ 
chryOII_rev 5’-ATGAATTCCCCGTCGTCCGCCGCGCG-3’ 
chryOIII_for 5’-ATTCTAGAGACCCGTTCCCGCAGCTC-3’ 
chryOIII_rev 5’-ATGAATTCGAACACGAAGGCTGTCGT-3’ 
chryOIV_for 5’-GCGGTTCTAGACCGCGCGCACCGGCTGCCCGGG-3’ 
chryOIV_rev 5’-CCGGTGAATTCACAGGAATCCGATGGCGGT-3’ 
chryA_ina_for 5’-CGCGAATTCCGACGCCGTACGGGAGCTGCT-3’ 
chryA_ina_rev 5’-CCAAAGCTTCCGTCCCGGCCGCCGGCCTGC -3’ 
chryCMT_in_for 5’-CGGAAGCTTTCGTCAACGCCGCCGT-3’ 
chryCMT_in_rev 5’-GGCGCGAATTCGGGCGGCGAGGTC-3’ 
Tsr_for 5’- CAGCCCGGGAGATCTTGATAAGGCGAATACTT 
CATATG -3’ 
Tsr_rev 5’- TCGCCCGGGAGATCTGTGATCATCACTGACGAA 
TCGAGGTCGAGGAAC -3’ 
chryF_probe_for 5’-GCCCTVGTSACSGGNGGNACCAGY-3’ 
chryF_probe_rev 5’-GTTGCCVAGNCCGCCGCASACGTT-3’ 
KS_probe_for 5’-GTSTCSACSGGSTGYACSTCSGGS-3’ 
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KS_probe_rev 5’-SCCGATSGCSCCSAGSGARTGSCC-3’ 
DH_probe_for 5’-CSGGSGSSGCSGGSTTCATSGG-3’ 
DH_probe_rev 5’-CAGTGGTCSACGTGSAGCCACTCSCG-3’ 
 
 
 
Construction and Screening of S. albaduncus Genomic Library 
 
Genomic DNA of S. albaduncus was isolated following standard protocol  (3). 
The genomic DNA was partially digested with Sau3AI, dephosphorylated with calf 
intestinal phosphatase (CIP) and ligated to pOJ446 vector digested with BamHI and 
HpaI. The ligation sample was transduced into E. coli XL1-Blue MRF using Gigapack III 
XL packaging extract (Stratagene). A titering of 2300 colonies was obtained for the 
library. Two sets of degenerate primers (a standard KS-probe-for and KS-probe-rev, and 
a newly designed DH-probe-for and DH-probe-rev) were used to amplify the internal 
nucleotide sequences of ketoacyl synthase (KSα) and NDP-D-glucose-4,6-dehydratase 
from the genomic DNA of S. albaduncus. The amplified KSα fragment was labeled with 
DIG and used to screen positive colonies. The positive colonies were further screened 
with the NDP-D-glucose-4,6-dehydratase probe. Colony hybridization and southern blot 
analyses revealed three cosmid clones for S. albaduncus genomic libraries. A probe 
suited to detect a type II PKS-associated ketoreductase gene (gilF homologue) was also 
constructed (chryF_probe_for and chryF_probe_rev) to probe for cosmids that contained 
chryF. Three positively hybridizing colonies yielded cosmids cosChryF1, cosChryF2, and 
cosChryF3.   CosChryF2 demonstrated the most overlap with cosChry1–1 according to 
the restriction analysis map. Thus, cosmids cosChry1–1 and cosChryF2 were selected for 
sequencing. 
 
Sequencing and annotation of the chry cluster 
Sequencing of the cosmids was carried out involving a standard shotgun approach 
using the HyperMu™ MuA Transposase kit (Epicentre) following the reported protocol 
used by the sequencing facilities of the Advanced Genetic Technologies Center (AGTC) 
located in the College of Agricultural Sciences of the University of Kentucky 
(http://www.uky.edu/Centers/AGTC/). Phred/Phrap/Consed software package 
(http://www.phrap.org.) was used to process and assemble raw sequence data into larger 
59 
 
contigs. The small gaps between contigs were filled by primer walking. Frame plot 
(http://www.nih.go.jp/~jun/cgi-bin/frameplot.pl) and ORF finder 
(http://www.ncbi.nlm.nih.gov/projects/gorf/) were used to assign the open reading 
frames. Functional assignments of ORFs were performed through database comparison 
using BLASTX and BLASTN search tools on the server of the National Center for 
Biotechnology Information, Bethesda, Maryland, USA (http://www.ncbi.nlm.nih.gov). 
 
Introduction of chry cosmids into Streptomyces lividans via Conjugation 
 
Cosmid DNA was introduced into S. lividans TK 24 via conjugation with E. coli 
ET12567/pUZ8002 containing cosmids cosChry1-1and cosChryF2.  The E. coli donor 
was grown overnight supplemented with kanamycin 50 μg/mL; chloramphenicol 25 
μg/mL; apramycin 50 μg/mL in a 7 mL culture tube.  The cells were centrifuged, washed 
twice with sterile LB, and resuspended in 500 μL of 2 x YT broth (1.6% tryptone, 1% 
yeast extract, and 0.5% NaCl (pH 7.0)).  S. lividans TK 24 spores were taken from a 5-6 
day old M2 agar plate, scraped into 500 μL 2 x YT broth, heat shocked at 50 °C, placed 
on ice for 5 minutes, and finally mixed with the E. coli donor cells.  200 μL aliquots were 
plated on MS agar plates (mannitol 20 g/L, soya flour 20g/L, agar 20g/L, 10mM final 
conc. MgCl2) and incubated at 28 °C for 24 hours before being overlaid with apramycin 
(50 μg/mL) and nalidixic acid (100 μg/mL).  Exconjugants were picked after 3-5 days of 
incubation at 28 °C. 
 
Production and Isolation of Gilvocarcin-related metabolites 
 
For production of gilvocarcin-related metabolites, a small chunk of spores from a 
3-5 day old M2 agar plate of S. albaduncus or S. lividans TK 24 (cosG9B3)-derived 
strains was grown in 100 mL of Soytone-Glucose medium (Glucose 20 g/L, soy peptone 
10g/L, CaCO3 2 g/L, CoCl2 1 mg/L) in a 250 mL baffled flask at 28 °C in an orbital 
shaker (250 RPM) .  This culture was supplemented with apramycin (50 μg/mL) and/or 
thiostrepton (25 μg/mL) when appropriate.  After 4-5 days, 25 mL of the culture was 
collected in a 50 mL Falcon-style centrifuge tube, extracted with 25 mL ethyl acetate, and 
centrifuged for 5 minutes at 3000 RPM.  The EtOAc layer was pipetted off and collected 
in a round bottom flask (RBF) and the organic solvent was dried in vacuo under reduced 
60 
 
pressure conditions.  The remaining yellow oil was dissolved in a small amount of 
methanol, filtered through a 0.2 μm syringe-driven filter, and subjected to HPLC/MS and 
UV-analyses. A linear gradient of acetonitrile and acidified water (solvent A = 0.1% 
formic acid in H2O; solvent B = acetonitrile; 0–15 min 25% B to 100% B; 16–24 min 
100% B; 25–26 min 100% to 25% B; 27–29 min 25% B) was used to separate 
compounds.  A Symmetry C18 (4.6 250 mm, 5 μm) column was used for analytical scale 
separations.  A flow rate of 0.5 mL/min was used for analytical scale separations. 
Micromass ZQ 2000 (Waters) equipped with HPLC (Waters alliance 2695 model) and 
photodiode array detector (Waters 2996) were used to analyze the compounds. 
Atmospheric pressure chemical ionization (APCI) and Electrospray ionization (ESI) 
probes were used to detect molecular ions. 
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CHAPTER 3:  IN VIVO STUDIES AND CLONING OF DEOXYSUGAR 
CASSETTES DIRECTING BIOSYNTHESIS OF NDP-D-FUCOFURANOSE AND 
NDP-D-VIRENOSE 
 
INTRODUCTION 
 
NDP-D-fucofuranose and NDP-D-virenose serve as integral structural moieties in 
the activity of both gilvocarcin V (39) and chrysomycin A (42), respectively.  Both are 
characterized by being 6-deoxygenated sugars distinctive tailoring steps:  ring contraction 
to a furanose for NDP-D-fucofuranose and C-methylation for NDP-D-virenose (see 
Figure 28).  These sugars are relatively scarce in nature:  NDP-D-fucofuranose is a 
requisite component of E. coli O52 antigen, and NDP-D-virenose is present as a residue 
of Coxiella burnetii phase I lipopolysaccharide (131-133).  As such, both NDP-D-
virenose and NDP-D-fucofuranose both enhance the biological activity of these antigenic 
polysaccharides through their interactions with host immune systems.  Beyond this, the L- 
configurated fucofuranose is a key component of hygromycin B, and the structure 
elucidation gilvocarcin V was the first example of a D-configurated fucofuranose (Figure 
24).  NDP-D-virenose is fairly unique among branched sugars, as most are 2’-
deoxygenated, e.g. NDP-L-mycarose, NDP-D-mycarose, NDP-L-axenose, and NDP-L-
chromose B (134-136) (Figure 24). 
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Figure 24 Structures of NDP-D-fucofuranose (97) and NDP-D-virenose (96). 
Compared to NDP-activated furanose (NDP-L-fucofuranose 98) and branched pyranose 
(NDP-L-axenose (99), NDP-D-mycarose (100), NDP-L-mycarose (101), and NDP-L-
chromose B (102)) sugars. 
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Common examples of branched sugar biosynthesis 
 
The biosynthesis of branched-chain sugars involves specialized enzymes that 
attach one or two carbon unit extensions using S-adenosyl methionine or pyruvate as 
cofactors (137).  Deoxysugars with single carbon extensions use C-methyltransferases 
that catalyze nucleophilic attack of a corresponding NDP-activated deoxysugar enolate to 
a +CH3 moiety of an enzymatically-bound S-adenosyl methionine cofactor (Figure 25).  
This S-adenosyl methionine can be positioned above or below the NDP-4’-keto species 
(si-face or re-face) which imparts the stereochemistry of the methyl group (Figure 25) 
(137).  An example of C-methylation catalyzed by the product of chryCMT is indicated in 
Figure 25. 
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Figure 25 SAM-dependent C-methylation by ChryCMT of NDP-4-keto-6-deoxy-D-
glucose to afford 95. 
 
Nature’s strategies for catalyzing pyranose-furanose transformations 
 
Furanoses are scarce in polyketide pathways, but along with pyranoses, the 
furanose conformation is energetically favored (64).  The C-glycosidically linked D-
fucofuranose of gilvocarcin V possesses all of the stereocenters of gilvocarcin, and it is 
believed to be essential for binding to histone H3 (46, 64).  As such, identification of the 
enzymatic strategies that nature uses to contract pyranoses to furanose sugars, such as D-
fucofuranose, merits some discussion.  Primarily, most of the enzymes that are known to 
catalyze furanose ring contraction are mutases, such as UDP-galactose mutase.  This 
enzyme catalyzes pyranose to furanose ring contraction of UDP-D-galactose in an FAD-
dependent manner.  (The crystal structure of K. pneumoniae UDP-galactose mutase was 
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crystallized with 2.25 Ǻ resolution and bound flavin (FAD) by Beis et al.) (138) (Figure 
26).  The UDP-galactose mutase from Deinococcus radiodurans was crystallized to 2.36 
Ǻ resolution with bound UDP-D-galactose by Partha et al. (139).  The UDP-D-galactose 
substrate is stabilized through interactions of the FAD 4-position oxygen with the C4-
hydroxyl of UDP-D-galactose, and several water molecules bond with conserved active 
site residues to correctly position the sugar substrate:  His88, Arg364, Tyr371, Asn372, 
and His109 (139) (Figure 26).   
These mutases are very similar with the recently characterized Fcf2, which 
catalyzes the identical pyranose to furanose ring contraction for NDP-D-fucopyranose to 
97 (131).  Fcf2, unlike the UDP-galactose mutase enzymes, catalyzes ring contraction in 
a cofactor-free manner (131).  Furthermore, the 4-C-D-fucofuranose moiety of 
gilvocarcin has been shown to rearrange from a furanose to pyranose ring in an acid-
catalyzed manner, without the presence of a specific enzyme (140).  However, this results 
in a mixture of β- and α-connected fucopyranose moieties.  The D-fucofuranose moiety of 
For Streptomyces griseoflavus, it might be plausible that the NDP-D-fucose to NDP-D-
fucofuranose ring contraction might occur in an enzymatically controlled fashion.  For 
the analogous reaction in Escherichia coli, it can be theorized that an internal basic amino 
acid in Fcf2 performs the same catalytic role that the enzymatically-bound FADH- plays 
in the galactose mutases.  An amino acid residue could attack the anomeric carbon of 
NDP-D-fucose, thereby causing opening of the ring oxygen.  An internal base could 
catalyze removal of the proton of 4-OH, therby allowing for a facile intramolecular attack 
of the 4-alkoxide onto the enzymatically bound anomeric center, affording 97 (Figure 
27). 
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Figure 26 Crystal structures of pyranose-furanose contraction enzymes. 
A) Crystal structure of UDP-galactose mutase from K. pneumoniae with bound FAD by 
Beis et al(138). .  B)  Crystal structure of UDP-galactose-mutase from D. radiodurans 
with bound UDP-galactose by Partha et al.(139).  C) FADH- -dependent catalysis of 
UDP-D-galactose ring contraction mechanism. 
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Figure 27 Routes to NDP-D-fucofuranose ring contraction. 
A) Cofactor free catalysis of NDP-D-fucose ring contraction to NDP-D-fucofuranose (97) 
catalyzed by Fcf2 and unknown Gil enzyme.  B) Suggested routes to NDP-D-
fucofuranose ring contraction, as GilN- (glycosyltransferase) or GilL- (NAD-dependent 
epimerase/dehydratase)-mediated routes. 
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RESULTS AND DISCUSSION 
 
Identification of gilL and gilN candidate genes for NDP-D-fucofuranose 
biosynthesis 
 
In the gilvocarcin pathway, several candidate enzymes for biosynthesis of 97 were 
previously identified through bioinformatics analyses and inactivation experiments.  GilD 
and gilE were identified as encoding the enzymes NDP-glucose synthase and NDP-4,6-
dehydratase to catalyze transformation from D-glucose-1-phosphate (30) to NDP-D-
glucose (31) and NDP-4-keto-6-deoxy-D-glucose (32), respectively (see Figure 28).  
GilU was demonstrated to be a truncated ketoreductase involved in 4’-ketoreduction of 
32 to afford NDP-D-fucose 103 (See Figure 28). GilU was previously inactivated in 
cosG9B3 by Liu et al., and heterologous expression of the mutagenized cosmid resulted 
in accumulation of 4’-hydroxygilvocarcins and defucogilvocarcins (72).  Hydration of 
NDP-4-keto-6-deoxy-D-glucose (32) resulted in a substrate that closely resembled the 
putative NDP-D-fucose substrate of the ring contraction enzyme, and amazingly, both the 
ring contraction and the glycosyltransfer of the surrogate NDP-4-hydroxy-D-fucose sugar 
are carried out in vivo.  The gilU-deleted mutant strain, S. lividans (cosG9B3-GilU-), 
evinced important considerations about the deoxysugar biosynthesis of the D-
fucofuranose moiety.  The ring contraction enzyme and GilGT both demonstrate some 
substrate flexibility towards a foreign donor substrate.  However, disruption of gilU 
caused detrimental downstream effects, in that unglycosylated defucogilvocarcins were 
predominantly accumulated in this strain.  Also, this strain was successfully used by 
Shepherd, Liu et al. as a transformation host for flooding of the gilvocarcin pathway with 
foreign deoxysugars, effectively resulting in polycarcin (53) and 4-C-β-D-olivosyl 
gilvocarcin analogues (119). 
The identity of the enzyme involved in ring contraction is currently unknown.  The 
gil cluster does not contain any Fcf2/UDP-galactose mutase-type candidates for the 
contraction of NDP-D-fucose (98) to NDP-D-fucofuranose (97) (131).  However, gilL and 
gilN are two candidate ORFs whose encoded products could potentially be involved in 
ring contraction of the sugar.  Figure 27 illustrates that gilN encodes a hypothetical 297 
amino acid glycosyltransferase that could catalyze ring contraction of the sugar in the 
enzymatic pocket, then attach it to the 1-OH of the acceptor substrate.  A subsequent 
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Fries-like rearrangement by GilGT might result in the anticipated C-4 glycosylation.  Or, 
alternatively, the product of gilL, a putative 212 amino acid NAD-dependent 
epimerase/dehydratase (similar BLAST description to gilU), may represent a novel sugar 
ring-contraction enzyme.  To clarify this question, both gilN and gilL had been previously 
inactivated, but the resulting cosmids cosG9B3-GilN- and cosG9B3-GilL- have not been 
successfully characterized through heterologous expression.  
 
Generation of a G9B3-gilN- and G9B3-gilL- deletion cosmids and heterologous 
expression 
 
Previous work by Carsten Fischer and Lili Zhu had resulted in cosG9B3-derived 
cosmids in which individual gil genes had been deleted via the PCR Redirect technology 
(see Materials and Methods, Chapter 3).  The resulting cosmids cosG9B3-GilN- and 
cosG9B3-GilL- were introduced into Streptomyces lividans via a conjugation procedure 
between S. lividans and E. coli ET12567/pUZ8002 (see Materials and Methods, Chapter 
2).  Despite screening several 
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Figure 28 Biosynthetic pathways to NDP-D-fucofuranose and NDP-D-virenose. 
 
transformants, S. lividans TK 24 (cosG9B3-GilL-) exconjugants were fermented in SG 
media after 4-5 days and the methanolic extracts were chromatographed via HPLC/MS, 
there was no difference in the production spectrum as compared to extracts of control 
strain S. lividans TK 24 (pOJ446) with empty plasmid (See Materials and Methods, 
Chapter 2).  Conjugation was repeated with S. albus, which has been noted to be an 
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optimal strain for heterologous production of antibiotic gene clusters as compared to S. 
lividans, so the conjugation protocol was repeated using S. albus as transformation host.  
Still, no heterologous expression of cosG9B3-GilL- could be achieved, likely owing to 
poor cosmid utilization by the Streptomyces spp. hosts. 
S. lividans TK 24 (cosG9B3-GilN-) was confirmed to lack a complete gilN gene 
by amplification of the ~200 base pair FLP scar via colony PCR (Figure 29). 
Exconjugants were fermented in 100 mL SG medium for 4-5 days, and methanolic 
extracts were chromatographed via HPLC/MS to visualize the production pattern.  This 
strain was determined to be producing metabolites with a gilvocarcin chromophore.  As a 
result, this strain was cultured in 5 liters of SG media to isolate enough of the metabolites 
for structural elucidation.   
 
Structure determination of metabolites accumulated by S. lividans TK 24 
(cosG9B3-gilN-) strain 
 
Culturing of the gilN-deleted disruption strain encoding a putative 
glycosyltransferase revealed metabolites with gilvocarcin chromophores (See Materials 
and Methods, Chapter 3).  Two metabolites with a gilvocarcin-type chromophore were 
identified at Rt= 14.65 min-1 and Rt= 15.30 min-1, respectively.  Low resolution ESI/MS 
revealed a peak of 481 amu (-)ESI-MS mode for the metabolite with Rt= 14.65 min-1 and 
a peak of 493 amu (-)ESI-MS mode for the metabolite with Rt= 15.30 min-1.  A minor 
product was identified with Rt=16.18 min-1, and it was identified as homorabelomycin 
(55) via UV, mass, and identical retention time upon co-injection with standard 
homorabelomycin.  The identities of these metabolites were assigned via mass, UV, and 
1H-NMR spectral analysis.  Because the anticipated metabolites of the gilN-deleted 
mutant could have been structural isomers of 38 and 39 with C-glycosidically-linked 
pyranose sugars instead of D-fucofuranose, it was necessary to isolate enough of the 
compounds for structural elucidation. 
The major compound was identified to be gilvocarcin V (39) based on identical 
retention time to 39 as determined by co-injection with standard gilovcarcin V, identical 
low resolution mass (493 amu [M-H] (-ve) mode), and analysis of the 1H NMR-coupling 
constants of the sugar moiety (Figure 30 and Table 3.2).  The 1’-H signal appeared as a 
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doublet at δ 6.19 with J=5.5 Hz.  The 2’-H (δ 4.67) and 3’-H (δ 3.86) both indicated an 
integration of one proton and a multiplet splitting pattern.  This resembles the trans-axial 
splitting of the 2’-H and 3’-H signals of D-fucofuranose.  Furthermore, the 4’-H appeared 
at δ 3.51 as a doublet of doublets with J= 4.2, 5.9 Hz, and 5’-H was at δ 3.86 with a 
multiplet splitting pattern.  The 6’-CH3 was at δ 1.24 as a doublet with J= 6.5 Hz.  
Because furanoses have a compact, “envelope” conformation, the coupling constants 
between their protons are less than 7 Hz.  The rest of the 1H-NMR signals corresponded 
to the chromophore of gilvocarcin V when compared to published spectral data.  
Furthermore, the yield of this metabolite was comparable to that of wildtype S. 
griseoflavus and S. lividans (cosG9B3) (yield ~11.0 mg/L), therefore GilN appears to be 
not involved in GV biosynthesis.  Therefore, by process of elimination, it seems possible 
that gilL could encode a novel NAD-dependent epimerase/dehydratase enzyme involved 
in ring contraction of 103 to yield 97.   
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Figure 29 1H-NMR spectrum of gilvocarcin V isolated from S. lividans (cosG9B3-
gilN-) (500 MHz).   
Electrophoresis gel detailing colony PCR of ~200 base pair FLP scar from the gilN- 
mutant.  
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Figure 30 Structures of metabolites isolated from S. lividans (cosG9B3-gilN-). 
 
The presence of chryL in the chry cluster might be more clear upon this hypothesis that 
gilL might encode a putative ring contraction enzyme.  Obviously, S. albaduncus does 
not produce a C-glycosidically-linked furanose, but the Mercian strain that produces 
furanose compounds, Mer-1020 dA (49) and Mer-1020 dD (52), may employ a 
GilL/ChryL-like enzyme to ring contract the 4-keto-D-virenose moiety of the Mer-1020 
dC and Mer-1020 dB compounds.  Or, possibly, this occurs nonenzymatically and 
spontaneously. 
 
Construction of NDP-D-fucofuranose and NDP-D-virenose and intermediate-synthesizing 
cassettes for in vivo interrogation of GTs 
 
Previously, Salas et al. have demonstrated the ubiquity of cloning entire 
deoxysugar operons onto single plasmids for in vivo overexpression experiments  (39).  
This approach has resulted in generation of novel tetracenomycins and steffimycins with 
altered glycosylation patterns (141).  However, this approach has mostly focused on 2,6-
dideoxygenated and 2,3,6-trideoxysugars, while only one construct exists with a 2’-
hydroxysugar encoding L-rhamnose (pRHAM) (39).  Therefore, constructs which can 
direct biosynthesis of NDP-D-virenose and NDP-D-fucofuranose might be useful for in 
vivo glycodiversification.  To investigate the role of the various NDP-D-virenose 
biosynthetic genes in encoding biosynthesis of 96, and to evaluate the role of gilL in ring 
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contraction of 97, constructs were generated directing the biosynthesis of these sugars 
and their intermediates.  For this, pUWL201PW and pEM4 were used for expression of 
entire or combinations of the deoxysugar biosynthetic pathways.  Both pEM4 and 
pUWL201PW are Streptomyces spp. expression vectors that use the constitutive, strong 
ermE* promoter to overexpress cloned genes (128, 142).  For this, chryCMT was 
amplified upstream of its putative ribosomal binding site and cloned into pEM4, to yield 
pEN1.  ChryGT was cloned into pEN1 to yield pEN2, and both of these constructs were 
introduced into the S. lividans TK 24 (cosG9B3-GilU-) and S. lividans TK 24 (cosG9B3-
GilGT-) via protoplast transformation.  The resulting transformants were screened for 
their production of novel gilvocarcin-related compounds, however, unfortunately no new 
metabolites were accumulated in these strains.  This can be explained by the failure of 
GilGT to accept a branched sugar donor, or the failure of the pEN1 construct to encode a 
functional C-methyltransferase.  Simultaneously, the failure of pEN2 may account for 
ChryGT’s inability to accept five-membered sugar donors. 
ChryGT was replaced by chryU in pEN2 to afford pEN3 for heterologous 
expression in other pathways with NDP-glucose synthase and NDP-4,6-dehydratase.  
Furthermore, a series of pUWL201PW constructs were prepared with an entire NDP-D-
virenose pathway.  pUWL201PW affords a couple advantages:  several unique cloning 
sites for introduction of genes or combinations of genes, the aforementioned ermE* 
promoter, and an optimized ribosomal binding site.  First, ravDE were cloned into 
pUWL201PW in the PstI/BamHI sites to provide NDP-glucose synthase and NDP-4,6-
dehydratase (construct pUWL-DE).  RavDE have been proven to be functional through in 
vivo heterologous expression of the ravidomycin gene cluster and through in vitro 
characterization of their ability to produce NDP-4-keto-6-deoxy-D-glucose (30, 143).  
Cloning of chryCMT afforded pKVIR and addition of chryU afforded pVIR*II.  pKVIR 
is intended to biosynthesize NDP-4-keto-D-virenose (95), while pVIR*II is intended to 
biosynthesize NDP-D-virenose (96). 
A series of constructs intended to encode NDP-D-fucofuranose biosynthetic genes 
were prepared.  GilU was cloned into a unique site of pUWL-DE to afford pFUCO, 
which should biosynthesize NDP-D-fucose (103) in vivo.   GilL was cloned into this 
construct to afford pFUCOII, which should encode NDP-D-fucofuranose biosynthesis 
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(97).  All together, these constructs potentially biosynthesize rather unique 2-hydroxy-6-
deoxysugars that are not encoded in many biosynthetic pathways.  Furthermore, they 
might prove useful in interrogating the substrate flexibility of glycosyltransferases in 
other polyketide-producing organisms.  
 
SUMMARY 
 
In this chapter, gilL and gilN were both studied as potential candidates for the ring 
contraction step of D-fucofuranose, gilL encoding an NAD-dependent 
epimerase/dehydratase and gilN encoding a putative glycosyltransferase.  Subsequent 
inactivation of gilN in cosG9B3, and expression of this deleted cosmid, resulted in 
production of gilvocarcin V and M, which were verified by co-injection with standard 39  
and 40, mass, UV, and 1H-NMR spectral characterization.  Furthermore, production of 
gilvocarcin V in this strain was close to wildtype yields (~11.0 mg/L), which indicates 
that gilN plays no role in gilvocarcin biosynthesis.  GilL, then, appears to be a likely 
candidate for ring contraction.  Like gilU, gilL demonstrates similarity to NADH-
dependent epimerases/dehydratases, and its similarity to chryL might indicate a common 
ring contraction enzyme in both S. griseoflavus and the Mercian strain.  As heterologous 
expression of cosG9B3-gilL- was not possible, A number of different constructs were 
prepared with genes implicated in biosynthesis of NDP-D-fucofuranose and NDP-D-
virenose. 
EXPERIMENTAL 
 
Table 4 Bacterial strains and plasmids used in Chapter 3 
 
Strain/Plasmid Name Relevant Characteristics Reference 
Strains   
S. lividans TK 24 
(cosG9B3-GilN-) 
Produces 39 and 40.  S. 
lividans with cosG9B3-
GilN-deleted cosmid. 
This work. 
Plasmids   
pET-28a(+) KmR.  E. coli protein 
expression vector.  Used for 
subcloning. 
Novagen. 
pUC19 AmpR.  E. coli cloning 
vector. 
Stratagene. 
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pUWL201PW AmpR, TsrR.  E. coli-
Streptomyces shuttle vector.  
Used to overexpress genes 
under ermE* promotion. 
(144) 
pEM4 AmpR, TsrR.  E. coli-
Streptomyces shuttle vector.  
Used to overexpress genes 
under ermE* promotion. 
(145) 
pEN1 AmpR, TsrR.  chryCMT 
cloned under ermE* in 
pEM4. Intended to produce 
NDP-4-keto-D-virenose in 
strain with endogenous 
NDP-glucose synthase & 
4,6-DH. 
This work. 
pEN2 AmpR, TsrR.  chryCMT and 
chryGT cloned under 
ermE* in pEM4.  Intended 
to produce NDP-4-keto-D-
virenose and ChryGT in 
strain with endogenous 
NDP-glucose synthase & 
4,6-DH. 
This work. 
pEN3 AmpR, TsrR.  chryCMT and 
chryU cloned under ermE* 
in pEM4.  Intended to 
produce NDP-D-virenose in 
strain with endogenous 
NDP-glucose synthase & 
4,6-DH.  
This work. 
pFUCO AmpR, TsrR.  gilU, ravDE 
cloned under ermE* in 
pUWL201PW.  Intended to 
produce NDP-D-fucose. 
This work. 
pFUCOII AmpR, TsrR.  gilLU, ravDE, 
cloned under ermE* in 
pUWL201PW.  Intended to 
produce NDP-D-
fucofuranose. 
This work. 
pKVIR AmpR, TsrR.  chryCMT, 
chryDE cloned under 
ermE* in pUWL201PW.  
Intended to produce NDP-
4-keto-D-virenose. 
This work. 
pVIR*II AmpR, TsrR.  chryCMT, 
chryU, ravDE cloned under 
This work. 
76 
 
ermE* in pUWL201PW.  
Intended to produce NDP-D-
virenose. 
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Figure 31 DNA electrophoresis gels of D-fucofuranose and D-virenose constructs. 
(Upper)  Plasmid maps of pFUCO, pFUCOII, pVIR*II.  (Lower Left) NdeI/HindIII digest of 
pVIR*II.  (Lower Middle)   HindIII/BamHI digest of pFUCO.  (Lower Right) NdeI/HindIII 
digest of pFUCOII. 
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Table 5  Physico-chemical characterization of metabolites of S. lividans (cosG9B3-GilN-) 
strain 
 
O
O
OH OCH3
OCH3
O
HO
HO
H3C
HO
 
Gilvocarcin V (39) 
 
Rrel= 15.30 min-1; Yield:  11.0 mg/L 
 
MW= 494 g/mol (C27H28O9) 
 
Negative mode APCI-MS:  m/z=493 [M-H] (low res) 
 
UV maxima (from HPLC-diode array):  250 (90%), 287 (100%), 398 (35%) 
 
Position Gilvocarcin V (39) 
δH (500 MHz) 
1-OH 9.71 (1H, s) 
2-H 6.95 (1H, d, J=8.5) 
3-H 8.06 (1H, d, J=8.5) 
7-H 7.99 (1H, d, J=2.0) 
9-H 7.76 (1H, s) 
10-OCH3 4.19 (1H, s) 
11-H 8.48 (1H, s) 
12-OCH3 4.12 (1H, s) 
1′-H 6.19 (1H, d, J=5.5) 
2′-H 4.67 (1H, m) 
3′-H 3.86 (1H, m) 
4′-H 3.51 (1H, dd, J=4.2, 5.9) 
5′-H 3.86 (1H, m) 
6′-CH3 1.24 (1H, d, J=6.5) 
1”-H 6.94 (1H, dd, J=18.0, 11.0) 
2”-He 5.50 (1H, d, J=11.0) 
2”-Hz 6.14 (1H, d, J=18.0) 
                                                             a) Dimethyl sulfoxide-d6, J in Hz 
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Table 6  Oligonucleotides used in Chapter 3 
 
 
Primer Name Oligonucleotide Sequence 
chryCMT_XbaI_
for 
5’- ATTTCTAGACCTTCCCGACGCCCCGTG-3’ 
chryCMT_NdeI_
for 
5’- ATTCATATGCCTTCCCGACGCCCCGTG-3’ 
chryCMT_SpeIE
coRI_rev 
5’- ATTGAATTCTACTAGTGCGGCGGCG GGGTGC-3’ 
chryU_SpeI_for 5’-ATACTAGTCGGAATGCCGACAACT-3’ 
chryU_EcoRI_re
v 
5’-GTCGAATTCGAGGTCTCCTCGGATCG-3’ 
chryGT_SpeI_for 5’- ATACTAGTGCTAGCACGGCGGCGCCG TTTCC-3’ 
chryGT_EcoRI_r
ev 
5’-ATGAATTCAGGCGGGAGCAGGCGGG -3’ 
chryDE_PstI_for 5’-ATCTGCAGTTTGTCCACGCTGTTGTTT-3’ 
chryDE_BamHI_
rev 
5’-TTCGGATCCAATGCCCTATGCGAT-3’ 
gilU_HindIII_for 5’- ATAAGCTTGCAGTGAGGCACTC CTGTCGTC -3’ 
gilU_EcoRI_rev 5’-ATGAATTCCGGCCTGGGTCTTTTGT CGTTC -3 
ravDE_PstI_for 5’-GTTCTGCAGTCC GCAGTGAATTCC CGG -3’ 
ravDE_BamHI_r
ev 
5’-TTA AGGATCCGAGATGAGTGCGCACCCA-3’ 
gilL_NdeI_for 5’- ACCATATGAAAGTAGCAGTGCTCGGT-3’ 
gilL_HindIII_rev 5’- ACAAGCTTGACACACGTGTCCCTGGT-3’ 
gilN_FRT_for 5’-
CGTCAGCGGAGCAGCCGGGTGGAGTGGGGTGAGGGCATG
ATTCCGGGGATCCGTCGACC -3’ 
gilN_FRT_rev 5’-
CCTCGTTCTCTTCTGCCGCCGCGTTCGCCCTTCGGGTCATG
TAGGCTGGAGCTGCTTC -3’ 
gilN_ctrl_for 5’-CTGTTCGTGTGGGGCGGG-3’ 
gilN_ctrl_rev 5’-TCGCCGCCGCGGCCCGGTCCGCA -3’ 
 
Isolation of metabolites from S. lividans TK 24 (cosG9B3-GilN-) 
 
For the isolation of substantive amounts of the major metabolite from S. lividans 
TK 24 (cosG9B3-GilN-), a 5 liter fermentation of the organism in SG media was carried 
out in a two stage fermentation process.  In brief, a glycerol stock of S. lividans TK 24 
(cosG9B3-GilN-) was thawed and 100 μL of the revived strain was plated on an M2 agar 
plate supplemented with 50 μg/mL apramycin and incubated at 28 °C for 5 days.  In a 
80 
 
first stage growth phase, spores of this organism were inoculated into a 100 mL flask of 
sterilized SG media in a 250 mL baffled flask, and this flask was incubated in an orbital 
shaker for 3 days (250 RPMs, 28 °C).  For the production phase, five liters of sterilized 
SG media was apportioned in 500 mL amounts in 10 baffled 2 liter Erlenmeyer flasks.  
This media was supplemented with 50 μg/mL apramycin and 5% (v/v) of the culture 
from the growth phase flask was inoculated into each of the production phase flasks.  
This fermentation was carried out for five days.  The culture was collected, filtered with 
celite (50 g/L fermentation), and the resulting mycelial cake was extracted twice with 
acetone, dried in vacuo under reduced pressure, and the rest of the aqueous phase was 
dried by lyophilization.  The culture filtrate was passed over a 5 × 10 cm C18 reverse 
phase silica column, washed with water, and the retained material was eluted in a 
gradient of 20%, 40%, 60%, 80%, and finally 100% MeOH:H2O.  The major metabolites 
were mostly eluted in the 80% and 100% gradients of MeOH.  The fractions containing 
gilvocarcins were compiled, the solvent was dried in vacuo, and the water was removed 
by lyophilization on a freeze drier. 
The individual peaks were resolved via semi-preparative high-performance liquid 
chromatography (HPLC) on a Sun-Fire semi-prep C18 column (19×150 mm, 5 μm) on a 
Waters 1525 EF platform with a Waters 2487 dual absorbance detector UV lamp.  A 
gradient of 0.2% formic acid in double distilled water and acetonitrile was used  (Solvent 
A= 0.2% formic acid in water, solvent B=acetonitrile; 0–15 min 25% B to 100% B; 16–
24 min 100% B; 25–26 min 100% to 25% B; 27–32 min 25% B, flow rate 2.5 mL/min).  
The eluted material under each peak was collected, dried in vacuo, and finally 
lyophilized.  Sample purity was verified via HPLC/MS analysis to assure the presence of 
a single peak.  The sample was further dried under nitrogen gas for 2-3 hours, and finally, 
dissolved in DMSO-d6 for 1H-NMR measurements.  NMR was recorded on a Varian 
VNMR 500 MHz spectrometer. 
 
PCR Redirect inactivation of gilN and conjugal transfer of cosG9B3-gilN- 
 
The disruption cassette for inactivation of gilN was amplified using a 
chloramphenicol resistance template and 59-nucleotide long primers gilN_FRT_for and 
gilN_FRT_rev (see Table 3.3).  The boxed-in regions of the primers indicate genetic 
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regions of 39 base pairs directly upstream and downstream of the gilN ATG start codon 
(gilN_FRT_for) and the gilN TGA stop codon (gilN_FRT_rev), respectively, and the 20 
nucleotides that are not boxed-in bind to the chloramphenicol resistance cassette. The 
cassette was introduced into E. coli BW25113/pKD20, containing cosmid G9B3 (Apr-
resistant), which encodes all of the genes for gilvocarcin biosynthesis in Streptomyces sp. 
The disrupted cosmid (cosG9B3-CHL-gilN-), containing the chloramphenicol resistance 
cassette, was introduced into E. coli XL-Blue MRF’/pcp20.  This E. coli strain harbors an 
FLP-recombinase gene that recognizes genetic sites on both sides of the gilN-CHL 
genetic locus of cosG9B3-CHL-gilN-, and it excises this genetic locus resulting in an in-
frame 81 base pair scar.  AprR, ChlS sensitive colonies were identified by replica plating 
and verified by PCR analysis using a pair of control primers that amplify a region~100 
base pairs upstream and downstream of gilN,  gilN_ctrl_for  and gilN_ctrl_rev (see Table 
3.3). While the original gilN PCR products from cosG9B3 showed products of 966 base 
pairs, after FLP-mediated excision of the disruption cassette, a PCR product of ~250 bp 
was obtained (Table 3.3).  CosG9B3-gilL- was generated in a similar fashion.  The 
mutated cosmids cosG9B3-gilL- and cosG9B3-gilN- were introduced into Streptomyces 
lividans TK24 by conjugation from E. coli ET12567 carrying the non-transmissible 
helper plasmid pUZ8002 as described by Kieser et al. (3)  
 
Cloning of 6-deoxy-2’-hydroxy-hexose biosynthesizing plasmids 
 
For the generation of plasmids that could direct the biosynthesis of NDP-D-
fucofuranose and NDP-D-virenose, the various genetic components of their biosyntheses 
were amplified via polymerase chain reaction using cosChry1-1 and cosG9B3 as 
templates (Figure 30).  Pfu polymerase was used to amplify genes from template DNA 
as described in chapter 2, except for gilU, which was cloned with Taq polymerase, blunt 
ended, then cloned into TOPO vector.  All PCR products were ligated into TOPO cloning 
vector following the manufacturer’s protocols.  ChryCMT was amplified from cosChry1-
1 with two sets of forward primers and reverse primers, one pair for incorporating 
XbaI/EcoRI  restriction sites and one pair for incorporating NdeI/HindIII  restriction sites, 
for pEM4-based and pUWL201PW-based cloning, respectively.  TOPO-chryCMT was 
digested with XbaI/EcoRI and ligated into the same sites of pEM4 downstream of the 
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ermE* promoter to give pEN1.  This resulting construct was digested with SpeI/EcoRI 
for ligation of chryGT to yield pEN2.  For pEN3, chryGT was digested out with 
SpeI/EcoRI and chryU was ligated into the same restriction sites.  For vectors with an 
enhanced ribosomal binding site and for expressing entire NDP-D-fucofuranose and 
NDP-D-virenose biosynthetic pathways, pUWL201PW was chosen.  RavDE and chryDE 
were amplified independently, cloned into TOPO vector, and digested with PstI/BamHI 
and ligated into a unique restriction site downstream of the ermE* promoter of 
pUWL201PW to give pUWL(chryDE) or pUWL(ravDE). TOPO-chryCMT(NdeI) was 
digested with NdeI/EcoRI and ligated into the same sites of pET-28a(+) to give pET-
28a(+)-(chryCMT).  ChryU was ligated into the SpeI/EcoRI site of this vector, to yield 
pET-28a(+)-(chryCMT+chryU), which was then digested with NdeI/HindIII to give a 
~2.4 kb chryCMT-U band, which was then rescued and ligated into the NdeI/HindIII sites 
of pUWL(ravDE) to afford pVIR*II.  ChryCMT from pET-28a(+)-(chryCMT) was 
digested out and ligated into the NdeI/HindIII sites of pUWL(chryDE) to give pKVIR.  
Digestion of gilU with HindIII/EcoRI from TOPO-gilU and subsequent ligation of it into 
pUWL(ravDE) afforded pFUCO.  pFUCOII was generated by ligation of gilL cut with 
NdeI/EcoRI into pFUCO in the same sites. 
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CHAPTER 4:  ALTERING THE GLYCOSYLATION PATTERN OF 
TETRACENOMYCINS 
INTRODUCTION 
 
Tetracenomycin C (8) and elloramycin (106) are anthracycline-like polyketides 
produced by Streptomyces glaucescens and Streptomyces olivaceus Tü 2353.  
Tetracenomycin C was discovered by Weber et al. in 1979, and elloramycin was 
discovered and its structure solved by Rohr et al. in 1985 (146-147).  The cloning of the 
biosynthetic gene loci for 8 and 106 by Hutchinson et al. paved the way for further 
characterization of the enzymatic components for these compounds, and polyketides as a 
whole (148-149)  The biosynthesis of these molecules was fundamental for 
understanding the role individual enzymes in polyketide synthesis and establishing 
minimal gene sets for cyclization/aromatization (150-153).  The biosynthesis of 8 and 
106 was found to have tetracenomycin B3 as a branching point between them, in the case 
of elloramycin having 8-O-rhamnosylation by ElmGT and in the case of tetracenomycin 
C 8-O-methylation by TcmN (Figure 32) (154). 
The minimal PKS consisting of ElmKLM installs the poly-β-ketothioester, which 
is cyclized by ElmNI, J, and I to afford tetracenomycin F1 (Figure 32).  ElmH installs 
the quinone oxygen, and ElmG is a novel monooxygenase-dioxygenase that catalyzes the 
triple hydroxylation of tetracenomycin A2 to afford tetracenomycin C (8) (155).  The 4- 
and 12a- oxygens are installed stepwise from molecular diatomic oxygen, while the 4a-
oxygen is installed from attack of water onto the oxirane.  In the process, the aromaticity 
of the D ring of tetracenomycin is broken, thereby resulting in a hypsochromic shift in the 
UV spectrum from ~450 nm (e.g. red anthraquinones TCM B3 and D3) to ~412 nm (e.g. 
yellow 8-DMTC, 105).  In the biosynthesis of elloramycin, ElmGT glycosylates 8-O 
position of 105 with L-rhamnose, and subsequent O-methylations of the 2’, 3’, and 4’-OH 
positions of the L-rhamnose moiety by ElmMI, ElmMII, ElmMIII, and O-methylation of 
the 4a-OH by ElmD (Figure 32)(126, 156).   
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ElmGT is one of the most flexible glycosyltransferases in secondary metabolism 
 
Cos16F4 was hypothesized to harbor a sugar flexible glycosyltransferase after it 
was heterologously expressed in the mithramycin producer, S. argillaceus, and the 
urdamycin producer, S. fradiae (157).  When expressed in PKS-deletion mutants of both 
producing strains, D-olivosyl (107), L-rhodinosyl (116), D-mycarosyl (108), and D-
olivosyl-1,3-D-olivosyl (109) tetracenomycin analogues were accumulated in the 
fermentations of these recombinant organisms (Figure 33) (157-158).  Furthermore, 
these derivatives were produced in a S. argillaceus mutant in which all four 
glycosyltransferases were inactivated, thereby indicating that the glycosyltransferase 
responsible for the sugar transfer was encoded on cos16F4 (157).  The identification of 
the 1149 nucleotide sequence for elmGT enabled new experimentations regarding 
deoxysugar biosynthesis.   
Salas et al. expounded upon the cosmid expression experiments of Rohr et al. by 
cloning accessory plasmids that encoded deoxysugar biosynthetic genes into a single 
combinatorial operon.  By cloning genes from the oleandomycin biosynthetic pathway, L-
oleandrose biosynthetic genes were sequentially cloned into plasmid “pLN2” and 
successfully co-expressed with cos16F4 to afford L-olivosyl tetracenomycin C (113) and 
several congeners (e.g. 114,Figure 33) that were O-methylated by the ElmMI, ElmMII, 
and ElmMIII O-methyltransferases (Figure 32) (39, 159).  By deleting the oleV  (2,3-
dehydratase) and oleW (3-ketoreductase) genes from this construct resulted in pLN2Δ or 
pRHAM plasmids (e.g. NDP-L-rhamnose biosynthesis) that when co-expressed with 
cos16F4 in S. lividans restored production of elloramycin A (106) (39).  These initial 
experiments revealed remarkable flexibility of the deoxysugar biosynthetic genes oleL 
(3,5-epimerase) and oleU (4-ketoreductase) in accepting both NDP-4-keto-2,6-
deoxyhexose and NDP-4-keto-6-deoxyhexose intermediates.  Furthermore, it proved that 
deoxysugar biosynthetic genes could be cloned into a single operon for heterologous 
overexpression in a foreign host.  These experiments demonstrated that ElmGT had 
unprecedented substrate flexibility towards foreign D- and L-configurated deoxysugar 
donor substrates.  Furthermore, substrate flexibility on behalf of the deoxysugar 
biosynthetic enzymes revealed that it would be possible to exploit the “plug and play” 
construction of pLN2 to incorporate other genes that would alter the stereochemistry of 
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deoxysugars produced in vivo.  Taken together, these results yielded a platform in which 
the substrate flexibility of ElmGT could be interrogated and different deoxysugar 
constructs could be assayed for their ability to produce novel glycosylated 
tetracenomycins.   
This proof of concept yielded many other deoxysugar constructs that produced 
novel tetracenomycin derivatives (107-120), which were able to be characterized via 
mass, UV, and various 1H, 13C, and 2D  NMR spectroscopic analyses (Figure 32) (39, 
160-163).  Unfortunately, the antitumoral activity of many of these compounds was 
worse than 106, with the exception of 118, which exhibited GI50 values in several breast 
(MDA-MB-231), NSCL (A549), and colon (HT-29) cancer cell lines of below 10-5 molar 
concentrations in the sulforhodamine B cytotoxicity assay (162).  Very likely, the 
presence of a C-3’-methyl branch on the α-L-mycarose moiety is partly responsible for 
the slightly improved cytotoxicity of this derivative.   
Surprisingly, accumulation of 113 in the culture broth of S. lividans 
(cos16F4)/pRHAM indicated that ElmGT could accept NDP-D-glucose (30) as a donor 
substrate (163).  This was surprising because many glycosyltransferases involved in 
polyketide biosynthesis discriminate against nondeoxygenated sugars, such as NDP-D-
glucose (30).  Instead, 6-deoxygenation appears to be a structural pre-requisite before 
many glycosyltransferases will bind a sugar donor substrate, even though NDP-D-glucose 
is present as an intermediate in many biosynthetic pathways.  Interestingly, NDP-D-oliose 
(35) was never transferred by ElmGT, neither when a sugar plasmid directing its 
biosynthesis was introduced, nor when cos16F4 was heterologously expressed in S. 
argillaceus, which produces NDP-D-oliose endogenously (158, 160).  As such, 111 is the 
only example in which a D-configurated sugar with an axial 4-OH has been transferred by 
ElmGT; the axial 3-OH may force it to have a slight conformational change in the active 
site that allows it to bind.  One other “limitation” of ElmGT appeared to be its apparent 
inability to transfer ketosugars; one plasmid, pRHAMΔU, which directs NDP-4-keto-L-
rhamnose biosynthesis, did not result in any glycosylated tetracenomycins when it was 
co-expressed with cos16F4.  Recently, mutation of active site residues of ElmGT has 
been shown to modulate transfer of specific deoxysugars (164).  
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Figure 33 Elloramycin analogues generated by combinatorial biosynthesis. 
Previously reported differentially glycosylated derivatives of 8-demethyl tetracenomycin 
C (105).  ElmGT demonstrates remarkable substrate flexibility to a variety of L- and D-
configurated NDP-deoxysugar donors (107-120).  
 
Aminosugars:  their importance for glycodiversification, bioactivity, and solubility  
 
Incorporation of aminosugars into a glycosylated antibiotic is one important 
strategy for altering its bioactivity through glycodiversification.  Aminosugars are 
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important for the bioactivity of many antibiotic compounds.  Among the foremost of 
these are the aminoglycosides, such as kanamycin and neomycin, which are broad 
spectrum antibiotic agents that bind to the 30S subunit of the ribosome of bacteria.  The 
biosynthesis of these important antibiotics features generation of a diversity of 
aminosugars and specialized glycosyltransferases that catalyze their attachment.  Being 
that these compounds are purely carbohydrate derived, they are highly soluble in water 
and can be packaged as a salt. 
Macrolides, such as methymycin (3) and erythromycin A (7), employ an 
aminosugar, NDP-D-desosamine, which enables binding to the 30S subunit of the 
ribosome as a mechanism of action (165).  NDP-D-desosamine is a particularly intriguing 
aminosugar, from the standpoint that it is 4-deoxygenated.  The desosamine biosynthetic 
pathway has been studied extensively by the Hung-wen Liu group, and it was 
demonstrated that NDP-4-keto-6-deoxy-D-glucose (32) is the substrate for a novel PLP-
dependent 4-aminotransferase, DesI, which generates TDP-4-amino-4,6-dideoxy-D-
glucose (121), which is then oxidatively deaminated by DesII to afford TDP-3-keto-4,6-
dideoxy-D-glucose (122), which undergoes PLP-dependent 3-amination by DesV to 
afford TDP-3-N,N-didemethyl-D-desosamine (123) (Figure 34) (166-170). 
Medermycin is a member of the benzoisochromanequinone family of polyketides, 
and its only distinguishing characteristic is the C-glycosidically linked aminosugar D-
angolosamine.  It has activity against gram positive bacteria, and like 123, possesses a 
dimethylamino functionality at 3-position, in the case of 123 3,4,6-trideoxygenation and 
in the case of 124 2, 3, 6-trideoxygenation (Figure 34).  The dimethylamino functionality 
is important for converting the amine functionality into a tertiary amine, which is 
potentially useful for the formation of a quaternary ammonium cation in solution.  In the 
biosyntheses of both 123 and 124, a keto group is the handle for transamination:  for 123, 
the 3-keto group from 2,3 dehydration by Med16, and in the case of 124, the 4-keto 
group of NDP-4-keto-6-deoxy-D-glucose and the resulting 3-keto group from DesII 
deamination of 121 (Figure 34). 
Daunorubicin (25) and doxorubicin (26) are canonical polyketide anticancer 
drugs. Central to their activity is the α-glycosidically linked L-daunosamine residue (126, 
Figure 34), that is responsible for positioning these drugs within the minor groove of 
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DNA (171).  The L-acosamine sugar (125) of 4’-epidoxorubicin (epirubicin) affords this 
drug with faster clearance, and as a result, it evinces lessened cardiotoxicity as compared 
to 26.  Hutchinson et al. were able to genetically engineer a 4’-epirubicin-producing 
strain of S. peucetius 29050 by inactivating the host 4-ketoreductase, dnmV, and 
integrating a copy of the equatorial-reducing 4-ketoreductase, avrE, into the chromosome 
(171) (Figure 34).  This experiment demonstrated the ubiquity of 
inactivating/recombining deoxysugar biosynthetic genes to steer flexible 
glycosyltransferases towards accepting alternate sugar donors. 
As a result, constructs pertaining to the biosynthesis of 121-127 were previously 
cloned by Madan Kharel and Tao Liu, yet the functionality of these plasmids to encode 
successful aminosugar synthesizing pathways had not successfully been addressed.  One 
of the aims of this present work is to individually transform each of these aminosugar 
plasmids into S. lividans (cos16F4) in an effort to interrogate ElmGT’s ability to transfer 
sugar donor intermediates that may be accumulated in these recombinant strains 
(Chapter 4 Experimental). 
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RESULTS AND DISCUSSION 
 
Reconstitution of cos16F4 8-demethyl tetracenomycin C heterologous production 
 
Previously in the Rohr lab, S. argillaceus (MtmPKS-)/cos16F4 and S. fradiae 
(UrdA-)/cos16F4 strains were generated by heterologously expressing cos16F4 in 
vivo(172).  However, no glycerol stock for the S. lividans (cos16F4) strain used by Salas 
et al. for co-expression of “sugar plasmids” along with elm biosynthetic machinery was 
available.  Moreover, it was necessary to re-establish a producing strain for co-expression 
experiments.  The advantage of using S. lividans as a host strain for heterologous 
expression of cos16F4 is that it possesses no overt deoxysugar biosynthesis of its own, 
therefore, expression of cos16F4 in S. lividans results in accumulation of the aglycone, 8-
demethyl tetracenomycin C.  Therefore, it was envisioned that cos16F4 could be 
transformed efficiently via either protoplast transformation or electroporation.  Because 
cos16F4 is a pKC505-derived vector, it lacks the necessary oriT for conjugation with E. 
coli ET12567/pUZ8002, as was used to transform the cosmids in Chapter 1 (Materials 
and Methods).  Therefore, protoplasts of S. lividans TK 24 were prepared and 
transformed with cos16F4 DNA.  Several days later, thirteen colonies expressing the 
AprR were selected and plated on an M2 agar plate supplemented with apramycin.  One 
colony exhibited excellent growth and a dark red-orange pigmentation, and this colony 
was fermented in 100 mL SG media supplemented with apramycin.  After four days, this 
strain was extracted with EtOAc, and the extract had a characteristic red-orange hue.  To 
this end, 20 μL of this methanolic extract was analyzed by HPLC/MS and a single peak 
eluting at Rt=12.0 min-1, with a characteristic UV absorption of the tetracenomycins (UV 
(MeOH) λmax at 212, 289, 412 nm) (Figure 35).  The compound demonstrated a parent 
fragmentation of 459 amu [M-H] (ESI-MS (–ve) mode, Figure 35) which was consistent 
with the reported mass/UV spectra for 8-demethyl tetracenomycin C.  Furthermore, the 
extract exhibited strong blue fluorescence when exposed 360 nm UV light.  This strain, S. 
lividans (cos16F4) was saved for further transformation experiments with deoxysugar 
cassettes. 
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Figure 35 (Upper) HPLC Chromatogram trace of S. lividans (cos16F4) 
methanolic extract, 8-demethyl tetracenomycin C (105) Rt=12.0 min-1.  (Lower)  ESI-MS 
(low res) [459 amu, M-H] (–ve) mode of 105.  Characteristic UV-vis of 8-demethyl 
tetracenomycin C (105). 
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Heterologous expression of aminosugar and 2’-hydroxysugar synthesizing 
cassettes 
 
Previously, constructs directing the biosynthesis of NDP-D-angolosamine and 
NDP-3-N,N-didemethyl-D-desosamine were cloned using the strong constitutive ermE* 
promoter of pEM4 (Chapter 2, Table 2.1; Chapter 4, Table 4.1).  The desosamine 
biosynthetic genes were cloned sequentially into pEM4 by Dr. Kharel, synthesizing three 
cassettes that would biosynthesize 121-123 (Dr. Kharel, Unpublished Results).  pDesI 
contains desIII, desIV, and desI and should biosynthesize aminosugar 121; pDesII 
contains desIII, desIV, desI, and desII and should biosynthesize 3-ketosugar 122; pDesIII 
contains desIII, desIV, desI, desII, and desV and should synthesize didemethyl NDP-D-
desosamine.  pDmnI was made by replacing the oleW 3-ketoreductase gene of pLN2 with 
the daunosamine 3-aminotransferase, dnrJ, and it was anticipated to encode biosynthesis 
for 125.  For biosynthesis of 126, NDP-L-daunosamine, a gene complement of dnrJUV 
was substituted for the oleWLU 3-ketoreductase, 3,5-epimerase, and 4-ketoreductase 
genes of pLN2.  The incorporation of these genes should afford 3-transamination, 3,5 
epimerization, and axial 4-ketorduction to yield 126. 
Upon transforming each of these constructs independently into the S. lividans 
(cos16F4) strain, and analyzing methanolic extracts of the transformants, most of these 
strains failed to accumulate glycosylated tetracenomycins.  Most likely, ElmGT is 
incapable of transferring aminosugars.  As an alternative explanation, the aminosugar 
plasmids may not synthesize the intended aminosugars in vivo.  Surprisingly, in extracts 
of S. lividans (cos16F4)/pDmnI, an additional peak with Rt= 15.7 minutes was 
accumulated, in addition to 105 (Figure 36).  This peak demonstrated a parent 
fragmentation of 659 amu in (-ve) ESI-MS mode, which corresponds to the mass of 
elloramycin A (106).  No other glycosylated tetracenomycins could be identified in these 
extracts when investigating the UV spectrum at 385 nm wavelength.  This finding can be 
explained because pDmnI also contains oleSELU, which are the gene complement of the 
pRHAM plasmid that is known to produce NDP-L-rhamnose in vivo (39).  OleLU 
demonstrate flexibility towards both NDP-6-deoxyhexoses and NDP-2,6-deoxyhexoses.  
The deletion of oleLU and replacement of these genes with dnrJUV in pDmnII 
effectively eliminated this NDP-L-rhamnose pathway, as 106 was not accumulated in that 
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strain.  The failure to accumulate tetracenomycins with appended aminosugars is not 
unusual, as there are virtually no examples of glycosyltransferases in secondary 
metabolism that show flexibility towards aminosugar donors that do not already bind an 
aminosugar donor as a natural substrate.  Recently, in the S. venezuelae pikromycin 
biosynthetic pathway, the DesVII desosaminyltransferase responsible for transferring 
NDP-D-desosamine to its macrolide aglygones was found to require the co-expression of 
DesVIII in order to form a catalytically active glycosyltransferase (173).  Without 
DesVIII, DesVII was catalytically inactive, however, when co-expressed with DesVIII 
then separated, DesVII was catalytically active.  The erythromycin, doxorubicin, and 
tylosin biosynthetic pathways all possess candidate ORFs for such aminosugar 
glycosyltransferase auxillary proteins:  EryCII, DnrQ, and TylM3 (173).  Very likely 
aminosugar glycosyltransferases require these chaperone proteins for proper folding; the 
one glycosyltransferase where this does not appear to be the case is RavGT, which can 
transfer both NDP-D-fucofuranose and NDP-D-ravidosamine without an apparent 
chaperone (30).  To prove the functionality of these constructs, very likely they will need 
to be expressed in blocked pathways from which they were expressed (e.g. pDmnI or 
pDmnII in daunosamine disruption mutants of S. peucetius; pDesI, pDesII, pDesIII in 
desosamine disruption mutants of S. venezuelae). 
 
Figure 36 HPLC chromatogram of S. lividans (cos16F4)/pDmnI extract.   
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Heterologous expression of 2-hydroxysugar plasmids and ketosugar plasmids 
 
pFUCO, pFUCOII, pVIR*II, and pKVIR were all introduced into S. lividans 
(cos16F4) via protoplast transformation.  Fucosylated and virenosylated tetracenomycins 
were expected to be accumulated in the recombinant strains.  Unfortunately, methanolic 
extracts failed to reveal the presence of glycosylated tetracenomycins.  Again, either the 
constructs failed to synthesize the intended deoxysugars in vivo, or ElmGT was unable to 
successfully accept the donor substrate.  There is some evidence to support this latter 
finding, because in at least two separate cases, ElmGT was unable to accept a D-
configurated sugar that has an axially positioned 4’-OH (158, 160).  When cos16F4 was 
heterologously expressed in the mithramycin producer S. argillaceus, and when cos16F4 
was co-expressed with a plasmid directing biosynthesis of NDP-D-oliose (35), no D-
oliosyl tetracenomycin C was isolated and described (158, 160).  This indicates that 
ElmGT has poor tolerance for D-configurated sugar donors with axially configurated 4-
OH groups, which applies to sugars 96 and 103.  However, these constructs may not also 
be functioning in vivo. 
Additionally, ketosugar constructs were generated by deletion of 4-ketoreductases 
from pFL942 and pLN2-derived constructs (39) (Figure 37).  pKOL was generated by 
deleting oleU from pLN2 and re-ligating the plasmid, and it should direct biosynthesis of  
NDP-4-keto-L-olivose (Figure 37 and Figure 38) pFL952 (e.g. NDP-4-keto-L-mycarose, 
Figure 37) was constructed by deleting eryBIV from pFL942 and re-ligating, and 
cmmUII and oleY were removed from pMP1*UII to afford pDKOL (e.g. NDP-4-keto-D-
olivose) (Figure 37).   
 
Figure 37 Ketosugar plasmid maps generated for this work.   
Genes are color-coded according to function:  Pink (NDP-glucose-synthase); Blue (4,6 
dehydratase);  Green (2, 3-dehydratase); Yellow (3-ketoreductase); Grey (O-
methyltransferase not functioning in this construct), Purple (3-C-methyltransferase); Red 
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(3,5 epimerase (oleL)) or 5-epimerase (eryBVII));   Appropriate restriction sites used for 
cloning are indicated. 
 
In these latter two constructs, mtmD and mtmE are under the control of one divergent 
ermE* promoter, and the other sugar genes are under the control of another divergent 
ermE* promoter.  Plasmid maps for all of these constructs are depicted in Figure 37.  
 The activities of OleS (NDP-glucose-synthase), OleE (NDP-glucose-4, 6-
dehydratase), OleV (2, 3-dehydratase), OleL (3, 5-epimerase), and OleW (3-
ketoreductase) catalyze the conversion of NDP-D-glucose to NDP-4-keto-2, 6-dideoxy-D-
glucose during the biosynthesis of NDP-L-olivose (Figure 38). The 4-ketoreduction step 
catalyzed by OleU represents the last step of the NDP-L-olivose biosynthetic pathway.  
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Figure 38 Deoxysugar biosynthesis for ketosugars encoded by pKOL, pDKOL, and 
pFL952.   
Blue sugars are encoded final products of these pathways.  Enzyme names in brackets 
indicate genes that were deleted from these constructs. 
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Thus, the absence of oleU from pLN2 in pKOL would lead to the accumulation of NDP-
4-keto-L-olivose, which could be utilized by ElmGT as an alternative donor substrate 
when the natural substrate (TDP-L-rhamnose) is not available. To test this hypothesis, the 
pKOL plasmid was expressed in the S. lividans (cos16F4) strain. 
Interestingly, expression of pKOL in S. lividans (cos16F4) resulted in the 
accumulation of two major peaks with Rt  (10.76 and 11.26 min., respectively), in 
addition to 8-DMTC, when ethyl acetate extracts were analyzed by HPLC/MS (Figure 
39).  Both peaks showed UV absorption typical for a tetracenomycin-type compound. 
Low resolution ESI/MS revealed a peak of 585 amu (-ve mode) pertaining to the 
molecular ion of the compound and a pseudomolecular ion of the hydrated species at 603 
amu (-ve mode), indicating the addition of water to the molecule.  These data suggested 
that this compound could be a new tetracenomycin analogue with an attached NDP-4-
keto-2, 6-dideoxy ketosugar. Under aqueous condition, ketosugars can easily interconvert 
from the keto form to a hydrate form. The second peak possessed an m/z value of 587 in 
(-) ESI mode.  These mass data suggested the presence of a glycosylated tetracenomycin 
in which the sugar was fully reduced. Both peaks possessed a fragmentation ion 
corresponding to the 8-DMTC aglycone (m/z 457, M-H-).  This strain was fermented in a 
large scale fermentation (7.2 L) for isolation and spectroscopic characterization of the 
metabolites.  Unfortunately, expression of pFL952 and pDKOL failed to accumulate 
appreciable amounts of glycosylated metabolites.  Very likely, the encoded donor sugar 
substrates are not recognized by ElmGT. 
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Figure 39 HPLC analyses of the metabolites:  
 trace A, 8-demethyl-tetracenomycin C (A) (Rt. 12.98 min.) isolated from S. lividans 
(cos16F4); trace B, metabolites isolated from the S. lividans (cos16F4)/pKOL mutant, 8-
demethyl-(4’-keto)-α -L-olivosyl-tetracenomycin C (B (Rt. 10.76 min.) and D (Rt. 12.26 
min.) denote hydrated and keto forms, respectively) and 8-demethyl-α -L-olivosyl-
tetracenomycin C (C) (Rt. 11.26 min.)  
Structural Elucidation of Metabolites Accumulated by the S. lividans (cos16F4)/ 
pKOL strain 
 
The structure of 8-demethyl-8-(4΄-keto)-α-L-olivosyl-tetracenomycin C (127, 
Figure 40) was solved through NMR and mass spectral analyses. The (-) HR-ESI MS of 
3 showed two peaks at 585.1267 amu and 603.1363 amu, which corresponded to the 
molecular formula of its keto form (C28H26O14 , calcd. molecular weight 585.1317 [M-H-
]) and its hydrate from (C28H26O14, calcd. molecular weight 603.1423 amu [M-H-]), 
respectively. 1H NMR data of 127 revealed 2 singlets for two aromatic protons (δ 7.94 
and δ 7.66) and two methoxy signals corresponding to the 3-OCH3 (δ 3.81) and 9-OCH3 
(δ 3.97) of 8-DMTC, respectively (1H and 13CNMR table in Table 4.3).  The anomeric 
proton of the sugar appeared as a broad singlet (δ 6.16) which suggested its α 
configuration. A pair of protons at δ 2.13 and δ 2.24 corresponded to the C-2′ methylene 
protons. A 4΄-H signal was not observed, indicating the presence of keto/hydrated-keto 
group. The splitting of the 3΄-H (dd, J= 12.0, 6.5 Hz) at δ 4.68 indicated a large diaxial 
coupling with 2΄-Ha and an axial-equatorial coupling with 2′-He. The 5΄-H appeared as a 
quartet (J= 6.5 Hz) at δ 4.39, which indicated coupling with 6΄-CH3.  The 1H, 1H-COSY 
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exhibited two spin systems for the sugar moiety, one stretching from 1΄-H to 3΄-H, and 
the other stretching from 5΄-H to 6΄-CH3, which strongly indicates the presence of a 
ketone/hydrated ketone at C-4΄ (Figure 40).  The 13C showed a carbonyl signal at δ 
207.4, which indicates that 127 is present predominantly in the ketosugar form when 
measured in Methanol-d4.  The HMBC demonstrated correlations between 6’-CH3 
protons and both 5’-C and 4’-carbonyl, which indicated that the ketone was present at 4’-
position (Figure 40).  These data suggested the structure of 127 as 8-demethyl-8-(4΄-
keto)-α-L-olivosyl-tetracenomycin C. 
  Compound 114 was eluted at the identical retention time when co-injected with 
standard 8-demethyl-8-α-L-olivosyl-tetracenomycin. The identity of 114 as 8-demethyl-
8-α-L-olivosyl-tetracenomycin was further confirmed through the comparison of 1H 
NMR data with published 1H NMR data.  
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Figure 40 Selected 2D-NMR for 127.   
1H-1H-COSY (▬), and selected HMBC (→) correlations of 8-Demethyl-8-(4'-keto)-α-L-
olivosyl-tetracenomycin C (127). 
 
 The presence of 127 was quite interesting, because ElmGT has never been shown 
to carry a ketosugar before.  As such, isolation and characterization of 127 represents the 
first successful attempt to overcome ElmGT’s inflexibility towards a ketosugar.  As a 
result, it seems plausible that ElmGT demonstrates at least some substrate flexibility to 
this L-configurated ketosugar, because of its close stereoelectronic similarity to NDP-L-
rhamnose.  It is possible that ElmGT binds the hydrated form of NDP-4-keto-L-olivose, 
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which would present three hydroxyl groups to ElmGT, much like NDP-L-rhamnose also 
possesses three hydroxyl groups that may be recognized. However, it is also surprising 
that ElmGT was unable to accept the NDP-4-keto-D-olivose, NDP-4-keto-L-rhamnose, 
and NDP-4-keto-L-mycarose sugars (39).  NDP-L-mycarose was previously shown to be 
a poor substrate for ElmGT (only ~10% of all tetracenomycins in the S. lividans 
(cos16F4)/pFL942 strain were L-mycarosylated tetracenomycins) (162).   
 Production of 114 along with 127 by S. lividans (cos16F4)/pKOL was surprising. 
It is speculated that a pathway-independent ketoreductase of S. lividans TK 24 might be 
responsible for the conversion of NDP-4-keto-L-olivose to NDP-L-olivose, and the latter 
is probably utilized by ElmGT as an alternate substrate to yield 114. Pathway 
independent reductions have been reported previously in the literature.  Earlier in the 
pikromycin biosynthetic pathway, a D-quinovosyl macrolide was accumulated instead of 
the anticipated 4-keto-6-deoxy-D-glucosyl analogue when desI was inactivated in 
Streptomyces venezuelae (168).  To search for possible sugar ketoreductases in 
Streptomyces lividans TK 24 that could be responsible for reduction of NDP-4-keto-L-
olivose, thus possibly explaining the presence of 114, the amino acid sequence for OleU 
was compared to encoded proteins in the Streptomyces lividans genome using the protein 
BLAST public database.  One such candidate was indicated in the search, SSPG_00655 
(30% sequence identity/42% sequence similarity).  This candidate has a domain that 
shows similarity to RfbD, which is a 4-ketohexulose reductase responsible for equatorial 
4-ketoreduction of NDP-4’-keto-L-rhamnose in the NDP-L-rhamnose pathway.  This 
enzyme may be responsible for the 4-ketoreduction witnessed in 114. 
 
Biological activity of 127 towards Streptomyces prasinus 
 
To evaluate the biological activity of 127, 1 mg mL-1 methanolic solutions of 127 
and 106 were prepared.  106 was included as a positive control.  Streptomyces prasinus 
NRRL B-2712 was chosen as a test organism, because it was the most sensitive gram 
positive organism tested against 106 (146).  Disc diffusion assays were performed in 
triplicate as previously described (146), and both 106 and 127 demonstrated activity 
against S. prasinus.  However, 127 (mean zone of inhibition 12±2 mm diameter) 
demonstrated less antibacterial activity than 106 (mean zone of inhibition 24±2 mm 
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diameter).  This is not surprising, as many tetracenomycin derivatives with substitutions 
in the 8-O-glycoside moiety exhibit lower antibacterial activity and antitumoral activity 
than 106, which demonstrates that the 8-O-permethylated L-rhamnose moiety is 
important for the biological activity of elloramycin. 
 
Glycosyltransfer of ketosugars is a rare phenomenon; expanding the catalogue of 
known substrates for ElmGT 
 
ElmGT represents one of the most flexible glycosyltransferases with respect to its 
ability to accommodate a large number of sugar donor substrates as compared to 
glycosyltransferases in other secondary metabolite biosynthetic pathways. ElmGT 
reportedly utilizes various NDP-D-sugars: D-olivose, D-mycarose, D-diolivose, D-
amicetose, D-boivinose, D-digitoxose, and D-glucose.  ElmGT also accepts a number of 
NDP-L-sugars: L-rhamnose, L-rhodinose, L-digitoxose, L-olivose, L-amicetose, L-mycarose 
and 4-deacetyl-L-chromose B. However, ElmGT has not been previously shown to 
accommodate NDP-ketosugars. In this context, production of 127 through the expression 
of pKOL in S. lividans (cos16F4) was interesting, especially, as earlier efforts to 
glycosylate 8-DMTC with NDP-4-keto-L-rhamnose were unsuccessful (Rodriguez, et al., 
2000).  
Despite the many glycosyltransferases discovered, those which can attach 
ketosugars to their acceptor co-substrates are relatively scarce.  MtmGIV (and possibly 
MtmGIII) from the mithramycin pathway has/have been shown to handle NDP-4-keto-D-
olivose and NDP-4-keto-D-mycarose to generate novel premithramycin and mithramycin 
analogues in Streptomyces argillaceus strains in which mtmC (3-C-methyltransferase) 
and mtmTIII (4-ketoreductase) genes were disrupted (Remsing, et al., 2002).  EryBV 
from the erythromycin pathway has been shown to accommodate NDP-4-keto-L-
mycarose (Salah-Bey, et al., 1998).  Similarly, BgtfA from the balhimycin pathway is 
capable of utilizing NDP-4-keto-L-vancosamine as a natural sugar donor substrate (Pelzer 
S  - Sussmuth, et al.).  The unprecedented flexibility of ElmGT towards NDP-4-keto-L-
olivose reported in this communication is particularly encouraging for further studies 
towards understanding the structural role of ElmGT in binding deoxysugar substrates. 
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SUMMARY 
  In summary, cos16F4 was used to heterologously express 8-demethyltetra-
cenomycin C and the glycosyltransferase ElmGT.  Various “sugar plasmids” were co-
expressed with resulted in recombinant strains, and co-expression of plasmid pKOL, 
which biosynthesizes NDP-4-keto-L-olivose resulted in accumulation of the new 
tetracenomycin analogue 8-demethyl-8-(4'-keto)-α-L-olivosyl-tetracenomycin C.  This 
analogue was structurally elucidated through HR-ESI mass, 1H-NMR, 13C-NMR, 1H,1H-
COSY, and HMBC NMR spectroscopy.  It was determined to have roughly 50% of the 
antimicrobial activity of elloramycin A towards Streptomyces prasinus. 
EXPERIMENTAL 
 
Bacterial Strains and Culture Conditions 
 
Escherichia coli XL1 blue (Invitrogen) was used as a host for routine cloning 
experiments and was grown on LB agar or in LB broth at 37 °C.  S. lividans TK24 and 
derivative strains were grown on M2 agar or in YEME liquid medium at 28 °C for 3 days 
for preparation of protoplasts following the previously reported protocol (3).  When 
antibiotic selection of recombinant strains was required, 25 μg/mL apramycin, 25 μg/mL 
thiostrepton, or 100 μg/mL of ampicillin were used. Protoplast transformation was carried 
out to introduce the cosmid cos16F4 into Streptomyces lividans TK 24 following the 
standard protocol (3, 174).  An apramycin resistant colony was selected for the 
production of 8-demethyl-tetracenomycin and was used as host for the expression of a 
newly generated deoxysugar biosynthetic construct(s).   
Bioactivity conditions against Streptomyces prasinus NRRL B-2712 were carried 
out as previously described (146).  In brief, spores of Streptomyces prasinus were grown 
on plates (0.4% yeast extract, 1.0% malt extract, 0.4% glucose, 2.0% agar).  The strain 
was grown for 50 hours until the plate was well-sporulated, then the spores were 
collected, diluted in sterile water, and adjusted to OD 1.3 (560 nm).  0.5 mL of the spore 
suspension was plated on each of 3 plates, and methanolic test solutions were prepared at 
a concentration of 1 mg/mL.  6 mm filter discs were prepared from Wattman filter paper 
using a hole punch, were sterilized in a 50 mL centrifuge tube, soaked in the antibiotic 
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solution, allowed to dry in a laminar flow hood for 30 minutes, then grown in the 
presence of S. prasinus.  Zones of inhibition were measured in triplicate and averaged. 
 
Generation of plasmids directing the biosynthesis of ketosugars, 
aminosugars, and 2-hydroxysugars 
 
The 4-ketoreductase gene (oleU) was removed from plasmid pLN2 (Rodriguez, et 
al., 2002). NheI and SpeI were used to digest pLN2, thereby releasing the oleU fragment. 
DNA gel electrophoresis was carried out to remove the oleU gene and the resulting 
fragment (~14kb) was rescued and re-ligated to generate pKOL. In this construct, all of 
the sugar genes are under strong ermE* promotion.  The plasmid map for this construct is 
depicted in Figure 37.  This plasmid was introduced into the S. lividans (cos16F4) strain 
through protoplast transformation.  Plasmid pFL952 was prepared as described 
previously (134).  In brief, plasmid pFL942 (directs biosynthesis of NDP-L-mycarose), 
was digested with SpeI/NheI, thus releasing the eryBIV 4-ketoreductase. The ~14kb 
plasmid was rescued, self-ligated using T4 DNA Ligase, and then transformed into XLI 
Blue E. coli for amplification of the construct. 
Plasmids pVIR*II, pFUCOII, pFUCO, and pKVIR were prepared as discussed in 
Chapter 2, Materials and Methods.  Plasmids pRavI, pDmnI, pDmnII, pDesI, pDesII, 
and pDesIII were prepared by Dr. Madan Kharel (Personal Communication).  Plasmid 
pTLAG was cloned by Dr. Tao Liu (Dissertation). 
 
Table 7  Plasmids used in Chapter 4 
 
 
Plasmid Name Relevant Characteristics Reference 
Cos16F4 AprR. Directs biosynthesis 
of 8-DMTC (105) in 
Streptomyces.  Encodes 
ElmGT, pKC505-derived 
cosmid. 
(149) 
pLN2 AmpR, TsrR.  OleVWSELUY 
under ermE* promotion.  
NDP-L-olivose. 
(135) 
pFL942 AmpR, TsrR.  OleV, 
MtmDE, EryBII, BIII, BIV, 
BVII  under divergent 
(134) 
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ermE* promotion.  NDP-L-
mycarose. 
pMP*UII AmpR, TsrR.  OleVW, 
cmmUII, OleY, MtmDE, 
under divergent ermE* 
promotion.  NDP-L-
mycarose. 
(160) 
pRavI AmpR, TsrR.  RavDE, NMT, 
AMT, IM under ermE* 
promotion. NDP-D-
ravidosamine 
Madan Kharel, Personal 
Communication 
pDmnI AmpR, TsrR.  OleSEVLU 
DnrJ under ermE* 
promotion. NDP-L-
acosamine 
Madan Kharel, Personal 
Communication 
pDmnII AmpR, TsrR.  OleSEV, 
DnrJUV under ermE* 
promotion. NDP-L-
daunosamine 
Madan Kharel, Personal 
Communication 
pDesI AmpR, TsrR.  DesIII, DesIV, 
DesI under ermE* 
promotion.  NDP-4-amino-
6-deoxy-D-glucose (121) 
Madan Kharel, Personal 
Communication 
pDesII AmpR, TsrR.  DesIII, DesIV, 
DesI, DesII under ermE* 
promotion.  NDP-3-keto-
4,6-dideoxy-D-glucose 
(122). 
Madan Kharel, Personal 
Communication 
pDesIII AmpR, TsrR.  DesIII, DesIV, 
DesI, DesII, DesV under 
ermE* promotion.  NDP-3-
N,N-didemethyl-D-
desosamine (123). 
Madan Kharel, Personal 
Communication. 
pTLAG2 AmpR, TsrR.  Med20, 18, 
17, 16, 15, 14 under ermE* 
promotion.  NDP-D-
angolosamine 
Tau Liu, Dissertation. 
pKOL AmpR, TsrR.  OleVWSELY 
under ermE* promotion.  
NDP-4-keto-L-olivose. 
This work. 
pFL952 AmpR, TsrR.  OleV, 
MtmDE, EryBII, BIII, BIV, 
BVII under divergent ermE* 
promotion.  NDP-4-keto-L-
mycarose. 
(134) 
pFUCO AmpR, TsrR.  gilU, ravDE This work. 
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cloned under ermE* in 
pUWL201PW.  Intended to 
produce NDP-D-fucose. 
pFUCOII AmpR, TsrR.  gilLU, ravDE, 
cloned under ermE* in 
pUWL201PW.  Intended to 
produce NDP-D-
fucofuranose. 
This work. 
pKVIR AmpR, TsrR.  chryCMT, 
chryDE cloned under 
ermE* in pUWL201PW.  
Intended to produce NDP-
4-keto-D-virenose. 
This work. 
pVIR*II AmpR, TsrR.  chryCMT, 
chryU, ravDE cloned under 
ermE* in pUWL201PW.  
Intended to produce NDP-D-
virenose. 
This work. 
 
 
Table 8  Bacterial strains used in Chapter 4 
 
Strain Name Relevant Characteristics Reference 
S. lividans TK24 (cos16F4) 
§ 
 
Harbors cos16F4.  Produces 
105. 
(149) 
S. lividans (cos16F4)/pRav1 § co-expressed with pRavI.  
Produces 105. 
This work. 
S. lividans 
(cos16F4)/pDmnI 
§ co-expressed with pDmnI.  
Produces 105 and 106. 
This work. 
S. lividans 
(cos16F4)/pDmnII 
§ co-expressed with pDmnI.  
Produces 105. 
This work. 
S. lividans (cos16F4)/pDesI § co-expressed with pDesI.  
Produces 105. 
This work. 
S. lividans 
(cos16F4)/pDesII 
§ co-expressed with pDesII.  
Produces 105. 
This work. 
S. lividans 
(cos16F4)/pDesIII 
§ co-expressed with 
pDesIII.  Produces 105. 
This work. 
S. lividans 
(cos16F4)/pTLAG2 
§ co-expressed with 
pTLAG2.  Produces 105. 
This work. 
S. lividans 
(cos16F4)/pFUCO 
§ co-expressed with 
pFUCO.  Produces 105. 
This work. 
S. lividans 
(cos16F4)/pFUCOII 
§ co-expressed with 
pFUCOII.  Produces 105. 
This work. 
S. lividans 
(cos16F4)/pVIR*II 
§ co-expressed with 
pVIR*II.  Produces 105. 
This work. 
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S. lividans 
(cos16F4)/pKVIR 
§ co-expressed with 
pKVIR.  Produces 105. 
This work. 
S. lividans (cos16F4)/pKOL § co-expressed with pKOL.  
Produces 105, 114, 127. 
This work. 
S. lividans 
(cos16F4)/pDKOL 
§ co-expressed with 
pDKOL.  Produces 105. 
This work. 
S. lividans 
(cos16F4)/pFL952 
§ co-expressed with 
pFL952.  Produces 105. 
This work. 
 
 
 
Table 9  Physicochemical characterization and NMR data of 8-Demethyl-8-(4'-keto)-α-L-
olivosyl-tetracenomycin C (127). 
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Rrel= 10.76 min-1; Yield:  2.0 mg/L 
 
MW= 586 g/mol (C28H26O14) 
 
Negative mode APCI-MS:  m/z=585 [M-H] (low res), m/z=603 (hydrate); (-) HR-ESI 
MS (keto form calc. 585.1317 amu, found 585.1267 amu [M-H-]; hydrate form calc. 
603.1423, found 603.1363 amu [M+18]) 
 
UV maxima (from HPLC-diode array):  210 (60%), 286 (100%), 409 (20%) 
NMR Data (d4-methanol) 
Position 8-Demethyl-8-(4'-keto)-α-L-olivosyl-tetracenomycin C (127)a 
δC (125 MHz) δH (500 MHz) 
1 193.0 - 
2 100.8 5.62 (s) 
3 176.1 - 
3-OCH3 57.8 3.81 (s) 
4 70.7 4.88 (d, 1.5) 
4-OH - - 
4a 85.9 - 
4a-OH - - 
5 194.8 - 
5a 141.5 - 
6 122.1 7.91 (s) 
6a 129.6 - 
7 112.4 7.55 (s) 
8 155.4 - 
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9 130.9 - 
9-OCH3 53.4 3.97 (s) 
9-CO 169.5 - 
10 139.5 - 
10-CH3 21.3 2.79 (s) 
10a 122.6 - 
11 167.8 - 
11-OH - - 
11a 110.6 - 
12 198.2 - 
12a 84.6 - 
12a-OH - - 
1′ 96.4 6.16 (s) 
2′ 37.3 2.24 (ddd, 15.0, 12.0, 3.0, Ha), 
2.13 (dd, 15.0, 6.5, He) 
3′ 70.6 4.68 (dd, 12.0, 6.5) 
3′-OH - - 
4′ 207.4 - 
4′-OH - - 
5′ 72.5 4.39 (q, 6.5) 
6′ 14.3 1.12 (keto, d, 6.5) 
1.16 (hydrate, d, 6.5) 
 
Isolation of tetracenomycins from recombinant S. lividans (cos16F4) strains 
 
S. lividans (cos16F4)/pKOL was grown on M2 agar medium at 28 °C 
supplemented with thiostrepton and apramycin for 5 days. For small scale production of 
tetracenomycins, an agar chunk of bacterial spores was inoculated in 250 mL Erlenmeyer 
flasks containing 100 mL of Soytone-Glucose (SG) medium supplemented with 
antibiotics for 4-5 days.  25 mL of the culture was extracted with ethyl acetate and the 
organic layer was dried in vacuo.  Extracts were then redissolved in methanol and were 
subjected to HPLC/MS analyses on a MicroMass ZQ 2000 (Waters) instrument equipped 
with HPLC (Waters alliance 2695 model) and photodiode array detector (Waters 2996).  
A Sun-Fire semi-prepC18 column (19 × 250 mm, 5 μm) and Symmetry C18 (4.6 x 250 
mm, 5 μm) analytical column were used for semi-preparative and analytical scale 
separations, respectively. A gradient of acetonitrile and 0.1% formic acid in water was 
used to separate compounds as reported previously (See Chapter 3, Materials and 
Methods).   
For larger scale production of glycosylated tetracenomycins, 7.2 L of SG medium 
and allocated into 800 mL portions in 9 baffled 2 L Erlenmeyer flasks.  The production 
media was supplemented with antibiotics and inoculated with freshly prepared spores 
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from M2 agar plates of the recombinant strains. Fermentation was carried out for 5 days 
at 28 °C in an orbital shaker.  The culture was harvested, mixed with celite (50 g/L 
fermentation broth), and then filtered.  The mycelial cake was discarded, and the culture 
broth was passed through Amberlite® XAD16 resin (column dimensions 80 cm x 4 cm). 
The column was washed with 100% distilled water, and crude tetracenomycins were 
obtained by elution with 2 L of methanol.   The solvent was dried in vacuo.  This extract 
was separated via silica gel column chromatography using 200 mL gradients of 
dichloromethane and methanol from 0-100% of methanol, increasing in 5% each step.  
Fractions containing tetracenomycins were pooled, dried in vacuo, and further purified 
using semi-preparative HPLC as described previously (Chapter 3, Materials and 
Methods).  Using this protocol, 14.4 mg and 12.2 mg of compounds 127 and 114 were 
isolated, respectively. (-) High resolution ESI spectra of pure compounds were recorded 
at the University of Wisconsin Biotechnology Center.  NMR spectra were recorded on a 
Varian VNMR 500 MHz spectrometer using deuterated methanol as solvent. 
 
 
 
 
 
 
 
 
 
 
 
Copyright © S. Eric Nybo 2011  
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CHAPTER 5:  ALTERING THE GLYCOSYLATION PATTERN OF 
MITHRAMYCINS  
INTRODUCTION 
 
Biological activity of mithramycin 
 
The aureolic acid antibiotic mithramycin (70) has been well-studied by various 
groups for the tremendous potential it exhibits as an antineoplastic, Alzheimer’s, and 
Parkinson’s drug (79, 83-84, 86, 90-91, 93).  As an anticancer agent, it has been used to 
treat Paget’s bone disease, bone-related malignancies, and testicular carcinoma (88).  It 
binds to the minor groove of GC-rich DNA, especially in proto-oncogenes c-src and c-
myc, and as such, it is a de facto inhibitor of Sp1-dependent pathways (87, 89, 91, 94).   
Overexpression of Sp1 has been implicated in Alzheimer’s disease and colon, breast, and 
pancreatic cancers.    Mithramycin binds as a homodimer in head to tail fashion, that is 
coordinated by a Mg2+ cation (87).  Structurally, mithramycin consists of a tricyclic core 
and possesses a dihydroxy-methoxy-oxo-pentyl side chain at 3-position, which is 
responsible for interaction with the phosphate backbone (86).  The disaccharide 
consisting of D-olivose, D-olivose is important for binding to DNA, perhaps by stacking 
on top of the dimer aromatic core (86).  The trisaccharide is also essential, because the D-
mycarose moiety is positioned in the floor of the minor groove of DNA, and it provides 
stabilization of the MTM-Mg2+dimer complex by virtue of hydrogen bonding with both 
strands of DNA(98).  Mithramycin, however, is contraindicated due to severe hepatic, 
renal, and gastrointestinal cytotoxicities (86).   
Mithramycin has also found use as part of a multi-drug therapy with bevacizumab 
in down-regulating VEGF (vascular epithelial growth factor) (111).  Mithramycin itself 
has been independently confirmed to decrease c-myc/c-src expression in cancer cell lines, 
inhibiting Sp1 from binding to these promoters (70 inhibits c-src promotion in a 
luciferase-reporter assay to about 30% of the expression of a control sample not treated 
with 70) (86).  As such, mithramycin has been increasingly employed in multi-drug 
therapies to target cancers that are refractory to treatment with a single chemotherapeutic.  
Mithramycin’s Sp1-dependent inhibition effectively blocks all downstream cell signaling 
pathways that depend on Sp1-promoted upregulation, and this may work in tandem with 
other compounds that target some other aspect of cancer cell/Alzheimer’s proliferation, 
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for example VEGF or beta amyloid precursor protein, for example (86-87, 90-91, 93, 
111). 
Despite its tremendous potential as a cancer therapeutic, mithramycin and the 
other first generation aureolic acids suffer from severe drawbacks.   Because these 
molecules are biosynthesized naturally, they have not been optimized for binding to 
mammalian targets, such as protooncogenes, and as such, these drugs exhibit detrimental 
effects in healthy somatic cells and cancer cells alike.  Due to the severe cytotoxic side 
effects of 70, combinatorial biosynthetic methods have been employed in the Rohr and 
Salas labs to generate novel mithramycin analogues with better drug properties:  lessened 
cytotoxicity or higher potency (e.g. IC50).  These alterations have focused on derivatizing 
the polyketide aglycone and substitutions in the saccharide pattern.  These “second 
generation” combinatorial mithramycin/premithramycin analogues have revealed 
tremendous insights into the biosynthesis and of 70.  Furthermore, the isolation of several 
analogues has revealed unanticipated substrate flexibility displayed by the enzymatic 
machinery, and some of these analogues possess enhanced potency and reduced 
cytotoxicity as compared to mithramycin.   
Pathway engineering studies to alter the mithramycin/premithramycin polyketide 
skeleton 
 
The Rohr and Salas labs have previously conducted several inactivations of genes 
responsible for modification of the polyketide.  Inactivations of mtmMI and mtmMII 
revealed the functions of these encoded proteins as the 4-O-methyltransferase that installs 
the methoxy group onto 4-demethylpremithramycinone (27), and the 7-C-
methyltransferase responsible for installing the 7-C-methyl sidechain of 70 (23).  The 
accumulation of 7-demethylmithramycin (82) in the S. argillaceus (mtmMII-) strain 
revealed that all of the downstream biosynthetic enzymes could process the 7-desmethyl 
substrates, however, this compound failed to exhibit any in vivo cytotoxicity, indicating 
the importance of the 7-C-methyl group for binding to DNA (Figure 41) (86).  
Disruption of mtmOI and mtmOIII did not result in disruption of mithramycin 
biosynthesis, however, disruption of mtmOII led to production of premithramycinone G 
(87, Figure 41) (24).  This improperly cyclized molecule reveals important implications 
for MtmOII’s role in early mithramycin biosynthesis, either by installing a ketone to 
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allow for fourth ring cyclization and/or installation of the 2-oxygen of 70.  Inactivation of 
mtmOIV resulted in the accumulation of premithramycin B (80), a tetracyclic 
premithramycin that features the intact trisaccharide (D-olivose, D-oliose, D-mycarose) at 
2-position and the disaccharide at 6-position (D-olivose, D-olivose) (Figure 41) (95, 103).  
Elucidation of the structure of 80 lead to the elaboration of MtmOIV being a highly 
specific Baeyer-Villiger monooxygenase (BVMO) responsible for oxidative cleavage of 
the fourth ring to afford the canonical tricyclic mithramycin scaffold (95, 103, 109, 175).   
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Figure 41 Premithramycin and mithramycin-type compounds 
from inactivating genes responsible for altering the polyketide-derived portion of 
mithramycin. 
 
MtmOIV is unique in that it is a BVMO for which the substrate is known.  The fact that 
MtmOIV only recognizes a fully glycosylated premithramycin B molecule indicates that 
this rigid structural specificity is an intrinsic means by which the mtm pathway avoids 
wasteful and promiscuous generation of less active mithramycins with fewer sugars (95, 
103, 109, 175).  However, this same rigidity also prevents MtmOIV from turning over 
novel premithramycin substrates that may bear unusual or foreign deoxysugars.  
The inactivation of the mtmW gene resulted in novel mithramycins with 
unexpectedly shorter side chains, thereby revealing its role in the 3-sidechain 
ketoreduction step of the β-diketone intermediate (Figure 13).  The accumulated products 
were called mithramycin SK (for shortened ketone) (128), demycarosyl-mithramycin SK, 
mithramycin SDK (shortened diketone) (129) , and mithramycin SA (130) (shortened 
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acid) (Figure 42) (89, 97).  The anticipated product was the mithramycin β-diketone 
compound (81), however, because this possesses a highly reactive β-diketone motif, 
subsequent carbon migration rearrangements occur.  If water attacks the 2”-ketone, a 
hydrate can form.  A retro-aldol reaction results in subsequent deprotonation of one of the 
hydroxyl protons that can restore the ketone, and result in severance of the 2”-3” carbon-
carbon bond, which affords mithramycin SA (130). Or, if water abstracts a proton from 
the 3”-hydroxy, carbon migration can result in shifting of the 4”-acyl group to the 2”-
position (Figure 42).  From this species, water either attacks the aldehyde directly, 
resulting in elimination of formic acid, which affords mithramycin SK (128), or water 
abstracts a proton from 2”-hydroxyl, which results in elimination of formaldehyde, and 
formation of mithramycin SDK (129) (Figure 42).  Feeding experiments with [1-13C]-
acetate and [1,2-13C2]-acetate confirmed that the 3”-carbon is excised during this 
rearrangement (97). 
The antitumoral activities of 128-130 were evaluated in 60 cell line panel by 
using the NCI sulforhodamine B cytotoxicity assay.  Mithramycin SA 130 demonstrated 
very weak binding to Salmon testes DNA and exhibited weak in vivo cytotoxicity, due in 
large part to the fact that its 3-side chain is much too short to interact specifically with the 
phosphate backbone of DNA (86-87).  Mithramycin SK 128, however, demonstrated 
1500-fold less cytotoxicity than mithramycin, and furthermore, it demonstrated up to 90 
times higher activity than mithramycin in squamous, melanoma, leukemia, and CNS 
cancer lines (86-88).  Furthermore, mithramycin SK was able to inhibit polyploidy in 
actively dividing cancer cells (112).  Mithramycin SDK 129, however, severely inhibits 
Sp1- 
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Figure 42 Spontaneous rearrangements of Mithramycin SK (128), mithramycin SDK 
(129) and mithramycin SA (130).   
Mechanisms for rearrangements of 3-pentyl side chain of mithramycin β-diketone to 
form mithramycin SK (128), mithramycin SDK (129), and mithramycin SA (130).  
Structures of metabolites from mtmW-disrupted strain S. argillaceus M7W1 with 
shortened side chains in blue. 
 
dependent pathway transcription, up to 90% at a 100 nM concentration in a luciferase-
based reporter assay (as compared to 40% for 70 and 60% for 128) (89).  The IC50 for 
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129 was up to 2-fold lower than for 70 and 128 (87).  Astonishingly, when orthotopic 
ovarian tumor xenografts were introduced into a mouse model, then treated with 400 
μg/kg/day of 70, 128, or 129, median survival in the 129 treated group was 80 days (as 
compared to 55 for the control group without mithramycin treatment), yet 4 of the 10 
mice treated with 129 survived past 100 days tumor free (87, 89). These studies cemented 
mithramycin SDK as the best-in-class aureolic acid derivative with most potential for 
further clinical trials. 
Altering the glycosylation pattern of premithramycins/mithramycins through 
“flooding” of the pathway with nucleoside-diphosphate-activated deoxysugars and 
inactivation experiments 
 
As discussed in Chapter 4, glycodiversification is a powerful strategy for altering 
the structure and activity of a particular drug.  The successful implementation of this 
strategy requires the accumulaton of nucleoside-diphosphate-activated deoxysugars that 
are not normally produced in the strain and the successful interrogation of a donor-
flexible glycosyltransferase.  The Salas group demonstrated the effectiveness of 
interrogating the substrate-flexible ElmGT with a variety of plasmid-borne NDP-
deoxysugars.  In Chapter 4, the successful generation and structure elucidation of a new 
ketosugar-bearing tetracenomycin (127) illustrated this approach in vivo.   
The mithramycin biosynthetic pathway features five glycosyltransfer events and 
four glycosyltransferases, therefore inactivation experiments of various deoxysugar 
biosynthetic genes and glycosyltransferases were undertaken (98-99).  Inactivation of 
mtmGI, mtmGII, mtmGIII, and mtmGIV and feeding of 4A-deolivosyl-premithramycin B 
to the mtmGI-deleted mutant established the unambiguous order of glycosylation events 
leading to 70 (96, 100, 105) (Figure 13).  While inactivation of several of the deoxysugar 
biosynthetic genes (e.g. mtmV, mtmU, mtmC, mtmDE) resulted in accumulation of early 
pathway intermediates premithramycinone or premithramycin A1, inactivation of 
mtmTIII and mtmC revealed an unanticipated accumulation of premithramycins and 
mithramycins with alterations to the saccharidal moieties (88, 98-99) (Figure 43).  These 
molecules revealed substrate flexibility on the part of MtmGIV and/or MtmGIII towards 
accepting ketosugars. 
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As a further extension of their work, the Salas lab envisioned that transformation 
of S. argillaceus with various sugar plasmids could result in mithramycin molecules with 
substitutions in the saccharide chain.
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Figure 43 Structures of mithramycin-type compounds resulting from S. argillaceus 
mtmTIII- and mtmC- (83-86) inactivations.   
Mithramycins resulting from overexpression of NDP-L-digitoxose plasmid in S. 
argillaceus. 
 
Overexpression of several of these resulted in novel mithramycins that were active or 
slightly less active than 70 in the cancer cell lines tested (111).  When plasmid pLNBIV 
(encodes NDP-L-digitoxose biosynthesis) was introduced into S. argillaceus via 
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protoplast transformation, four new mithramycins were identified (131-134) with 
substitutions in the saccharide pattern (112).  Two of these compounds were the result of 
“jamming” of glycosyltransferases, 133 and 134.  From a biosynthetic perspective, these 
compounds were interesting and revealed unexpected flexibility by the 
glycosyltransferases.  Very likely, jamming of MtmGIV/MtmGIII results in accumulation 
of 133 and jamming of MtmGII results in accumulation of 134.  133 indicated an 
acceptor flexibility of mtmGIV and possibly acceptor/donor flexibility of MtmGIII to 
transfer NDP-D-mycarose to premithramycin A1.  132 was unique from all mithramycins 
generated by these experiments, because it was the only compound to feature an L-sugar 
(NDP-L-digitoxose), yet a simple ring flip to the 4C1 conformer likely accounts for its 
acceptance by MtmGIII (the 4C1 conformer of NDP-L-digitoxose possesses the same 
stereochemistry at 3- and 4-position as NDP-D-oliose, the natural substrate of MtmGIII).  
All compounds exhibited unanticipated substrate specificity on behalf of MtmOIV, but 
compound  131 demonstrated much improved bioactivity over 70 in many of the cancer 
cell lines tested by the NCI (112).  In ER+ MCF-7 breast cancer cells, mithramycin 
induced 37.8% apoptosis, whereas 131 induced 64.8% apoptosis.  In ER- MDA-231 
cells, mithramycin only induced 2.6% apoptosis; however, 131 induced an amazing 
63.6% apoptosis.  131 is essentially an isostere of mithramycin, possessing the same 
stereochemistry of the E sugar (NDP-D-digitoxose vs. NDP-D-mycarose), yet it lacks the 
3-C-methyl branch.  Because the D-mycarose moiety sits in the floor of GC-rich minor 
grooves and forms hydrogen bonds with both strands of DNA, the methyl group may 
cause steric interference (98).  Apparently, the D-digitoxose substitution greatly enhances 
the activity of 131 as compared to mithramycin, yet, in both ER+ and ER- breast cell 
cancer lines, it possessed the highest level of biological activity compared to the other 
glycorandomized mithramycins produced in these studies.  ER- breast cell cancer 
desparately requires novel treatments to overcome its considerable chemoresistance 
(112).  This validates the approach of glycodiversification towards optimizing the ligand 
binding of mithramycin-type compounds. 
 
MtmOIV is the Baeyer-Villiger Monooxygenase (BVMO) that catalyzes fourth ring 
scission in biosynthesis of mithramycin 
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MtmOIV catalyzes the key oxidative cleavage of mithramycin biosynthesis that 
results in generation of an active tricyclic compound(95, 103, 109, 175).  MtmOIV and 
its sister enzyme from chromomycin A3 biosynthesis, CmmOIV, have both been 
crystallized and their active site residues determined through mutagenesis experiments 
(176) (Figure 44).  Some of these mutants, such as MtmOIV-R204A feature mutations in 
key residues, such as arginine 204, that are responsible for limiting MtmOIV’s tolerance 
to premithramycin substrates.  In this case, arginine 204 is considered to be a key 
gatekeeper residue that allows for the stabilization of the trisaccharide chain of 
premithramycin B in the enzymatic active site.  Mutation of arginine 204 to alanine 
achieved a significant reduction of the Km of MtmOIV-R204A with respect to its affinity 
for premithramycin B, while retaining a comparable kcat to the wildtype enzyme.  As 
such, MtmOIV reduces bound FAD to FADH via NADPH, after which diatomic oxygen 
binds to form the key peroxyflavin species (Figure 44).  The peroxyflavin species attacks 
the 1-position carbonyl, forming the Criegee intermediate, oxygen inserts into the carbon-
carbon bond, and the lactone collapses to form mithramycin DK (81).  Substrate flexible 
MtmOIV mutants will be useful for future combinatorial generation of mithramycins, and 
part of the aim of this work is to generate strains and characterize suitable 
premithramycins for such an approach. 
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Figure 44 MtmOIV-catalyzed Baeyer-Villiger monooxygenative cleavage of 
premithramycin B. 
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RESULTS AND DISCUSSION 
 
Despite the considerable advances that have been made to understand the 
biosynthesis and generate novel derivatives of mithramycin, new interrogations of 
biosynthetic machinery involving uninvestigated deoxysugar donor substrates and 
recombinations of sugar plasmids with restricted mutants of S. argillaceus remain to be 
tested.  The work of the Salas group in heterologous expression of NDP-deoxysugar 
cassettes served as the impetus and inspiration for envisaging new mithramycin scaffolds.  
Based on what is already known about the substrate flexibility of the mtm GTs, several 
novel strains were prepared and preliminary investigation of the compounds accumulated 
in these novel strains was undertaken. 
In preliminary screening of recombinant strains for the presence of additional 
mithramycin-type/premithramycin compounds, methanolic extracts of recombinant 
strains were compared to extacts of the parent wild-type or restricted S. argillaceus strain.  
Additional peaks were visualized via a UV photodiode array detector on a Waters HPLC-
MS as discussed in Chapter 3.  Premithramycin-type compounds are clearly distinctive 
based on their tetracyclic ring system, and as such, they possess a characteristic UV 
spectrum with absorption maxima at 230 nm, 280 nm, 329 nm, and 424 nm.  
Mithramycins, with a tricyclic chromophore and 3-aliphatic side chain, were clearly 
identified with absorption maxima at 230, 278, 317, and 411 nm (111).  In this case, the 
hypsochromic shift from 329 nm to 317 nm from the MtmOIV-catalyzed opening of the 
fourth ring is particularly diagnostic for distinguishing premithramycin and mithramycin-
type compounds. 
The generation of a novel fermentation method towards demycarosyl-3D-β-D-
digitoxosyl mithramycin and generation  and structure elucidation of demycarosyl-3D-β-
D-digitoxosyl mithramycin SK were achieved using a different methodology different 
from that of the EntreChemTM biotech company (personal communication, Dr. Rohr), and 
our lab’s methodology is being drafted into a manuscript for submission soon. 
 
Generation of S. argillaceus wildtype strains overexpressing NDP-activated L- 
sugars 
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Several strains were reported by Salas et al. to produce novel premithramycin-
type compounds, but were not further investigated.  As such, the production spectrum of 
these strains could serve as a useful point of reference for evaluating the production of 
other deoxysugar plasmid-containing Streptomyces argillaceus strains.  Streptomyces 
argillaceus was independently transformed with pLN2 (NDP-L-olivose), pLNBIV (NDP-
L-digitoxose), and pRHAM (NDP-L-rhamnose) to afford strains S. argillaceus 
(pLNBIV), S. argillaceus (pLN2), and S. argillaceus (pRHAM), respectively. As 
reported previously, extracts of S. argillaceus (pRHAM) accumulated only mithramycin, 
premithramycin A1, and a small amount of an unknown compound (111).  This 
compound demonstrated a mass of 557 amu in (-)APCI-MS mode [M-H], which could 
correspond to 14 mass units higher than premithramycin A1.  This compound could 
correspond to a D-mycarose-substituted premithramycin A1, or more likely, 
premithramycin A1’ with the 7-C-methyl group.  S. argillaceus (pLN2) produced 
mithramycin and two premithramycin type compounds with a mass each of 674 amu [M-
H] in APCI (-ve) mode.  As reported previously, these could correspond to two novel 
premithramycins with disaccharides corresponding to D-olivose-1,3-L-olivose and L-
olivose-1,3-L-olivose (111).  What is clear from the overexpression of NDP-activated L-
sugars in S. argillaceus is that they result in “jamming” of the glycosyltransferases, and 
the accumulation of these premithramycin-type compounds.  This is not unexpected, 
because the mtm GTs normally bind D-configurated sugars, and in only a handful of cases 
have glycosyltransferases from secondary metabolism been shown to accommodate both 
D- and L-configurated sugars:  GilGT (NDP-L-rhamnose, NDP-D-olivose, NDP-D-
fucofuranose), ElmGT (many sugars, see Chapter 4), and UrdGT2 (NDP-L-rhodinose 
and NDP-D-rhodinose) (177).  Furthermore, much of this jamming seems to occur with 
regards to MtmGIII. 
In extracts of S. argillaceus (pLNBIV), ten metabolites in addition to 
mithramycin (70) were accumulated (Figure 45).  Four of these are known to be 
mithramycins described previously (131-134), and as such, were able to be assigned 
according to retention time, UV spectrum, and mass analyses.  In addition, six 
premithramycin type compounds were accumulated.  Three of these were identified based 
on identical retention time with standard compounds and mass analyses as 
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premithramycin A1 (76), premithramycin A1’, and premithramycinone.  However, three 
of these compounds are unknown and exhibit atypical UV-Vis absorption spectra for 
premithramycin type compounds.  These three compounds exhibit a sharp absorption 
maximum at 406 nm.  From this experiment, it was apparent that mithramycin was still 
the major metabolite in the production spectrum, and extract from S. argillaceus 
(pLNBIV) was essential to developing a robust HPLC semi-preparative separation 
program.  Also, the three unidentified premithramycins may be good candidates for 
pathway engineering.  This could be achieved by inserting a copy of a mutagenized 
mtmOIV gene (e.g. R204A) into the chromosome of S. argillaceus (pLNBIV).  
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Figure 45 HPLC traces of metabolites of S. argillaceus (pLNBIV).   
Trace A represents extracts from S. argillaceus wildtype, which produces mithramycin 
(70).  Trace B represents extracts from S. argillaceus (pLNBIV), which produces 70 
along with novel mithramycins with substitution in the saccharide chains (131-134, 
Figure 44), premithramycin A1 (76), * represents the 7-C-methyl derivative of 76, 
premithramycin A1’.  27 is premithramycinone and § indicates premithramycin-type 
metabolites with atypical UV (a sharp UV absorption maximum at ~406 nm). 
 
Expression of aminosugar and 2’-hydroxysugar plasmids in S.argillaceus wildtype 
 
Deoxysugars directing the biosynthesis of various aminosugars (see Chapter 4) 
were introduced into S. argillaceus wildtype.  Most of these deoxysugar plasmids failed 
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to alter mithramycin biosynthesis, however, the S. argillaceus (pDesIII) (NDP-N,N-
didemethyl-D-desosamine) strain accumulated premithramycin A1 and an additional 
premithramycin-type compound that was not investigated.  Additionally, the S. 
argillaceus (pDmnI) strain accumulated premithramycinone and premithramycin A1, 
which may result from accumulation of NDP-L-rhamnose jamming MtmGIII, as in the S. 
argillaceus (pRHAM) strain (Figure 46).  Furthermore, an additional premithramycin 
was accumulated with Rt=21.3 min-1. 
 
Figure 46 HPLC chromatogram of the metabolites from S. argillaceus (pDmnI) strain. 
This strain accumulates one unknown (yellow star) premithramycin in addition to 
mithramycin, premithramycin A1, and premithramycinone.   The structure of NDP-L-
acosamine is indicated as a reference for what the plasmid should biosynthesize. 
 The 2’-hydroxysugar plasmids pVIR*II, pEN3, pFUCO, and pFUCOII were all 
introduced into S. argillaceus wildtype via protoplast transformation.  It was envisioned 
that these plasmids should redirect mithramycin biosynthesis to incorporate 2’-
hydroxylated sugars.  In the case of pVIR*II or pEN3, it was envisioned that either NDP-
4-keto-D-virenose or NDP-D-virenose would be surrogate substrates for MtmGIV and 
would be incorporated at sugar E position.  In the case of pFUCO or pFUCOII, it was 
envisaged that NDP-D-fucopyranose or NDP-D-fucofuranose would be accumulated in 
the strain and incorporated into one of the saccharide chains (e.g. perhaps sugar D 
position, substituting NDP-D-fucose for NDP-D-oliose).  Or, alternatively, some 
collaboration between plasmid-borne enzymes and endogenous sugar tailoring machinery 
O
HO
H3C ONDP
H2N
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could result, or perhaps even jamming of the glycosyltransferases, as is witnessed in 133 
and 134 in the case of S. argillaceus (pLNBIV).  Expression of pFUCO and pFUCOII 
failed to result in new glycosylated mithramycins/premithramycins.  However, pVIR*II 
and pEN3 both successfully generated the same production pattern, indicating that likely 
the C-methyltransferase chryCMT at least is functional in these strains, and possibly the 
virenosyl 4-ketoreductase chryU, as well.  In these strains, S. argillaceus (pEN3) and S. 
argillaceus (pVIR*II), one new mithramycin was accumulated as a minor compound, and 
3 premithramycins were accumulated.  The premithramycins correspond to 
premithramycin A1, premithramycinone, and an unknown tetrasaccharidal 
premithramycin with a mass of 977 amu [M-H] in (-) APCI-MS mode, perhaps 
corresponding to a tetrasaccharidal premithramycin with an NDP-D-virenose moiety in E 
position (Figure 47).  The accumulation of premithramycin A1, as seen in other 
recombinant strains, indicates that NDP-D-virenose or one of its encoded intermediates 
jams MtmGIII and that perhaps 2’-hydroxysugars are poor substrates for mtm pathway 
GTs.  The mithramycin-type compound in these strains evinces a mass of 1099 amu in (-) 
APCI-MS mode, which could be expected for a compound 16 mass units larger than 
mithramycin.  Such an addition could be accounted for by the presence of an additional 
oxygen substituent, which would be expected if an NDP-D-virenose or its 4’-epimer were 
incorporated at E position.  This plasmid was also introduced into S. argillaceus M7W1 
strain to generate S. argillaceus M7W1 (pVIR*II), which was not further investigated.  
Both strains are promising for further structure elucidation studies and possibly for 
structure activity relationship (SAR) studies. 
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Figure 47 HPLC chromatogram of the metabolites from NDP-D-virenose expressing 
strains.  
(Upper Trace) extracts of S.argillaceus (pVIR*II) and (Lower Trace) S. argillaceus 
(CMT+U).  Strains both accumulate premithramycin A1, premithramycinone, a 
mithramycin-type compound Rt= 15.5 min-1(1099 amu, [M-H] (-) APCI-MS), and a 
premithramycin type compound Rt=19.5 min-1 (977 amu, [M-H] (-) APCI-MS).NDP-D-
virenose included as reference.  Red stars are mithramycin-type compounds, gold stars 
are premithramycin-type compounds. 
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Generation of Streptomyces argillaceus (pKOL) 
 
Given that MtmGIV has a demonstrated capacity for accepting ketosugar donor 
substrates (98), it was envisioned that transformation of S. argillaceus wildtype with 
plasmid pKOL would possibly result in flooding the pathway with NDP-4-keto-L-olivose 
and its attachment in E position (see Chapter 4).  Extracts of the resulting strain S. 
argillaceus (pKOL) revealed production of a new mithramycin-type compound with 
Rt=16.1 min-1 as the major product, in addition to a few minor premithramycin-type 
compounds (Figure 48).  This mithramycin demonstrated a mass of 1069 amu [M-H] in 
(-) APCI-MS mode, which indicates a loss of 14 mass units from mithramycin.  This 
mass did not correspond with any type of ketosugar-containing compound as was 
expected, as the anticipated keto/hydrate pseudomolecular ions were not present.  Most 
likely, this 14 amu difference corresponds to the difference of a C-methyl group.  As a 
result, it appeared as though there was a substitution of the D-mycarose moiety with an 
unmethylated 2,6-dideoxysugar.  Comparison with extract for S. argillaceus (pLNBIV) 
indicated the identical retention time with 131, and interestingly, the mithramycins from 
the pLNBIV mutant that resulted from “jamming” of the glycosyltransferases were 
absent in the pKOL-harboring strain. 
Accumulation of 131 in extract of S. argillaceus (pKOL) was unexpected, but it 
can be explained by collaboration of plasmid-borne biosynthetic machinery with 
endogenous host enzymes.  pKOL produces many intermediates that are also used by 
mtm pathway enzymes, which may be accepted by host tailoring genes and the 
glycosyltransferases.  In the normal biosynthesis of mithramycin, the genes are expressed 
at a rate that maintains a balanced enzymatic flux, which results in the efficient 
biosynthesis of mithramycin.  When pKOL is expressed in vivo, this enzymatic flux is 
imbalanced by the manifestation of foreign enzymes, which presently flood the pathway 
with NDP-activated deoxysugar donors and may divert it into unforeseen directions.  The 
accumulation of some of these donor sugar substrates may effectively deceive the 
endogenous glycosyltransferases, which results in the accumulation of side products.  
With respect to the in vivo expression of pKOL, it is remarkable that none of the other 
mithramycins that “jammed” the glycosyltransferases in the pLNBIV overexpression are 
present.  As such, it can be asserted that the lack of the plasmid-borne 4-ketoreductase is 
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responsible for removing the bottleneck that jammed the glycosyltransferases in previous 
experimentation.  In the case of pLN2 overexpression, only premithramycins were 
obtained in addition to 70, which indicates that the NDP-L-olivose is mostly accumulated 
in this strain and cannot be processed further than the disaccharide.  Furthermore, the 4-
ketoreductase gene eryBIV in pLNBIV must lead to the predominant accumulation of 
NDP-L-digitoxose, which can be transferred into the sugar D position by MtmGIII, but 
only as the 4C1 ring-flipped conformer, which is similar to NDP-D-oliose with regards to 
stereochemistry (Figure 49).  The D-digitoxose in E position likely results from 
accumulation of NDP-4-keto-2,6-dideoxyglucose, which is produced by oleSEVW in 
pKOL, which is then processed by one of two routes:  1) acceptance by MtmGIV and 
attached in E position, followed by MtmTIII-facilitated tautomerisation of the 3-OH to 
axial configuration, and finally 4-ketoreduction; or 2)  MtmTIII tautomerisation/4-
ketoreduction and glycosyltransfer of NDP-D-digitoxose (Figure 49).   
From a pharmacognosy perspective, the selective accumulation of 131 in a yield 
of ~5-6 mg per liter as the primary metabolite is a major boon, considering that the D-
digitoxose substitution in E position has been shown to have significant antitumoral 
improvement over mithramycin, especially in ER- breast cancer cell lines.  The complex 
production pattern of S. argillaceus (pLNBIV) and the hassle of separation have 
prohibited the further development of this compound.  Therefore, this experiment 
demonstrates a more effective route towards isolation of 131 via an improved 
fermentation method of a genetically manipulated strain of Streptomyces argillaceus. 
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Figure 48 HPLC chromatogram trace of metabolites from S. argillaceus (pKOL) strain.  
The main compound accumulated is demycarosyl-3D-β-D-digitoxosyl mithramycin (131).  
NDP-4-keto-L-olivose structure indicated as a reference for the sugar that pKOL 
biosynthesizes. 
O
HO
OPO3
-
OH
HO
OH
OleS/MtmD
O
HO
ONDP
OH
HO
OH
OleE/MtmE
O
H3C
HO
ONDP
OH
O
OleV O
H3C
O ONDP
O
OleW O
H3C
HO
ONDP
O
OleL
OH3C ONDP
O HO
NDP-4-keto-L-olivose
OH3C ONDPHO
HO
NDP-L-olivose
NDP-4-keto-D-olivose
OleU
pLN2
OH3C ONDPHO
OH
NDP-L-digitoxose
pLNBIV
EryBIV
132, jamming leads to 133-134
MtmTIII
O
H3C
OH ONDP
HO
NDP-D-digitoxose
O
H3C
OH ONDP
O
H3C
Normal substrate,
NDP-4-keto-
D-mycarose
MtmGIII
MtmGIII
disaccharide premithramycins
O
OH
HO
CH3
ONDP
4C1
MtmGIV,
MtmTIII 4-KR
MtmGIV
OOHOH
H3C
O CH3
OH
OH
O
OCH3
H
O
OHO
OOHO
HO
OHO
OO
OH
OOHO
OH
demycarosyl-3D-β-D-digitoxosyl-mithramycin  
Figure 49 Sugar biosynthesis of deoxysugar plasmids in S. argillaceus.  
129 
 
 
Generation of Streptomyces argillaceus M7W1/pKOL strain and identification of 
metabolites 
 
 
Having established an improved fermentation method for the production of 131 in 
S. argillaceus (pKOL), a recombination experiment was envisioned in which a restricted 
mutant of S. argillaceus could be transformed with pKOL to achieve novel 
mithramycin(s) with a modified polyketide framework and a sugar substitution.  For this 
experiment, S. argillaceus M7W1, which features a chromosomal disruption of the mtmW 
gene resulting in mithramycins with shorter aliphatic side chains (128-130), was used as a 
transformation host.  The resulting recombinant strain, S. argillaceus M7W1/pKOL was 
fermented for 5 days and methanolic extracts were visualized via HPLC/MS.  As 
predicted, several new peaks corresponding to mithramycin-type compounds were 
visualized (Figure 50).  Premithramycin A1 and premithramycinone were accumulated.  
Known metabolites mithramycins SK and SDK were recognized based on their UV-Vis 
spectrum, comparison of retention time with standard compound (mithramycin SK 
Rt=17.1 min-1 and mithramycin SDK Rt=19.2 min-1), and mass in (-) APCI-MS mode 
(1053 amu for mithramycin SK and 1051 amu for mithramycin SDK).  One other 
mithramycin-type compounds was recognized as demycarosyl-mithramycin SK based on 
its mass in (-) APCI-MS mode (910 amu).  Two new compounds that were not identified 
in extracts of S. argillaceus M7W1 demonstrated mithramycin-type UV absorption and 
possessed Rt=Δ-0.6 min-1 as compared to the corresponding mithramycin SK and SDK 
(Figure 50).  These compounds demonstrated masses that were 14 amu less than their 
mithramycin SK and SDK counterparts, indicating a substitution of an unmethylated 2,6-
dideoxysugar at E position (1039 amu for 135 and 1037 amu for 136, [M-H] (-) APCI-
MS).  This indicated that the molecular weight for 135 was 1040 amu and for 136 was 
1038 amu, which suggested that these new compounds might pertain to demycarosyl-3D-
β-D-digitoxosyl mithramycin SK (135) and SDK (136) (Figure 51). 
135 and 136 combine two of the most advantageous structural features as 
determined by previous SAR studies of mithramycin analogues (89, 97, 111-112).  Such 
heterologous expression experiments using restricted mutants have been performed 
before, namely transformation of sugar plasmids into a strain blocked in biosynthesis of 
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NDP-D-oliose (111), however, this marks the first successful attempt at combining two 
beneficial bioisosteres  in a single mithramycin molecule: a shortened 3-aliphatic side 
chain with a sugar substitution.   
 
Figure 50 HPLC chromatogram of metabolites from S. argillaceus M7W1/pKOL strain. 
  135 and 136 correspond to new metabolites generated in this strain.  § indicates 
demycarosyl-mithramycin SK normally produced in S. argillaceus M7W1.
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Figure 51 (Upper) Suggested structures of new mithramycin-type compounds 
isolated from S. argillaceus M7W1/pKOL recombinant strain. (Lower)  (-) APCI-MS 
mode mass data corresponding to the [M-H] molecular ion peaks of A) mithramycin 
SDK, B) 136, C) mithramycin SK, and D) 135. 
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Isolation and structure elucidation of demycarosyl-3D-β-D-digitoxosyl mithramycin 
SK 
 
A 10.0 liter fermentation of S. argillaceus M7W1/pKOL was carried out in a two 
step process and for five days (See Experimental Section).  To prevent the accumulation 
of mithramycin SA-related metabolites, the pH of the production medium (10.0 liters of 
liquid R5A medium, see Bacterial Strains and Culture Conditions) was adjusted to 
6.95.  After the third day, twenty-five milliliters of sample was extracted with twenty-five 
milliliters of ethyl acetate acidified with 50 microliters of formic acid, concentrated, and 
injected for HPLC-MS analysis.  The fermentation was allowed to continue for an 
additional twenty-four hours if premithramycins were present in the production spectrum, 
likely due to the flooding of the mithramycin pathway with NDP-deoxysugar substrates 
that had not yet been processed by MTM glycosyltransferases.  The fermentation was 
stopped after five days before the accumulation of mithramycin SA-metabolites. 
The culture was acidified to pH 5.5 and extracted three times with an equal 
volume of ethyl acetate, then was concentrated.  The resulting yellow-brown extract was 
fractionated over a reverse phase C18 silica column and the mithramycin compounds were 
purified via reverse phase HPLC.  From this, 22 milligrams of 135 were able to be 
purified, while the other mithramycin components were produced in insufficient yields or 
too poorly separated to allow for structural elucidation.   
The structure of the new mithramycin analogue was determined through HR-ESI 
mass spectral and 1D- and 2D-NMR spectroscopic methods, including 1H-NMR, 13C-
NMR, 1H-1H-gCOSY, 1H-13C-HSQC, and HMBC methods.  Further comparison with 
published literature concerning the sugar signals of 131(112) was corroborated with the 
HSQC and HMBC correlations.  The low resolution APCI (-ve mode) mass spectral 
analysis indicated an [M-H] peak of 1039.4 amu for 135, while the APCI (+ mode) 
indicated a parent peak of 1063.2 amu corresponding to [M+Na].  The HR-ESI mass 
spectral analysis indicated a found mass of 1039.4432 amu corresponding to a [M-H] 
peak and 1063.4337 amu corresponding to [M+Na], which established the molecular 
weight of the new mithramycin to be 1040.4 amu and the formula to be C50H72O23.  This 
revealed a difference of 14 amu between this compound and mithramycin SK, which 
could correspond to a difference of a single methylene group. 
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The 1H-NMR and 13C-NMR showed the characteristic signals of the tricyclic 
mithramycin polyketide skeleton (see NMR table in Experimental).  Two aromatic 
protons were observed as singlets (δH 6.87 and δH 6.69) as 5-H and 10-H, respectively, 
while the 2-H signal (δH 4.89, δC 78.0) appeared as a doublet with a large axial splitting 
shifted downfield due to the neighboring 1-CO moiety.  The 4ax and 4eq signals appeared 
as doublet of doublets (4-Hax at δH 3.25 (dd 16, 12 Hz), and 4eq at δH 3.00 (dd 16, 3)) with 
a large germinal splitting and a,a or a,e couplings, respectively, with the 3-H proton (δH 
3.50 dddd 16, 12, 4, 1; δC 41.5).  The 7-CH3 was evident based on a signal at δC 9.3 in the 
13C spectrum and δH 2.47 singlet in the 1H spectrum, indicating it to be the intact aromatic 
methyl group characteristic of mithramycins.  The position of 7-CH3 was confirmed 
based on HMBC correlations of the methyl protons with the 6-C and 8-C carbons (Figure 
52).  Nine aromatic signals were detectable in the 13C spectrum, while the 9-C was too 
small to observe.  This essentially left the problem of elucidating the structure of the new 
mithramycin to alterations in the C-3 side chain and delineating the nature of the 
saccharidal chains. 
The C-3 side chain of the new mithramycin was found to differ considerably from 
mithramycin due to the 1H and 13C signals.  The 1’-OCH3 was found as a singlet (δH3.83, 
δC 59.7), while the 2’-H proton was shifted downfield in the 1H spectrum (δH 4.85, δC 
80.2) as a doublet with a two Hertz coupling.  An additional acetoxy methyl singlet was 
found downfield at δH 2.49, which indicated an alpha ketone group.  Most importantly, an 
HMBC correlation between the δH 2.49 4’-H methyl protons and the C-3 carbonyl 
(δ211.0) established the proximity of the 3’-CO and 4’-CH3 groups.  HMBC correlations 
between the 2’-H and 3-C, 1’-methoxy, and 4’-C carbons further evidenced the presence 
of a shortened ketone side chain. 
The 13C spectrum indicated five anomeric signals (δ97.9, δ99.5, δ98.5, δ100.1, 
δ101.9) and five deoxysugar methyl groups (δ17.8, δ19.0, δ19.4, δ19.4, δ19.7), while the 
3E-CH3 of D-mycarose was missing.  The 1H-13C-HSQC revealed five aliphatic 
methylene carbons (δ37.9, δ41.6, δ38.5, δ33.3, and δ40.2), the sum total of which 
identified the characteristic presence of five 2,6-dideoxysugar moieties.  The 1H-1H- 
gCOSY revealed five deoxysugar spin systems stretching from 1H-6H.  Furthermore, 
five anomeric signals presented in the 1H spectrum (δ4.96, δ5.06, δ5.44, δ5.57, δ5.66) 
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with a large diaxial coupling and an a,e splitting, indicating them to be D-configured 2,6 
dideoxysugars as per Klyne’s rule (36).  The 13C and 1H upheld the presence of the 6-O-
D-olivose-1,3-D-olivose disaccharide, while the C sugar was likewise determined to be a 
2-O-connected D-olivose based on HMBC correlations between the 1C proton and 2-C 
and 2-H and 1C anomeric carbon.  The HMBC spectrum correlated the 1D anomeric 
proton to the 3C carbon, while the presence of a characteristic broad doublet δH 4.10 
(three Hertz coupling) indicated the 4D proton to be equatorial, which confirmed the 
presence of D-oliose at the D-sugar position.  The E sugar was found to be missing the 
3E-CH3 signal from the 13C spectrum and the missing methyl singlet from the 1H 
spectrum, while the 1H-1H-gCOSY indicated a spin system for this sugar stretching from 
1E-6E.  It was confirmed to be a β-D-digitoxose sugar, due to the presence of an 
equatorial 3E proton at δH 4.46 (broad d, 3 Hz) and shifted signals for the 2E (δC 40.2), 3E 
(δC 69.1), 4E carbons (δC 72.1).  The couplings of the 2-axial proton (δH 2.01 ddd 13, 10, 
3 Hz), the 4E proton (δH 3.63 dd 9, 3 Hz), and the COSY-correlation between 2Eeq, 2Eax, 
and 4E with the 3E proton established the D-digitoxose stereochemistry.  Altogether, the 
structure of 135 was confirmed to correspond to the new compound, demycarosyl-3D-β-
D-digitoxosyl mithramycin SK. 
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Figure 52 1H-1H-COSY (▬), and selected HMBC (→) correlations for demycarosyl-3D-
β-D-digitoxosyl-mithramycin SK. 
 
 
Generation of Streptomyces argillaceus M7W1/pKAM 
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As a further extension of the hypothesis that ketosugar plasmids may be 
potentially useful for producing differentially glycosylated analogues of mithramycin 
without untoward “jamming” of the glycosyltransferases, an NDP-L-cinerulose 
biosynthesizing plasmid was constructed from the NDP-L-rhodinose plasmid, pLNRHO, 
by deleting the 4-ketoreductase gene, urdZ3, resulting in plasmid pKAM.  It was 
envisioned that such a plasmid might direct biosynthesis of NDP-4-keto-2,3,6-trideoxy-
D-glucose, which might then be reduced by an mtm pathway 4-ketoreductase to NDP-D-
amicetose, which has then been shown to be transferred by MtmGI very efficiently into A 
position (Figure 52).  Previously, Salas et al. isolated a novel mithramycin when pFL844 
was expressed in S. argillaceus wildtype with a D-amicetose replacing the A and B 
disaccharide (Figure 52).  
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Figure 53 Biosynthetic pathways to trideoxygenated sugars.   
NDP-L-cinerulose (pKAM) indicated in red.  4-ketoreductases deleted from pathway 
(EryBIV/UrdZ3) indicated in brackets.  Structure of dideolivosyl-3A-β-D-amicetosyl-
mithramycin. 
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If the endogenous mtm sugar ketoreductases can collaborate efficiently with pKAM-
borne machinery, then overexpression of pKAM in the S. argillaceus M7W1 strain 
should result in the shortened chain derivatives of dideolivosyl-3A-β-D-amicetosyl-
mithramycin.  Surprisingly, extracts of S. argillaceus M7W1/pKAM contained no new 
peaks corresponding to mithramycins and only minor amounts of mithramycin SK.  
Instead, four peaks corresponding to premithramycins in excellent yield were 
accumulated.  Two of these peaks corresponded to premithramycin A1 and 
premithramycinone, yet two others corresponded to unknown premithramycins with one 
sugar and four sugars, respectively (Figure 53).  The monoglycosylated premithramycin 
evinced a molecular weight of 528 amu, as determined by (-) APCI-MS.  This 
corresponds to 16 mass units less than premithramycin A1, which likely indicates a 2,3,6-
trideoxygenated sugar at C position.  This could correspond either to a D- or L-
configurated amicetose sugar, which has never been characterized as being attached at C-
position before.  From a biosynthetic perspective, such an attachment is unproductive, 
because this sugar lacks the 3-OH handle which is necessary to establish the next 
glycosidic bond.  The premithramycin with four sugars demonstrated a mass of 928 amu, 
as determined by (-) APCI-MS, which corresponds to a premithramycin with possibly 
trisaccharide and monosaccharide chains, respectively.  The mass suggests that one or 
possibly two trideoxygenated sugars are incorporated onto this molecule, which given the 
sugar’s lack of a 3-OH, would necessarily restrict their glycosylation to the A and E sugar 
positions. Given that the amicetosyl-substituted mithramycin is efficiently turned over by 
MtmOIV, this premithramycin compound likely has a sugar attached in either E or A 
position that interfere with its turnover by MtmOIV.  This compound may be an excellent 
candidate for interrogating the substrate flexibility mutant MtmOIV oxygenases, given 
that it possesses a fully intact trisaccharide chain.  Furthermore, the production spectrum 
of this recombinant strain is not complex, and the yield of these compounds appears to be 
quite reasonable, which are encouraging for further structure elucidation and pathway 
engineering experiments.  
 The absence of the dideolivosyl-3A-β-D-amicetosyl-mithramycin derivatives with 
shortened side chains was surprising.  Quite possibly, MtmGI demonstrates flexibility to 
NDP-L-cinerulose or one of the pKAM-encoded pathway intermediates, and 
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glycosylation of this sugar at A position results in a molecule which MtmOIV cannot 
recognize.  The presence of a monosaccharidal premithramycin was also surprising, as 
this sugar has not been reported at C position before; yet, in previous combinatorial 
biosynthesis experiments involving amicetose sugars, those pathways progressed 
efficiently towards fully-formed mithramycins.  Therefore, this compound may not have 
been detected in those other strains.  Some jamming of glycosyltransferases by NDP-L-
cinerulose may be responsible for the accumulation of this latter compound.  As a result, 
it is hypothesized that transformation of pFL844 into S. argillaceus M7W1 would very 
likely result in accumulation of these shortened chain dideolivosyl-3A-β-D-amicetosyl-
mithramycin derivatives. 
 
 
Figure 54 HPLC chromatogram of metabolites from S. argillaceus M7W1/pKAM. 
This plasmid reprograms the biosynthesis to generate two novel premithramycins with 
attached trideoxygenated sugars.  Monosaccharide premithramycin, 526 amu (-)APCI-
MS, Rt=21.3 min-1.  Premithramycin with four sugars, 928 amu (-) APCI-MS, Rt=18.0 
min-1. 
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SUMMARY  
 
In summary, Chapter 5 has described some preliminary microbiology work 
towards glycodiversification of the mithramycin scaffold by interrogating the mtm 
pathway glycosyltransferases with “deoxysugar plasmids” that encode novel deoxysugars 
not previously transformed into Streptomyces argillaceus.  Through this work, several 
new recombinant strains with markedly altered production patterns have been produced, 
and the metabolites from these strains have been preliminarily characterized via UV-vis, 
APCI-MS mass, and retention time analyses.  A couple premithramycin compounds with 
four sugars have been identified, which could be isolated, structurally characterized, then 
used as substrates for interrogating mutant MtmOIV oxygenases.  Or, perhaps, an in vivo 
approach employing an integrative vector, such as pSET152, with a cloned copy of such 
an MtmOIV (e.g. MtmOIV-R204A) under ermE* promotion could be integrated into the 
chromosome of such a strain.   
Additionally, the promising antitumoral mithramycin compound 131 was 
produced selectively in fermentations of S.argillaceus (pKOL), which overexpresses the 
NDP-4-keto-L-olivose pathway.  The flooding of this pathway with NDP-activated sugar 
donors results in accumulation of NDP-4-keto-2,6-dideoxy-D-glucose, which is then 
transferred to E position as a D-digitoxose.  As a further extension of this work, the 
mtmW-disrupted mutant, S. argillaceus M7W1, was used as a transformation host for 
pKOL, which lead to the elaboration of two shortened-chain mithramycins, 135 and 136.  
The structure of 135 was confirmed via HR-ESI mass spectral and 1D- and 2D- NMR 
spectroscopic methods as demycarosyl-3D-β-D-mithramycin SK, which may exhibit 
exciting new biological activity.  The presence of two rationally designed and potentially 
pharmaceutically advantageous bioisosteres is unprecedented for a mithramycin 
molecule, and this also reflects on the substantial power of combinatorial biosynthesis to 
achieve improved analogues of complex natural products.   
Furthermore, as Chapters 4 and 5 have demonstrated, the flooding of sugar 
biosynthetic pathways with ketosugars provides a new approach towards the 
glycodiversification of polyketide molecules.  Because there are so few examples of 
glycosyltransferases in nature that can transfer a ketosugar, such interrogations are 
largely serendipitous and unexploited.  In Chapter 4, ElmGT was found to have an 
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unusual capacity to transfer NDP-4-keto-L-olivose to its aglycone, which revealed an 
unanticipated flexibility towards an NDP-ketosugar.  In Chapter 5, by utilizing the same 
sugar cassette, the S. argillaceus mithramycin biosynthetic pathway was interrogated in 
the same fashion.  Although MtmGIV has been demonstrated to attach NDP-D-
ketosugars to its acceptor substrate(s), no such ketosugar-decorated polyketide was 
detected.  Instead, the selective accumulation of 131 was achieved, which revealed that 
by pooling NDP-4-keto-D-olivose and NDP-4-keto-L-olivose, glycosyltransferase 
jamming was effectively circumvented (as exhibited by the absence of other mithramycin 
congeners or the appreciable accumulation of premithramycins in the production 
spectrum.)  Just as important, the NDP-4-keto-L-olivose did not appear to serve as a 
substrate for any of the other glycosyltransferases, and in theory, it may play an important 
role in inhibiting MtmC to allow for the accumulation of NDP-4-keto-D-digitoxose.  
Therefore, in S. argillaceus, the flooding of the MTM pathway with NDP-4-keto-D-
olivose is a necessary pre-requisite to steer the pathway towards production of NDP-4-
keto-D-digitoxose, which is likely accepted in the active site of ketoreductase MtmTIII in 
the absence of its C-3 methylated substrate.  Furthermore, because the D-digitoxose 
substitution is sufficiently tolerated by MtmOIV to allow for opening of the fourth ring, 
this strategy could be repeated in the S. argillaceus M7W1 strain to achieve the shortened 
ketone side chain. 
 
EXPERIMENTAL 
 
 
Table 10  Plasmids used in Chapter 5 
 
Plasmid Name Relevant Characteristics Reference 
pLN2 AmpR, TsrR.  OleVWSELUY 
under ermE* promotion. 
NDP-L-olivose. 
(135) 
pRHAM AmpR, TsrR.  OleVWSE 
under ermE* promotion. 
NDP-L-rhamnose. 
(134) 
pMP*UII AmpR, TsrR.  OleVW, 
cmmUII, OleY, MtmDE, 
under divergent ermE* 
promotion.  NDP-D-oliose. 
(160) 
pDmnI AmpR, TsrR.  OleSEVLU Madan Kharel, Personal 
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DnrJ under ermE* 
promotion. NDP-L-
acosamine 
Communication 
pDmnII AmpR, TsrR.  OleSEV, 
DnrJUV under ermE* 
promotion. NDP-L-
daunosamine 
Madan Kharel, Personal 
Communication 
pDesI AmpR, TsrR.  DesIII, DesIV, 
DesI under ermE* 
promotion.  NDP-4-amino-
6-deoxy-D-glucose (121) 
Madan Kharel, Personal 
Communication 
pDesII AmpR, TsrR.  DesIII, DesIV, 
DesI, DesII under ermE* 
promotion.  NDP-3-keto-
4,6-dideoxy-D-glucose 
(122). 
Madan Kharel, Personal 
Communication 
pDesIII AmpR, TsrR.  DesIII, DesIV, 
DesI, DesII, DesV under 
ermE* promotion.  NDP-3-
N,N-didemethyl-D-
desosamine (123). 
Madan Kharel, Personal 
Communication. 
pKOL AmpR, TsrR.  OleVWSELY 
under ermE* promotion.  
NDP-4-keto-L-olivose. 
This work. 
pFUCO AmpR, TsrR.  gilU, ravDE 
cloned under ermE* in 
pUWL201PW.  Intended to 
produce NDP-D-fucose. 
This work. 
pFUCOII AmpR, TsrR.  gilLU, ravDE, 
cloned under ermE* in 
pUWL201PW.  Intended to 
produce NDP-D-
fucofuranose. 
This work. 
pVIR*II AmpR, TsrR.  chryCMT, 
chryU, ravDE cloned under 
ermE* in pUWL201PW.  
Intended to produce NDP-D-
virenose. 
This work. 
pEN3 AmpR, TsrR.  chryCMT, 
chryU placed under ermE* 
in pEM4.  Intended to 
produce NDP-D-virenose in 
strain that produces 32. 
This work. 
pKAM AmpR, TsrR.  OleVWSELY , 
urdQ under ermE* 
promotion.  Produces NDP-
This work. 
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L-cinerulose. 
pLNRHO AmpR, TsrR.  OleVWSELY , 
urdQ,urdZ3 under ermE* 
promotion.  Produces NDP-
L-rhodinose 
This work. (39) 
 
 
Table 11  Bacterial strains used in Chapter 5 
 
Strain Name Relevant Characteristics Reference 
Streptomyces argillaceus § Produces mithramycin (70).  
Wildtype strain. 
(108) 
Streptomyces argillaceus 
M7W1 † 
Produces mithramycins 
SK/SDK/SA (128-130).  
mtmW-disrupted strain. 
(89, 97) 
Streptomyces argillaceus 
(pLN2) 
§ expressing pLN2.  
Produces 2 preMTMs and 
70. 
(111) 
Streptomyces argillaceus 
(pRHAM) 
§ expressing pRHAM.  
Produces 76 and 70. 
(111) 
Streptomyces argillaceus 
(pLNBIV) 
§ expressing pLNBIV.  
131-134, 76, 27, 70, and 3 
unknown pre-MTMs. 
(112) 
Streptomyces argillaceus 
(pDmnI) 
§ expressing pDmnI.  
Produces 70, 76, 27, and 
unknown preMTM. 
This work. 
Streptomyces argillaceus 
(pDmnII) 
§ expressing pDmnII.  
Produces 70. 
This work. 
Streptomyces argillaceus 
(pDesI) 
§ expressing pDesI.  
Produces 70.  
This work. 
Streptomyces argillaceus 
(pDesIII) 
§ expressing pDesIII.  
Produces 70 and unknown 
preMTM. 
This work. 
Streptomyces argillaceus 
(pFUCO) 
§ expressing pDesIII.  
Produces 70. 
This work. 
Streptomyces argillaceus 
(pFUCOII) 
§ expressing pDesIII.  
Produces 70. 
This work. 
Streptomyces argillaceus 
(pEN3) 
§ expressing pEN3. 
Produces 70, 76, 27.  2 
unknown preMTMs and 
unknown MTM 
This work 
Streptomyces argillaceus 
(pVIR*II) 
§ expressing pVIR*II. 
Produces 70, 76, 27.  2 
unknown preMTMs and 
unknown MTM. 
This work 
Streptomyces argillaceus † expressing pVIR*II.  This work. 
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M7W1/(pVIR*II) Uninvestigated. 
Streptomyces argillaceus 
(pKOL) 
§ expressing pKOL.  
Produces 70, 76, 27, 131, 
and two unknown 
preMTMs. 
 
This work. 
Streptomyces argillaceus 
M7W1/(pKOL) 
† expressing pKOL.  
Produces 128, 129, 76, 27, 
135, 136. 
This work. 
Streptomyces argillaceus 
M7W1/(pKAM) 
† expressing pKAM.  
Produces 76 and 27 and 2 
unknown preMTMs 
This work. 
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Table 12  Physicochemical and NMR Data for Demycarosyl-3D-β-D-digitoxosyl 
mithramycin SK (135). 
CH3
H3CO
OH
O
OH OH O
H
O
O
CH3
HO
OO
CH3
OH
OO
CH3
HO
OH
O
CH3
HO
O
O
O
CH3
HO
HO H3C
1A
1B
1C
1D
1E
1'
1
3
2
6
7 9
105
 
Rrel= 16.62 min-1; Yield:  2.2 mg/L 
 
MW= 1040.4 g/mol (C50H72O23) 
 
Negative mode APCI-MS:  m/z=1039.4 [M-H, 100%]; APCI-MS (+ mode):  1063.2 
[M+Na, 40%].  (-) HR-ESI MS ([M-H] calc. 1039.4359 amu, found 1039.4432 amu.  (+) 
HR-ESI MS [M+Na] calc. 1063.4362 amu, found 1063.4337 amu.) 
 
UV maxima (from HPLC-diode array):  UV (from HPLC-diode array):  λmax 211 (85%), 
278 (100%), 317 (15%), 332 (13%), 413 (18%) 
 
NMR Data (pyridine- d5) 
 
 
Position Demycarosyl-3D-β-D-digitoxosyl mithramycin 
SK (135) 
δC (125 MHz) δH (500 MHz, J in Hz) 
1 n.o.* - 
2 78.0 4.89 d (11) 
3 41.5 3.50 dddd (16, 12, 4, 1) 
4ax 28.3 3.25 dd (16, 12) 
4eq  3.00 dd (13, 3) 
4a 136.6 - 
5 100.4 6.87 s 
6 160.3 - 
7 111.9 - 
7-CH3 9.3 2.47 s 
8 160.6 - 
8a 109.2 - 
9 n.o.* - 
9a 109.5 - 
10 117.6 6.69 s 
10a 137.7 - 
1’ 81.1 4.62 dd (3,2) 
1’-OCH3 59.7 3.83 s 
2’ 80.2 4.85 d (2) 
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3’ 211.0 - 
4’ 27.5 2.49 s 
5’ - - 
1A 97.9 5.66 dd (10, 2) 
2Aax 37.9 2.20-2.25 (overlap) 
2Aeq  2.74 td (12, 5) 
3A 79.0 3.55 t (9, overlap) 
4A 76.1 3.60 m 
5A 74.0 4.19 dq (9, 6.5) 
6A 19.4 1.69 d (6.5) 
1B 99.5 5.06 dd (10, 2) 
2Bax 41.6 2.20-2.25 (overlap) 
2Beq  2.65 ddd (12, 5, 4) 
3B 73.5 4.17 (overlap) 
4B 78.6 3.89 t (10) 
5B 73.6 3.63 dq (10, 5) 
6B 19.0 1.53 d (6.5) 
1C 101.9 5.44 dd (10, 2) 
2Cax 38.5 2.10-2.15 (overlap) 
2Ceq  2.60-2.65 (overlap) 
3C 81.3 3.94 ddd (12, 10, 6) 
4C 74.7 3.46 dd (9, 6.5) 
5C 72.0 4.26 dq (9, 6.5) 
6C 19.7 1.60 d (6.5) 
1D 100.1 4.96 dd (10, 2) 
2Dax 33.3 2.20-2.30 (overlap) 
2Deq  2.20-2.30 (overlap) 
3D 77.2 4.00 ddd (12, 6, 3) 
4D 73.3 4.10 br d (3) 
5D 73.9 3.75 dq (6.5, 3) 
6D 19.4 1.61 d (6.5) 
1E 98.6 5.57 dd (10, 2) 
2Eax 40.2 2.01 ddd (13, 10, 3) 
2Eeq  2.35-2.45 (complex) 
3E 69.1 4.46 br d (3) 
4E 72.1 3.63 dd (9, 3) 
5E 71.1 4.42 dq (9, 6.5) 
6E 17.8 1.60 (6.5) 
 
 
Bacterial Strains and Culture Conditions 
 
Escherichia coli XL1 blue (Invitrogen) was used as a host for routine cloning 
experiments and was grown on LB agar or in LB broth at 37°C.  Streptomyces 
argillaceus or Streptomyces argillaceus M7W1 recombinant strains were grown on R5A 
agar: sucrose, 100 g/liter; K2SO4, 0.25 g/liter; MgCl2 · 6H2O, 10.12 g/liter; glucose, 10 
g/liter; Casamino Acids, 0.1 g/liter; yeast extract (Difco), 5 g/liter; and MOPS, 21 g/liter, 
R5 trace elements, 2 mL/liter.  For preparation of protoplasts, spores of S. argillaceus or 
S. argillaceus M7W1 were inoculated into 100 mL YEME liquid medium in a 250 mL 
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baffled Erlenmeyer flask at 28 °C for 3 days for preparation of protoplasts following the 
previously reported protocol (3).  When antibiotic selection of recombinant strains was 
required, 25 μg/mL apramycin, 25 μg/mL thiostrepton, or 100 μg/mL of ampicillin were 
used. Protoplast transformation was carried out to introduce the various sugar plasmids 
into Streptomyces argillaceus or Streptomyces argillaceus M7W1 following the standard 
protocol (3, 174).   
 
Generation of plasmids directing the biosynthesis of ketosugars, 
aminosugars, and 2-hydroxysugars 
 
The 4-ketoreductase gene (urdZ3) was removed from plasmid pLNRHO (39). 
NheI and SpeI were used to digest pLNRHO, thereby releasing the urdZ3 fragment. DNA 
gel electrophoresis was carried out to remove the urdZ3 gene and the resulting fragment 
(~14kb) was rescued and re-ligated to generate pKAM. In this construct, all of the sugar 
genes are under strong ermE* promotion.  pKOL was generated in a similar manner (see 
Chapter 4, Materials and Methods). 
Plasmids pVIR*II, pFUCOII, pFUCO, and pEN3 were prepared as discussed in 
Chapter 2, Materials and Methods.  Plasmids pDmnI, pDmnII, pDesI, pDesII, and 
pDesIII were prepared by Dr. Madan Kharel (Personal Communication).  pLN2, 
pRHAM, and pLNBIV were all prepared previously by Salas et al.  (39).  All plasmids 
were transformed into S. argillaceus or S. argillaceus M7W1 via protoplast 
transformation. 
 
Isolation of mithramycins from recombinant S. argillaceus M7W1/ (pKOL) 
strains 
 
One aprR/tsrR transformant corresponding to Streptomyces argillaceus 
M7W1/(pKOL) was plated on R5A agar plates supplemented with 25 μg/mL apramycin 
and thiostrepton at 28 °C for 5 days.  For small scale production of mithramycins, an agar 
chunk of bacterial spores was inoculated in 250 mL Erlenmeyer flasks containing 100 
mL of R5A medium supplemented with antibiotics for 4-5 days.  25 mL of the culture 
was extracted with ethyl acetate and 0.1% formic acid, and the organic layer was dried in 
vacuo.  Extracts were then redissolved in methanol and were subjected to HPLC/MS 
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analyses on a MicroMass ZQ 2000 (Waters) instrument equipped with HPLC (Waters 
alliance 2695 model) and photodiode array detector (Waters 2996).  A Semi-Prep 
Symmetry C18 column (7.8×300 mm, 5 μm) and Symmetry C18 (4.6x250 mm, 5 μm) 
analytical column were used for semi-preparative and analytical scale separations, 
respectively.  A gradient of acetonitrile and 0.1% formic acid in water was used to 
separate compounds as reported previously (105).  (Solvent A= 0.1% formic acid in 
water, solvent B=acetonitrile; 0–20 min 25% B to 70% B; 20-22 min 70%% B to 90% B; 
22–24 min 90% to 100% B; 24–26 min 100% B; 26-28 min 100% B to 25% B; 28-30 
min 25% B, flow rate 0.5 mL/min). 
For larger scale production of glycosylated mithramycins, spores of Streptomyces 
argillaceus M7W1/(pKOL) were grown in eight 100 mL trypticase soy broth (TSB) 
cultures supplemented with apramycin and thiostreptone at 28 °C for 30 hours.  In the 
production phase, 10.0 L of R5A liquid medium was allocated into 100 mL portions in 
100 baffled 250 mL Erlenmeyer flasks and the pH adjusted to 6.95 to promote the 
generation of mithramycins with SK and SDK side chains.  4% (v/v) of the TSB cultures 
was used to inoculate each flask, which was supplemented with antibiotics.  Fermentation 
was carried out for 3-5 days at 28°C in an orbital shaker.  After the third day, 25 mL of 
culture was extracted with ethyl acetate, dried, and then checked via HPLC/MS analysis 
to determine the production of mithramycin-type compounds.  If premithramycins were 
detected, fermentation was continued for another 24 hours.  As a result of the flooding of 
the pathway with NDP-deosyxugar intermediates, additional time was required to allow 
for all glycosyltransfer events and MtmOIV to process premithramycin-type compounds 
to active mithramycins.  After detection of mithramycin-type compounds via HPLC/MS, 
the culture was harvested (to avoid decomposition of metabolites to mithramycin SA), 
mixed with celite (50 g/L fermentation broth), and then filtered.  The mycelial cake was 
extracted with 400 milliliters of methanol and sonicated for thirty minutes.  The culture 
was acidified to pH 5.5 with concentrated HCl and extracted three times with 2 L of ethyl 
acetate.  The solvent was dried in vacuo.  The extracts were resuspended in ddH2O, 
poured over a reverse phase C18 silica column (column dimensions 5.0 cm x 13 cm) 
under vacuum (1-5 mbar).  The column was washed with 1 liter of 10:90 acetonitrile: 
ddH2O.  Three hundred milliliter fractions were taken, increasing the acetonitrile partition 
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by 10% each step from 0%-100%.  135 and 136 were found primarily in the 30%, 40%, 
50%, and 60% acetonitrile fractions.  The 30%, 40%, and 50% acetonitrile fractions were 
combined, dried in vacuo, finally being lyophilized to remove water.  This extract was 
dissolved in methanol, centrifuged, and the supernatant filtered for reverse phase HPLC 
chromatography. The individual peaks were resolved via semi-preparative high-
performance liquid chromatography (HPLC) on a Symmetry semi-prep C18 column 
(7.8×300 mm, 5 μm) on a Waters 1525 EF platform with a Waters 2487 dual absorbance 
detector UV lamp.  A gradient of 0.2% formic acid in double distilled water and 
acetonitrile was used  (Solvent A= 0.2% formic acid in water, solvent B=acetonitrile; 0–
20 min 25% B to 70% B; 20-22 min 70%% B to 90% B; 22–24 min 90% to 100% B; 24–
29 min 100% B; 29-31 min 100% B to 25% B; 31-34.5 min 25% B, flow rate 2.5 
mL/min).  The eluted material under each peak was collected, dried in vacuo, diluted 
with double distilled water (10 mL), and finally lyophilized.  Sample purity was verified 
via HPLC/MS analysis to assure the presence of a single peak.  Using this protocol, 22 
mg of 135 was isolated.  HR-ESI mass spectral analyses were conducted by the Biotech 
Department at the University of Wisconsin, and NMR measurements were conducted on 
a 500 MHz Varian VNMR instrument using deuterated pyridine as solvent.  
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Figure 55 1H-NMR data for demycarosyl-3D-β-D-digitoxosyl mithramycin SK recorded 
at 500 MHz. 
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Figure 56 13C-NMR data for demycarosyl-3D-β-D-digitoxosyl mithramycin SK recorded 
at 125 MHz. 
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